

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**









Ratio: 5.235 Gaps: 0  
Percent similarity: 100.000 Percent identity: 100.000

## alignment block:

US-09-673-254-1/rev x US-08-760-116-2 ..

Align seg 1/1 to: US-08-760-116-2 from: 1 to: 422

```

1351 GAGACGGGAGGAGCGCCCGGGTGGCCGTCGACCGCGTTCGGTTCGCCAT 1302
      |||
1  ValSerGlyGluAlaProArgValAlaValAspProPheAlaLysProHe 17
1301 GATGACCATGACGCGCAAGCCCGAGGTGCACGACGCTTCCGGGAGCGCG 1252
      |||
17 tMetThrMetGlnArgLysProGluValHisAspAlaPheArgGluAlaG 34
51 GCCCGGTGCTCGAGGTGAACGCCCGCGGGCGGAGACCGCGCTGGGTGATC 1202
      |||
34 LpProValValGluValAsnAlaProAlaGlyGlyProAlaTrpValIle 50
1201 ACCGATGACGCGCTCGCCCGCGAGGTGCTGGCCGATCCCGGGTTCGTGA 1152
      |||
51 ThrAspAspAlaLeuAlaArgGluValLeuAlaAspProArgPheValIly 67
1151 GAGCCCGGACCTCGCCCGCGCTGGCGGGGGGTGACGACGGTCTCG 1102
      |||
67 sasProAspLeuAlaProAlaAlaTrpArgLysValAspAspGlyLeuA 84
1101 ACATCCCGCTTCGGAGCTGGCTCGGTTTCACGCTCATGCGCGTGGACGC 1052
      |||
84 spIleProValProGluLeuArgProPheThrLeuIleAlaValAspGly 100
1051 GAGGGCCACGCGCGCTGGCGCCGATCCACGACGACCTGCTTCACCGCGG 1002
      |||
101 GluAlaHisAlaArgLeuArgLeuArgIleHisAlaProAlaPheAsnProAr 117
1001 CCGGCTGGCGCGAGCGGATCGCATCGCCGCGATCGCGCGCGCGCTGC 952
      |||
117 gArgLeuAlaGluArgThrAspArgIleAlaAlaIleAlaGlyArgLeuL 134
951 TCACCGGAACCTCGCCGACGCTCGCGCGGTGGGCAACCGCGCGAGCTG 902
      |||
134 eutThrGluLeuAlaAspAlaSerGlyArgSerGlyLysProAlaGluLeu 150
901 ATCGGCGGCTTCGCTACCATCTCCGCTGTGGTTCATCTGGAGAGTGTCT 852
      |||
151 IleGlyGlyPheAlaTrpHisPheProLeuLeuValIleCysGluLeuLe 167
851 CGGTGTGCGCGTCCACCGATCGCGCGATGGCCCGGAGCGCGTCCAGCTTC 802
      |||
167 uGlyValProValThrAspProAlaMetAlaArgGluAlaValIleServa 184
801 TCAAGGCACTGGCGCTCGCGCGCGCGAGAGGGGGGGGTACGGGCGG 752
      |||
184 euLysAlaLeuGlyLeuGlyGlyProGlnSerGlyGlyLysAspGlyThr 200
751 GACCTTGGCGGGGGGCGTGGCGGACACTCGGCGCTGAGAGAGCTGCTCT 702
      |||
201 AspProAlaGlyGlyValProAspThrSerAlaLeuGlnSerLeuLeuLe 217
701 CGAAGCCGTCGACTAGCCCGCGGAGACGACACCCCGACCATGACCCGCG 652
      |||
217 uGluAlaValHisSerAlaArgArgAsnAspThrProThrMetThrArgV 234
651 TGCCTGTAGAGGGCGCGGCGGAGTTCGGCTCGCTCCGACGACGCG 602
      |||
234 alLeuArgTrpGlnArgAlaGlnAlaGlnPheGlySerValSerAspAspGln 250
601 CTCGTCTACATGATCAGCGGCTCATCTTCGCGGCGACGACACACCGCG 552
      |||
251 LeuValIlyMetIleThrClyLeuIlePheAlaGlyHisAspThrThrCl 267
551 CTCCTTCTGCGGCTTCGCTCGCGGAGGTCCTGGCGGCGCGCTCGCGG 502

```

```

|||||
267 ySerPheLeuGlyPheLeuLeuAlaGluValLeuAlaGlyArgLeuAlaA 284
501 CGGATGCGGACGACGAGACGCGCTCTCCGGTTCGTGGAGAGCGCTGCCG 452
      |||
284 laAspAlaAspGlnAspAlaValAlaSerArgPheValGluGluAlaLeuArg 300
451 TACACCGCGCGGTGCCCTTACAGGTTGTGAGAGTTCGCTGCCACGAGGT 402
      |||
301 TyrHisProProValProTyrThrLeuTrpArgPheAlaAlaThrGluVa 317
401 GACCATCGCGCGCGTCCGCGCTGCCCGCGGAGCGCGCGGTGTGTGACA 352
      |||
317 LThrIleGlyGlyValArgLeuProArgGlyAlaProValLeuValAspI 334
351 TCGAGGCGACACACACCGGCGCGCGCATCAGACGAGCGCGCGCGCTTC 302
      |||
334 IeGluGlyThrAsnThrAspGlyArgHisHisAspAlaProHisAlaPhe 350
301 CACCGGACCGTCCCTCGTGGCGGCGGCTCACCTTCGCGGACGCGCGCA 252
      |||
351 HisProAspArgProSerTrpArgArgLeuThrPheGlyAspGlyProHi 367
251 CTACTGCATCGGGGAGACAGCTCGCCAGCTGGAGTTCGCGACGATGATCG 202
      |||
367 sTyrCysIleGlyGluGlnLeuAlaGlnLeuGlnSerArgTrpMetIleG 384
201 GCGTACTGCGGACGACAGTTCGCCGAGCGCGGACTGGCGCTGCCGTACGC 152
      |||
384 lYvalLeuArgSerArgPheProGluAlaArgLeuAlaValProTyrAsp 400
151 GAGTTGCGGTGTGGCGGAGGCGGCGGCGGACGCGCGCTCACCGCAACT 102
      |||
401 GluLeuArgTrpCysArgLysGlyAlaGlnThrAlaArgLeuThrGluLe 417
101 GCCGCTGCGCTGCGCG 86
417 uproValTrpLeuArg 422

seq_name: /cgn2_6/ptodata/1/1aa/5B_COMB.pep:US-09-096-982-9
seq_documentation_block:
: Sequence 9, Application US/09096982
: Patent No. 5962293
: GENERAL INFORMATION:
: APPLICANT: Strohl, William R.
: APPLICANT: Dickens, Michael L.
: APPLICANT: Desautel, Charles L.
: TITLE OF INVENTION: METHOD OF PRODUCING DOXORUBICIN
: NUMBER OF SEQUENCES: 9
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: CALFE, HALTER & GRISWOLD
: STREET: 800 Superior Avenue, Suite 1400
: CITY: Cleveland
: STATE: Ohio
: COUNTRY: USA
: ZIP: 44114-2688
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/096,982
: FILING DATE:
: CLASSIFICATION:
: ATTORNEY/AGENT INFORMATION:
: NAME: Goltick, Mary E.
: REGISTRATION NUMBER: 34829
: REFERENCE/DOCKET NUMBER: 22727/00131
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 216-622-8458
: TELEFAX: 216-241-0816

```

731 GGACACCTCGGCCCTGGAGAGCCTGCTCCTCGAAGCCGTGCACCTCAGCCC 682

COMPUTER: IBM PC compatible

```
; OPERATING SYSTEM: PC
```

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/653,650A  
FILING DATE:  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: GOLICK, Mary E.  
REGISTRATION NUMBER: 34829  
REFERENCE/DOCKET NUMBER: 22727/00131  
TELEPHONE: 216-622-8458  
TELEFAX: 216-241-0816  
INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 443 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-653-650A-9

alignment\_scores:  
Quality: 2104.50 Length: 432  
Ratio: 4.987 Gaps: 1  
Percent Similarity: 97.685 Percent Identity: 93.519

## alignment\_block:

US-09-673-254-1/rev x US-08-653-650A-9 ..

Align seg 1/1 to: US-08-653-650A-9 from: 1 to: 443

```
1378 GTACCCGGGGGGGGGGGG...TGCCTGATGAGCGAGCGGCCCG 1332
      |||.....:|||||:|||||:|||||:|||||:|||||:
12 ValProtyrtylAsnsergluglycysleuMetserGlyGluAlaProar 28
1331 GGTGGCGCTGACCCGCTGCTGCTCCATGATGACCATGACGAGC 1282
      :|||.....:|||||:|||||:|||||:|||||:|||||:
28 gValAlaValAspProhsercysProMetMetGlnAlaArgLysp 45
1281 CCGAGGTGACGACGCTTCGGGAGGCGGGCCGCTGTCGAGTGAC 1232
      |||.....:|||||:|||||:|||||:|||||:|||||:
45 rogluValAlaHisAspAlaPheArgGluAlaGlyProValAlaGluValAsn 61
1231 GCCCGCGGGGCGGACCGCGCTGTCATGACCATGAGCGCCCTGCGCG 1182
      |||.....:|||||:|||||:|||||:|||||:|||||:
62 AlaProAlaGlyGlyProAlaTrpValIleThrAspAlaLeuAlaAr 78
1181 CGAGGTGCTGGCGATCCCGGTTGTTGAAGACCCGACCTGCGCCCG 1132
      |||.....:|||||:|||||:|||||:|||||:|||||:
78 gGluValAlaValAspProArpPheValIleThrAspAlaLeuAlaAr 95
1131 CCGCGTGGGGGGGGTGGAGCAGCGTCTGACATCCCGTTCGGAGCTG 1082
      :|||.....:|||||:|||||:|||||:|||||:|||||:
95 hrAlaTrpArgGlyValAspAspGlyLeuAspIleProValProGluLeu 111
1081 CGTCCGTCACGCTCAATCGCGTGGAGCGGCGCACCGGCGCGCTGCG 1032
      |||.....:|||||:|||||:|||||:|||||:|||||:
112 ArgProhThrLeuAlaValAspGlyLeuAspHisArgArgLeuAr 128
1031 CCGCATCAGCAGCTGCTTCAACCGCGCGCTGCGGAGCGAGCGAG 982
      |||.....:|||||:|||||:|||||:|||||:|||||:
128 gArgIleHisAlaProAlaPheAsnProArpArgLeuAlaGluArgThra 145
981 ATGCGATCGCGGATCGCGCGCGCTGCTCAGCAGACTGCGGAGCGC 932
      |||.....:|||||:|||||:|||||:|||||:|||||:
145 spArgIleAlaAlaIleAlaAspArgLeuThrGluLeuAlaAspSer 161
931 TCGGCGGCTGCGGGAACCGCGGAGCTGATGCGGCGCTTCGGGTGCA 882
      |||.....:|||||:|||||:|||||:|||||:|||||:
162 SerAspArgserGlyGluProAlaGluLeuIleGlyGlyPheAlaTrpH 178
881 CTTCGCGCTGTGTGATCTGCGAGCTGTGCTGCTGCGGTCACCGCATC 832
```

```
|||||.....:|||||:|||||:|||||:|||||:|||||:
178 sPheProLeuLeuValIleGlyGluLeuLeuGlyValAlaProValThrAsp 195
831 CCGCATGCGCGCGGAGCGCGTGTCAAGGACACTCGGCGCTCGCG 782
      |||.....:|||||:|||||:|||||:|||||:|||||:
195 roAlaMetAlaArgGluAlaValGlyValLeuAlaLeuGlyLeuGly 211
781 GCGCCGACAGCGCGGGGTGACGCGACGAGCCCTGCGGCGGCTGCG 732
      |||.....:|||||:|||||:|||||:|||||:|||||:
212 GlyProGlnSerAlaGlyGlyAspGlyThrAspProAlaGlyAspAla 228
731 GGACACCTGCGCGCTGAGAGCTGTCTCTGAGCGGTGACCTGAGCC 682
      |||.....:|||||:|||||:|||||:|||||:|||||:
228 oAspThrSerAlaLeuGluSerLeuLeuGluAlaValAlaAlaAla 245
681 GCGGAGACGACACCGCGACCATGACCGCGCTGCTGACGAGCGCGG 632
      |||.....:|||||:|||||:|||||:|||||:|||||:
245 rGArgLysAspThrArgThrMetThrArgValLeuThrGluArgGluGln 261
631 GCGGAGTTCGCGCTGCTGCTGACGACAGCTGCTACATGATCAGCG 582
      |||.....:|||||:|||||:|||||:|||||:|||||:
262 AlaGluPheGlySerValSerAspAspGlnLeuValIleThrGln 278
581 GCTCATCTTCGCGCGGACGACGACACCGGCTCTCTGCGCTGCTGCG 532
      |||.....:|||||:|||||:|||||:|||||:|||||:
278 yLeuIlePheAlaGlyHisAspThrThrGlySerPheLeuGlyPheLeu 295
531 TCGCGAGGTCTGCGGCGCGCTGCGGCGGATGCGGAGGAGCGCGC 482
      |||.....:|||||:|||||:|||||:|||||:|||||:
295 euAlaGluValLeuAlaGlyArgLeuAlaAlaAspAlaAspGlyAspAla 311
481 GTCTCCGCTGCTGGAGGAGCGCTGCTGCTACACCGCGCGGCTGCG 432
      |||.....:|||||:|||||:|||||:|||||:|||||:
312 IleSerArgPheValGluGluAlaLeuArgHisProProValProTy 328
431 CAGCTTGTGAGGTTGCTGCTGCAAGGATGACCATGCGGCGCTCGCG 382
      |||.....:|||||:|||||:|||||:|||||:|||||:
328 rThrIleTrpArgPheAlaAlaThrGluValIleArgGlyValArgL 345
381 TCGCGCGGAGCGCGGCTGCTGCTGACATGAGGCGACACACCGAGC 332
      |||.....:|||||:|||||:|||||:|||||:|||||:
345 euProArgGlyAlaProValLeuValAspIleGluGlyThrAsnThrAsp 361
331 GCGCGCATCAGCAGCGCGCGGCTGCTGCTGCTGCTGCTGCTGCTG 282
      |||.....:|||||:|||||:|||||:|||||:|||||:
362 GlyArgHisHisAspAlaProHisAlaPheHisProAspArgProSer 378
378 gArgArgLeuThrPheGlyAspGlyProHisTyGlyIleGlyGluGln 395
231 TCGCCAGCTGAGAGTGGCGGACGATGTCGGCTACTGCGCAGCAGTTC 182
      |||.....:|||||:|||||:|||||:|||||:|||||:
395 euAlaGlnLeuGlnSerArgThrMetIleGlyValLeuAlaGlySerArgPhe 411
181 CCGGAGCGCGGCTGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 132
      |||.....:|||||:|||||:|||||:|||||:|||||:
412 ProGlnAlaArgLeuAlaValProTyGluGluLeuArgTrpCysArgL 428
131 GGGGGCCGACGAGCGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTG 86
      |||.....:|||||:|||||:|||||:|||||:|||||:
428 sGlyAlaGlnThrAlaArgLeuThrAspLeuProValTrpLeuArg 443
```

seq\_name: /cgn2\_6/plodata/1/laa/5B\_COMB.pep:US-09-096-982-8

seq\_documentation\_block:  
Sequence 8, Application US/09096982  
Patent No. 5962293  
GENERAL INFORMATION:  
APPLICANT: Strohl, William R.  
APPLICANT: Dickens, Michael L.  
APPLICANT: Desanti, Charles L.  
TITLE OF INVENTION: METHOD OF PRODUCING DOXORUBICIN

NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CALFEF, HALTER & GRISWOLD  
STREET: 800 Superior Avenue, Suite 1400  
CITY: Cleveland  
STATE: Ohio  
COUNTRY: USA  
ZIP: 44114-2688  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/096,982  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Golrick, Mary E.  
REGISTRATION NUMBER: 34829  
REFERENCE/DOCKET NUMBER: 22727/00131  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 216-622-8458  
TELEFAX: 216-241-0816  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 474 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-09-096-982-8

alignment\_scores:  
Quality: 2093.50 Length: 432  
Ratio: 4.973 Gaps: 1  
Percent Similarity: 97.454 Percent Identity: 93.056

alignment\_block:  
US-09-673-254-1/rev x US-09-096-982-8

Align seg 1/1 to: US-09-096-982-8 from: 1 to: 474

1378 GTACCCCGCGCGCGCGCG...TGCCCTGTGAGCGGCGAGCGCCCG 1332  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
43 ValProtyrclYasnserGluglYcysLeumetserlYgluAlaProAr 59  
1331 GGTGGCCGTGACCGCTTGCCTGCCATGATGACCATGCGGCGAAGC 1282  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
59 gValAlaValaAspProPheSerCysPrometMetThrMetGlnArgLysP 76  
1281 CCGAGGTGACGACGCGCTTCGCGGAGGCGCGCGGTGTCGAGGTGAAC 1232  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
76 roclYuaIhIsAspAlaPheArGluAlaGlyProValYalGluValaAsn 92  
1231 GCCCGCGGCGGCGACCGCGCTGATCATCACGATGACCGCTCGCCG 1182  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
93 AlaProAlaGlylYroAlaTrValIleThrAspAspAlaLeuAlaAr 109  
1181 CGAGGTGTCGCGCATCCCGGTTCTGGAAGGACCGCGACCTGCGCCCG 1132  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
109 ggluValleuAlaAspProArGheValIYsgLYProAspLeuAlaProT 126  
1131 CCGCGTGGCGGGGTGAGCAGCGGTCTGACATCCCGCTTCGCGAGCTG 1082  
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
126 hrAlaTrpArgglYValaAspAspGlyLeuAspIleProValIProGluLeu 142  
1081 CGTCCGTACGCTCATCGCGGTGAGCGGAGCGGACCGCGGCGCTGCG 1032  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
143 ArgProPheThrLeuIleAlaValaAspGlyGluAspHisArgArgLeuAr 159  
1031 CCGCATTCACGACGCTGCTTCAACCGCGCGCGCTGCGGAGCGGAGCG 982  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

159 gArgIleHIsAlaProAlaPheAsnProArGArgLeuAlaGluArgThra 176  
981 ATCCGATCCGCCGATGCGCGCGCGCTGCTCACCGAATCGCGGAGCC 932  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
176 sPArgIleAlaAlaIleAlaAspArgLeuThrGluLeuAlaAspSer 192  
931 TCGCGCGGTGCGCAACCGCGCGAGCTGTCGGCGGCTTCGCGTACA 882  
||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
193 SerAspArgSerGlygluProAlaGluLeuIleGlylYrheAlaTrhI 209  
881 CTTCGCGCTGTGGTCATCTGCGAGCTGCTGCGGTGCGCGTACCGATC 832  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
209 sPheProLeuLeuValIleCysGluLeuGlyYValIProValTrhAsp 226  
831 CGCGGATGCGCGCGGAGCGCTGACGCTTCAAGCGACCTGCGCTGCG 782  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
226 roAlaMetAlaArgGluAlaValGlyValLeuYsaIaLeuGlyLeuGly 242  
781 GCGCGGAGAGCGCGGGGTGAGCGGAGCGGACCGCTCGGCGGCGTGC 732  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
243 GlyProGlnSerAlaGlyglYAspGlylYrAspProAlaGlyAspValTr 259  
731 GACACCTCGCGCTGAGAGCTGCTGCGAAGCGCGTGCATCAGCC 682  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
259 oAspThrSerAlaLeuGluIserLeuLeuGluAlaValhIsAlaAla 276  
681 GCGGAGACGACCGCGCGACCATGACCGCGCTGTCAGGCGCGCGAG 632  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
276 rGArgLYsAspTrhArgThrMetThrArgValLeuYrGluArgAlaGln 292  
631 GCGGAGTTCGCTGCTGTCGAGACGACCATGCTGTATGATCATCAGCG 582  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
293 AlaGluPheGlySerValSerAspAspGlnLeuValYrMetIleThrGln 309  
581 GCTCATCTTGGCGCGCGCACAGACACCGCGCTCTTCCGCGCTCTGCG 532  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
309 YleuIlePheAlaGlyhIsAspTrhTrhGlySerPheLeuGlylYrheLeu 326  
531 TCGGAGAGTCTGCGCGCGCGCTGCGGCGGTGTCGCGAGGAGGAGCC 482  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
326 euAlaGluValleuAlaGlyArgLeuAlaAlaAspAlaAspGlyAspAla 342  
481 GTCTCCCGTTCGTGAGGAGCGCGCTGCTACACCGCGCGGTGCGCTTA 432  
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
343 IleSerArgPheValGluGluAlaLeuArgHIsIserProValIProTY 359  
431 CACGTTGTGAGCTGCTGCTGCGAGGAGGTGACCATGCGCGCGCTCGCG 382  
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
359 rSerLeuTrpArgPheAlaAlaTrhGluValIleArgGlyYValArgL 376  
381 TCGCGCGGAGCGCGGTGTCGTCGATGCGAGGCGGACGACACCGAG 332  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
376 euProArGlyAlaIProValleuValAspIleGluGlyTrhAspTrhAsp 392  
331 GCGCGCATCAGACGCGCGCGCAAGCTTCCACCGCGAGCGCTCTGTG 282  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
393 GlYArgHIsAspAlaProhIsAlaPhehIsIProAspTrhProSerAr 409  
281 GCGCGGCTACCTTGGCGGAGCGCGCGCTACCTGATGCGGAGGAGAGC 232  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
409 gArgArgLeuThrPheGlyAspGlyProhIsIYrCysIleGlyGluGln 426  
231 TCGCGGAGTGTGAGCGGAGCATGTCGCGTACGCGTACGCGAGCTTC 182  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
426 euAlaGlnLeuGluSerArgTrhMetIleGlyYalLeuAlYgSerArgPhe 442  
181 CCGGAGCGCGAGTGGCGCTGCGGTACGAGAGATGGGTGCGCGGAA 132  
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
443 ProGlnAlaArgLeuAlaValIProTYrGluGluLeuArgTrpYsArgLY 459  
131 GGGGCGCGACGCGCGGCTGACCGAATGCGCGCTGCTGCTGCGCG 86  
||||| |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
459 sGlyAlaGlnTrhAlaTrhLeuThrAspLeuProValITrPLeuArg 474

seq\_name: /cgn2\_6/ptodata/1/1aa/5B\_COMB.dep:US-08-653-650A-8  
seq\_documentation\_block:  
Sequence 8, Application US/08653650A  
Patent No. 5976830  
GENERAL INFORMATION:  
APPLICANT: Strohl, William R.  
APPLICANT: Dickens, Michael L.  
APPLICANT: Desanti, Charles L.  
TITLE OF INVENTION: METHOD OF PRODUCING DOXORUBICIN  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: CALFEE, HALTER & GRISWOLD  
STREET: 800 Superior Avenue, Suite 1400  
CITY: Cleveland  
STATE: Ohio  
COUNTRY: USA  
ZIP: 44114-2688  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/653,650A  
FILING DATE:  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Goltick, Mary E.  
REGISTRATION NUMBER: 34829  
REFERENCE/DOCKET NUMBER: 22727/00131  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 216-622-8458  
TELEFAX: 216-241-0816  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 474 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-653-650A-8  
alignment\_scores:  
Quality: 2093.50 Length: 432  
Ratio: 4.973 Gaps: 1  
Percent Similarity: 97.454 Percent Identity: 93.036  
alignment\_block:  
US-09-673-254-1/rev x US-08-653-650A-8 ..  
Align seg 1/1 to: US-08-653-650A-8 from: 1 to: 474  
1378 GACCCCGGGGGGGGGGGGG...TGCCCTGAGAGCGGAGCGCCCG 1332  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
43 ValProTyrGlyAsnSerGluGlyCysLeuMetSerGlyGluAlaPro 59  
1331 GGTGGCGCGCGACCGGTGCGTGCCTGATGACCATGACGCGCAAC 1282  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
59 gValAlaValAlaProPheSerCysProMetMetGlnArgLysP 76  
1281 CGAGGTGACAGCGCTCCGGAGGCGGCGCGCGGTGCGAGGTGAC 1232  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
76 roGluValHisAspAlaPheArgGluAlaGlyProValValGluValAsn 92  
1231 GCCCGCGGGGGGAGCCGCTGCGTCATACCGATGACGCGCGCGCG 1182  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
93 AlaProAlaGlyGlyProAlaTrpValIleThrAspAlaLeuAla 109  
1181 CGAGGTGCGCGCATCCCGGTGCGTGAAGACCCGACCTGCGCGCG 1132  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
109 gGluValLeuAlaAspProArgPheValLysGlyProAspLeuAlaPro 126

1131 CGCCCTGGCGGGGGGTGGAGCAGCGTCTGCATATCCCGTCCGAGCTG 1082  
:::|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
126 hrAlaTrpArgGlyValAlaAspArgLysPheValProValProGluLeu 142  
1081 CGTCCGTTACGCTCATCCGCGTGAGCGGAGGCCACCGCGCGCTGCG 1032  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
143 ArgProPheThrLeuIleAlaValAlaAspGlyGluAspHisArgArgLeu 159  
1031 CGCGATCCACGACCTGCGTTCACCGCGCGCGCGCGCGCGAGCGAG 982  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
159 gArgIleHisAlaProAlaPheAsnProArgArgLeuAlaGluArgThr 176  
981 ATCGCATCCCGCGATCCGCGCGCGCTGTCACCGCACTCCGCGCGCG 932  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
176 spArgIleAlaAlaIleAlaAspArgLeuThrGluLeuAlaAspSer 192  
931 TCCGGCGGTGCGGCAACCGCGCGAGCTGATCGCGGCTGCGTACCA 882  
||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
193 SerAspArgSerGlyGluProAlaGluLeuIleGlyGlyPheAlaTrp 209  
881 CTTCGCGCTGTTGTCATCTGCGAGCTGCTGCGTGGCGGTCCAGCATC 832  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
209 spPheProLeuLeuValIleCysGluLeuLeuGlyValProValThrAsp 226  
831 CGCGCATGCGCGCGCGAGCGCTCAGCGCTCAGGCACTCGCGCGCG 782  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
226 roAlaMetAlaArgGluAlaValGlyValLeuLysAlaLeuGlyLeuGly 242  
781 GCGCGCGAGCGCGCGGGGTGACGCGCACGACCTGCGGGGCGCTGCC 732  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
243 GlyProGlnSerAlaGlyLysArgLysPheThrAspProAlaGlyAspVal 259  
731 GACACCTGCGCGCTGGAAGCTGCTCTCAAGCGCTGCACTAGGCC 682  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
259 oAspTrpSerAlaLeuGlnSerLeuLeuGluAlaValHisAlaAla 276  
681 GCGGAGACGACACCGCGACCATGACCGCGCTGACGAGCGCGCGAG 632  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
276 rGArgLysAspThrArgTrpMetThrArgValLeuTrpGluArgAlaGln 292  
631 GCGGAGTTCGCTGCTCCGACGACGACGCTGCTACATGATCACCG 582  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
293 AlaGluPheGlySerValSerAspAspGlnLeuValTyrMetIleThr 309  
581 GCTCATCTTCCGCGCGCACGACACGCGCTCTTCTGCGCTTCTGCT 532  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
309 yLeuIlePheAlaGlyHisAspThrThrGlySerPheLeuGlyPheLeu 326  
531 TCGCGAGGTCTCGCGCGCGCTGCGCGGAGATGCGAGGAGGAGCG 482  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
326 euAlaGluValLeuAlaGlyArgLeuAlaAlaAspAlaAspLysPheAla 342  
481 GTCTCCCGTTCTGAGAGGCGCTGCGTACCAACCGCGGTGCGCTA 432  
:::|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
343 IleSerArgPheValGluGluAlaLeuAlaGlnHisProProValPro 359  
431 CACGTTGTGAGGTTGCTGCCAGGAGGTGACCATGCGGCGCTGCGCG 382  
|||:|||||: |||:|||||: |||:|||||: |||:|||||: |||:|||||  
359 rSerLeuTrpArgPheAlaAlaThrGluValIleArgGlyValArgL 376  
381 TCGCGCGGAGCGCGCGGTGCGTGGAGATGAGGAGGACCAACCGAG 332  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
376 euProArgGlyAlaProValLeuValAspIleGluGlyThrAsnThrAsp 392  
331 GCGCGCATCAGAGCGCGCGACGCTTCCACCGGAGACCTGCGTGG 282  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
393 GlyArgHisHisAspAlaProHisAlaPheHisProAspArgProSer 409  
281 GCGGCGGCTCACCTTGGGAGCGGCGCGCATGTCATGCGGAGGAGAC 232  
||||| |||:|||||: |||:|||||:|||||:|||||:|||||:|||||  
409 gArgArgLeuThrPheGlyAspGlyProHisTyrCysIleGlyGluGln 426

231 TCAGCCAGCTGGAGTCGCGCAGATGATGCGGTACTGCGCAGCAGGTTTC 182  
|||||  
426 euAlaGluMetGlnSerArgThrMetIleGlyValLeuArgSerArgpHe 442  
181 CCGGAGCCCGCAGCTGCGCGGTACGACGAGATTGCGGTGTCGCCGAA 132  
|||||  
443 ProGlnAlaArgLeuAlaValProTyrGluGluLeuArgTPrCysArgly 459  
131 GGGGGCCCGCAGCGCGGCTCAGCAGAACTGCCGCTGGCTGGCGC 86  
|||||  
459 scIlyAlaGlnThrAlaArgLeuThrAspLeuProValTPrLeuArg 474

seq\_name: /cgn2\_6/ptodata/1/iaa/5B\_COMB.pep:us-09-096-982-5

seq\_documentation\_block:

Sequence 5, Application US/09096982

Patent No. 5962293

GENERAL INFORMATION:

APPLICANT: Strohl, William R.

APPLICANT: Dickens, Michael L.

APPLICANT: Desanti, Charles L.

TITLE OF INVENTION: METHOD OF PRODUCING DOXORUBICIN

NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESS:

ADDRESSEE: CALFEY, HALTER & GRISWOLD

STREET: 800 Superior Avenue, Suite 1400

CITY: Cleveland

STATE: Ohio

COUNTRY: USA

ZIP: 44114-2688

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentln Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/096,982

FILING DATE:

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Goltick, Mary E.

REGISTRATION NUMBER: 34829

REFERENCE/DOCKET NUMBER: 22727/00131

TELECOMMUNICATION INFORMATION:

TELEPHONE: 216-622-8458

TELEFAX: 216-241-0816

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 422 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

-096-982-5

alignment\_scores:

Quality: 2076.00

Ratio: 5.027

Percent Similarity: 97.867

Percent Identity: 94.076

Length: 422

Gaps: 0

Align seg 1/1 to: US-09-096-982-5 from: 1 to: 422

1351 GTGAGCGCGAGCGCGCGGTGCGCGTGCAGCCGTCGCTGCCAT 1302

1 MetSerGlyGluAlaProArgValAlaValAspProPheSerCysProHe 17

1301 GATGACATGACGAGCGAGCGCGGTGCGCGTGCAGCGCTTCGCGAGGCGG 1252

17 tMetThrMetGlnArgLysProGluValHisAspAlaPheArgGluAlaG 34

1251 GCCCGGTGTCGAGGTGAACGCCCCCGGGGCGAGCCCGCTGGGTCAATC 1202  
|||||  
34 lProValValGluValAlaHisAlaProAlaGlyGlyProAlaTPrValIle 50  
1201 ACCGATGAGCCCTCGCCCGCGAGGTGCTGGCGATCCCGGCTGTGAA 1152  
|||||  
51 ThrAspAspAlaLeuAlaArgGluValLeuAlaAspProArgPheVally 67  
1151 GGACCCCGACCTCGCCCGCGCGCTGGCGGTGCGAGCGAGCGGTTCG 1102  
|||||  
67 scIlyProAspLeuAlaProThrAlaTPrArgGlyValAspAspGlyLeuA 84

1101 ACATCCCGCTTCGAGAGCTGCTCCGCTTCACGCTATCGCTGAGCGAGC 1052

84 sPlleProValProGluLeuArgProPheThrLeuIleAlaValAspGly 100

1051 GAGGCCACCGCGCGCTGCGCGCATCCAGCAGCACTGCGTTAACCCGCG 1002

101 GluAspHisArgArgLeuArgIleHisAlaProAlaPheAspProAr 117

1001 CGGGGTGGCGGCGAGCGAGATCGCATCGCGCGATCGCGCGCGCTGC 952

117 gArgLeuAlaGlnArgThrAspArgIleAlaAlaIleAlaAspArgLeu 134

951 TCACGGAATCGCGCAGCGCTCCGCGCGGTGCGGCAACCGCGCAGCTG 902

134 euThrGluLeuAlaAspSerSerAspArgSerGlyGluProAlaGluLeu 150

901 ATCGGCGGCTTGGGTGACCACTTCCGCTGTGTCATCTGCGAGCTGCT 852

151 lIleGlyGlyPheAlaTyrHisPheProLeuLeuValIleCysGluLeu 167

851 CGGTGCGCGGTGTCACGATCCGCGATGCGCGCGCGCAGCGCGCTGC 802

167 uGlyValProValThrAspProAlaMetAlaArgGluAlaValGlyVal 184

801 TCAAGGCACTCGGCTCGGCGCGCGCAGAGCGCGGGGTGAGCGCAGC 752

184 euLysAlaLeuGlyLeuGlyGlyProGlnSerAlaGlyGlyAspGlyThr 200

751 GACCTGCGCGGGGCGGTGCGGACACTCGCGCGCTGGAGCGCTGCTCT 702

201 AspProAlaGlyAspValProAspThrSerAlaLeuGluSerLeuLeu 217

701 CCAAGCGGTGACACTGAGCGCGCGGAGCAGCAGCCCGCATGACCGCG 652

217 uGluAlaValHisAlaAlaArgArgLysAspThrArgThrMetThrArg 234

651 TGCTGTACGAGCGCGCGCAGCGCGAGTTGCGTGGCTTCGACGACGAG 602

234 allLeuTyrGluArgAlaGlnAlaGluPheGlySerValSerAspAspGln 250

601 CTCGCTTACATGATGACCGCGGCTCATCTCGCGCGCGCGCAGCAGCG 552

251 LeuValTyrMetIleThrGlyLeuIlePheAlaGlyHisAspThrThr 267

551 CTCCTTCCTGAGGCTTCCTGCTCGCGGAGGTCTTGCGGCGCGCGCTCG 502

267 ySerPheLeuGlyPheLeuLeuAlaGluValLeuAlaGlyArgLeuAla 284

501 CGGATGCGCAGCAGGAGCGCGTCTCCGCGGTGCGGAGGAGCGCTGCGC 452

284 lAspAlaAspGlyAspAlaIleSerArgPheValGluValAlaLeuArg 300

451 TACACCGCGCGGTGCGCTTACACGTTGTCGAGTTCGTCACGAGAGGT 402

301 HisHisProProValProTyrSerLeuTyrPargPheAlaIleThrGluVal 317

401 GACCATGCGCGGCTTCGCGCTCCCGCGCGAGCGCGCTGTGTGAGACA 352

317 lValIleArgGlyValArgLeuProArgGlyAlaProValLeuValAspI 334

351 TCAGGGGACCAACACCGAGCGCGCATTCACGAGCGCGCGCAGCGCTTC 302

```
|||||
334 1e6lUGlYThraSnThraSpGIYArgHISHisAlaProHISAlaPhe 350
301 CACCCGGAGACGCCCTCGTGGGGGGCTCACCTTGGGGAGCGGCCGA 252
351 HIsProAspArgProSerArgArgLeuThrPheGlyAspGIYProH 367
251 CTACTGCATCGGGAGACAGCTGCCAGCTGGAGTCGCGCACGATGTCG 202
367 sTYrCysIlEGlYGlUGlInLeuAlaGlInLeuGIuSerArgThrMetIlEG 384
201 GCGTACTGCGGACAGAGTTCCCGAGAGCCGACTGGCGCTGCCGTACGAC 152
384 lYAlLeuArgSerArgPheProGlnAlaArgLeuAlaValProTYrGlu 400
151 GAGTTCGGTGGTGCCGGAAGGGGGCCAGAGCGCGCGCTCACCGAACT 102
401 GluLeuArgTYrPCysArgLysGIYAlaGlnThrAlaArgLeuThraSpLe 417
101 GCCCGTCTGGTGGCGC 86
417 uProValTrPLeuArg 422
```





## SUMMARIES

REFERENCE AUTHORS TITLE	JOURNAL MEDLINE
1 (bases 3983 to 6985) Scotti, C. and Hutchinson, C.R. <b>Enhanced</b> antibiotic production by manipulation of the Streptomyces pencellus dmr and dmmr genes involved in doxorubicin (adriamycin) biosynthesis	<u>J. Bacteriol. 178 (24), 7316-7321 (1996)</u> 97113559

REFERENCE 2 (bases 1 to 6985)  
 Lomovskaya, N., Otten, S. L., Doi-Katayama, Y., Fonstein, L., Liu, X.-C., Takatsu, T., Inventi, A., Filippi, S., Torti, F., Colombo, A. L. and Hutchinson, C. R.  
 Doxorubicin overproduction in Streptomyces peuceletii: cloning and characterization of the *dnru* ketoreductase and *dnrv* genes and the *doxa* cytochrome P-450 hydroxylase gene  
 J. Bacteriol. 181 (1), 305-318 (1999)

JOURNAL 3 (bases 3893 to 6985)  
 MEDLINE Scotti, C. and Hutchinson, C. R.  
 AUTHORS Direct Submission  
 TITLE Submitted (12-NOV-1996) School of Pharmacy, University of Wisconsin, 425 N. Charter St., Madison, WI 53706, USA  
 JOURNAL 4 (bases 1 to 6985)  
 Lomovskaya, N., Otten, S. L., Doi-Katayama, Y., Fonstein, L., Liu, X.-C., Takatsu, T., Inventi, A., Filippi, S., Torti, F., Colombo, A. L. and Hutchinson, C. R.  
 TITLE Direct Submission  
 JOURNAL Submitted (21-OCT-1998) School of Pharmacy, University of Wisconsin, 425 N. Charter St., Madison, WI 53706, USA  
 MARK Sequence update by submitter  
 ENT On Oct 22, 1998 this sequence version replaced gi:1684919.  
 FEATURES Location/Qualifiers  
 source 1..6985  
 /organism="Streptomyces peuceletii"  
 /strain="ATCC 29050"  
 /db\_xref="ATCC:29050"  
 /db\_xref="taxon:1950"  
 complement(83..1330)  
 /gene="doxa"  
 complement(183..1330)  
 /gene="CYP450 hydroxylase"  
 /note="CYP450 hydroxylase"  
 /codon\_start=1  
 /transl\_table=11  
 /product="daunorubicin C-14 hydroxylase"  
 /protein\_id="AAD04715.1"  
 /db\_xref="GI:3778995"  
 /translation="MAVDPFACPMPTMQRREVDAREAGPVEVNAAPGPAWITDIALREVLADPREVDLPDLPAPMAGVDGLDIPPELREFTLIAVDGEHRLRITHAPFNPRLAERIDRIATAGRLTELADASGSGKPAELIGFAHFLIYICELGVPYDPAMAREAVSVLKAIGGSGGSDGDPAGVDTLSLESLLEBNHSAKNDPPTMRVLYKERAQAFSGVSDQLVYMTTGLTFAGHDTGSLGLLEVLAVAGRIADADEAVSRVEALRHPPEVPTLMRFATEVTTIGVRLPGAPVLVDIEGNTDGRHDDAPAFHPRDRSMWRRLTFGDPGPHYCIQEIOLALSRMTIGVLRSEFPEARLAVYDELRLMKGAOTARLTETLPEVLR"  
 complement(1348..2175)  
 /gene="dnrv"  
 complement(1348..2175)  
 /gene="dnrv"  
 /codon\_start=1  
 /transl\_table=11  
 /product="doxorubicin biosynthesis enzyme Dnrv"  
 /protein\_id="AAD04716.1"  
 /db\_xref="GI:3778996"  
 /translation="MTRFAPGAPMWDLSGSPVDAASADFTYGLGWTATVSDPGAGYTFSSDGKLVAAVARRHIDTPYHRRPGNDQGMFAITVYFATDDDALTRKETAGEVINTPMDVYLGIMAVFADPAGAFVWRKGVMEAGVTVGSGVSEVLVTDGIGARAFYPAITGLADPTGLKGVTPVWHIGDIPVAGIQELGVTVGAVRPHMVLAVYHDCDATVRRVAVLGGSGSSEMRADTPRRRRADLLDPHGAGSVVELREGVYAAAGCAS"  
 complement(2279..3142)  
 /gene="dnru"  
 complement(2279..3142)  
 /gene="dnru"  
 /codon\_start=1  
 /transl\_table=11  
 /product="daunorubicin C-13 ketoreductase"  
 /protein\_id="AAD04717.1"  
 /db\_xref="GI:3778997"  
 /translation="MTASTPHGCTPRGGLSGRTVLVTGATSGIGRAALAVAROGARVVIAGDPERLRTVNEVARTAGAPADPAFDELROVRLGRLDRYPRIDVMSNVAGMFWSTRITTOGFEATITGVNHLAFLARLRLERLAGRLITSSDAYTQGRIDPD

gene  
 CDS  
 958 a 2535 c 2543 g 949 t

BASE COUNT  
 ORIGIN

DLNDRHRYSAAGAYCTSKOANIMTAARMRPDLVAVSHPEGRTTRIGCTVASSYFRNPFRISAAGKADITLVLASAPAEELTTGGTSDRRLSPVSGPTADAGLAALWEAGAAYVGTAAH"  
 complement(3139..3393)  
 /gene="qpsg"  
 complement(3139..3393)  
 /gene="qpsg"  
 /note="component of daunorubicin/doxorubicin polyketide synthase"  
 /codon\_start=1  
 /transl\_table=11  
 /product="daunorubicin acyl carrier protein"  
 /protein\_id="AAD04718.1"  
 /db\_xref="GI:3778998"  
 /translation="MAELSLKELREIMKOSIGEDVEDPLADADTVTEEDGLDSLAVLETVNHEKTYGVKLPDEELAEVRPHSMILFVNRRLRAA"  
 3493..4077  
 /gene="qpsH"  
 3493..4077  
 /gene="qpsH"  
 /codon\_start=1  
 /transl\_table=11  
 /product="daunorubicin biosynthesis enzyme"  
 /protein\_id="AAD04719.1"  
 /db\_xref="GI:3778999"  
 /translation="MDRRLSALPDARNRRLCTAPAGRRTRPGDORAAKHHTTQGYTM DALPDADPTESADCTDPGITYLDVQGFYAROMLDDGGREYDARTFADQGEVGG EAVGAGADIAARARTTDRPAEGITRRHMGITLVGKKPDEYARSYAVVLETPRDG 4129..5646  
 /gene="dnmt"  
 4129..5646  
 /gene="dnmt"  
 /note="catalyzes unknown step in biosynthesis of daunomycin, an intermediate of doxorubicin biosynthesis; deoxysugar biosynthesis enzyme"  
 /codon\_start=1  
 /transl\_table=11  
 /product="doxorubicin biosynthesis protein Dnmt"  
 /protein\_id="AAD04713.1"  
 /db\_xref="GI:1684920"  
 /translation="MTAOLARSVLARDGLSGNDREWMAADRSAAOVNHTERTPLDD LKMSRHPVTGTVSHHTGREFSIEGLDVHLPGAAPVPSQPIYVQPEPTLGEVYKER HGVLHCLVQAKFEPGNPGIGLQSPYVATRSNTRVYSGKAIPYLEHFRPTAEQVVA DIVQSEGSMEYFRKRNMTLVQYIDEVPLHEDFHWLITIGLHLLGYENTVNNDAITY LACLPRSEGAHPLADAPAGACGGGHHVYPARDPGCGRVDTCGRHSLVNNCAAY EGSLSHYDVLVSIADLRSTDTVYTRPALNLALPHMTERDGAIAHESGRLEVMADYV TASSREVPWSQPMIEPKDGVAAFLVRLIDGVLVHARVREGVVDVEIAPVOC TPQSLHALPEARERFLDAVLEAPPEVRVATVLAEGSGRFAVNTVMIVADHDID DGEYRWLTLLHQVLGRLRSHYVNVQARLVLACLSHSVSGPTRSAPVAPPRR"  
 5654..6985  
 /gene="dnrH"  
 5654..6985  
 /gene="dnrH"  
 /note="catalyzes formation of baumycins, C-4' glycosides of doxorubicin; putative glycosyl transferase; DnrH"  
 /codon\_start=1  
 /transl\_table=11  
 /product="putative baumycin biosynthesis protein"  
 /protein\_id="AAD04714.1"  
 /db\_xref="GI:1684921"  
 /translation="MRVLFAATMAARSHVYAQVTLASALRTAGHEVLVASOPVDLDIVY RAGLTAVRIGEDLNIEETREANASFEEDRNGLGLMNSNRDPPFMDHLAGMTMT AMVFNWVCEPWPVDLVLGARDRPLVYRDLVITAGPVAARLSGAARLILGPPOM GMRRTAFRLILDRQPELBDPLAEMLTWTLECCGSAGDSSEVLGQWITDTPPS MRLPDLPCVPARTVYPYNGSLPLGWLREPRPRRLCTLTGVSIGAEATGAGVAASD VLAAGDLDEVAVALPRELRELTGLPANNVRAVDVPPNALPSCSGIITHGSGCTF MTAIVHAIPLQIVPDMMDAMEKAHGLIARSGAGSYVDARVDSPELLREVLALDDPS YAAGARVAAEITGTPSPNDIYVLERLTAHRHAGACGGPALKSPSTGGA"



[illegible]

JOURNAL Submitted (08-MAR-1996) William R. Strohl, Ohio State University,  
484 West 12th Avenue, Columbus, OH 43210 USA

FEATURES Location/Qualifiers

source 1..3196  
/organism="Streptomyces sp."  
/strain="C5"  
/db\_xref="taxon:1931"

CDS 83..590  
function="unknown ketoreductase"  
/note="orf1"  
/codon\_start=1  
/transl\_table=1  
/protein\_id="AAB08047.1"  
/db\_xref="GI:1354267"  
translation="YPRIDVAGNAGMGFMSRTTQDGFETLLQVNHLAGFLARLLR  
ERLAGEGLITSSDAVYQGRIDPDLDNDRRHSAGAGYCSKQANITATFEARRRP  
DLVLSYHGEVGFRRICGTYASTYFRRNPFLRSAAKADITLVLLAAAPAEELITGGY  
YSDRLSPVSGCFITADGALAKLMEASAAAVDTAR"  
663..1501  
/gene="orf1a"  
/gene="orf1a"  
663..666  
/gene="orf1a"  
674..1501  
/gene="orf1a"  
function="unknown"  
/codon\_start=1  
/transl\_table=1  
/protein\_id="AAB08048.1"  
/db\_xref="GI:1354268"  
translation="MTSPAPGAPAMPDLGSPDVAASADFTYGLFGMTATVYSDPGAGG  
YTTSSDGKLYAAVAARHIDTPYHRTYGPFGMDQGMPIATVYFATNDADALIKRLET  
AGGVIMTPMDVLGKMAVFPADSGAFAVWRKGVMEGAEVTVPSGVGVELVTDD  
IGVARGYFRAVLGLAPADTGKRGVTDVPMHLDHPVAGTRBLGTVGAVRPMVAFLSV  
HDCATYRAVELGSGVSENEVDTPRGRRADLDLPHGAGFSVELREAYPAADGAS"  
1498..2766  
/gene="doxa"  
1498..2766  
/gene="doxa"  
/gene="doxa"  
function="hydroxylation of C-14 of daunomycin to produce  
doxorubicin"  
/codon\_start=1  
/transl\_table=1  
/evidence=experimental  
/product="daunomycin C-14 hydroxylase"  
/protein\_id="AAB08049.1"  
/db\_xref="GI:1354269"  
translation="MSEGAPRVAVDPSCPMHTWQRKPEVHDAREAGPYVEVNAAPAG  
GPAVITIDALAREVLADPRFKDPLAPAMRGVDDGLIPVELRPFLIAGDGD  
HRRIRIHPAFNFRRLAERTDRIALADRLTFLADSPSGEPALIGGFVHPL  
LVICELGVPVTPDPMAREAVGVKALGIGGPGSAGDGDPAAGDVPDTSALISLE  
AVNARRKQDTRMTRVLYKERRQAEFGVSDDQLYMTTGLIFAGHDPTGSFLGLVLA  
VLARLADADGDALISRFVEALRHPVPPTLMRFATEVIRGVLPKCAVPLVDI  
EGNVTDRHHDADPAHPDRPSRRRLTFGGPGHYCIGBOLAQESRTMIGVLRSPQ  
ARLAVPEELRWCKGGAQTARLTDLPVLMR"  
3038..3041  
/gene="dau1"  
3038..3196  
/gene="dau1"  
3050..>3196  
/gene="dau1"  
function="putative transcriptional activator"  
/codon\_start=1  
/transl\_table=1  
/product="dau1"  
/protein\_id="AAB08050.1"  
/db\_xref="GI:1354270"  
translation="MQINMLGPLYAHNHGTSVYPIAKKQPVESLLALQAGTVVPYPA  
LMEL"

BASE COUNT 476 a 1184 c 1079 g 457 t

ORIGIN

Query Match 89.5%; Score 2567.8; DB 1; Length 3196;

Best Local Similarity 94.1%; Pred. No. 9.5e-205;  
Matches 2697; Conservative 0; Mismatches 147; Indels 21; Gaps 2;

[illegible][illegible]

Matches	2681	Conservative	0	Mismatches	163	Indels	21	Gaps	2
QY	5	ccgcacacgggtatacagcgcaagcgagcccccacccgcgctgctgcggttggcggtcccgctg	64						
Db	2845	CCGCAACCGGGGACACCGGGCACCGGGACCGCCACCGCGCCGATGGGGCGGTGGCCCGCTG	2786						
QY	65	cc-ggtctgagcgacggcgagatcagcgagacgaacagggcaggttcggtggaacggcgagctt	123						
Db	2785	CCGGGTGCGGTCGGCCCATCAACGACGACAGCGGGGAGGTAGTGAAGCCGGCGGTGTCT	2726						
QY	124	gggaccccttcgcggagacacacgcgaactcgtctgtaagcgacggcagcttcggcctcgggga	183						
Db	2725	GGGGCCCCCTTCTTCGACACCACCGCAACTCTCTGATAGGCAAGGCAAGGCAAGTCGGGCTTGGGGGA	2666						
QY	184	aactctgagcgagtaagcccgatcatctgtctgcgactccacgctctgggacgagctgtctcccg	243						
Db	2665	ACCTGCTGGGCGAGTACGGCCGATATCTGTCGGGATTCGACATCGGGGAGACTGCTCTCCCGCA	2606						
QY	244	tgcagtagtgcggcccgctcgcgcaaggttaagccgcgcgacagaggaagcgctccggtga	303						
Db	2605	TGCAGTAGTGCGGCCCGCTGCGCGAAGGTAGGCGCGGCTTCGAAGGGCGGTTCGGGGTGA	2546						
QY	304	aagcgctgcggggcgctcgtgataaggcgcgctgggtatgttgcttcctcgtatgtccacagca	363						
Db	2545	AAGCGTGGCGGGCGTCTGTCATGCGGGCCCTCGGTGTTGGTGGCCCTTCGATGTCACCAAGTA	2486						
QY	364	ccggagctcgcggggcgacacggagccgcgcgatgttcaactccctcgttggagcgaaacttc	423						
Db	2485	CCGGGCTTCGGGGGGGAGCCGGACACCGCGGATGACACCTTCGTGGGACGCAACCTCC	2426						
QY	424	acacagctgtaagcgacccgagcggtgtgtaagcgagcgctcctccacgaacccgggaagcg	483						
Db	2425	ACAAAGAGTAGGGGACACCGCGGGGTGTGGCGAGCCCTCTCTTCACAAACCGGGAGATGG	2366						
QY	484	cgctctcgtcggacatcccgccgcgagcgggcccgccgaagactcccggaacaggaaccca	543						
Db	2365	CGTCCCGTGGCGGTTCGCGCGAGACGGCCCGCACGACCTCCGAAACAGGAACCCCA	2306						
QY	544	ggaaaggagccgggtgtgtgtgtcgttgcgcggcggaagatagaccccggtatcatgttgaacgagct	603						
Db	2305	GGAAAGAGCGGGGTGTGTGTGTGGCGGGCAAAATGATGTCGGGTGATCATGTAGACAGACT	2246						
QY	604	ggtctcggagaacccgaagccgaactcgtcctgcgcgcgtctacaaagcaagcggttatagg	663						
Db	2245	GGTCTCTGGAGACCCAGCCGAACCTGCTGTGCGGCTTCATAGACACCGCGGTATAGG	2186						
QY	664	tcgagggtgtcgtcttcgcgcgcgagcttgaagtgcaagcgctctcgaaggagcaagctctccagagcg	723						
Db	2185	TCCGGGTGTCCTTCCGCGCGGGCGCGGTGCAGGGCTTCGAGGAAGAAGGCTCTCCAGCGCCG	2126						
QY	724	agggtctcggacgcgcccccggaaggttcgctgtcaacccccgcgcgtctgcggggcgc	783						
Db	2125	ACGTTCTCGGGCACGTCGCCCGGACGGGTCCGTACCTCGTCACCGCGGCGGTCTGCGGGCCCG	2066						
QY	784	cgaagccgaagtctcttgaagaacgcttgaacgagctctgcgggacatctgcgcgagatcsgltaacg	843						
Db	2065	CGAGGCCGACGTCCCTTGAAGACACGCGAGCGGCTCGGGGCGCCATTGCGGGATGGGTGACCG	2006						
QY	844	gcaacacgaagcagctcgcgaatgataccaacagccgggaagtgtgtaagcgaaagccgcgata	903						
Db	2005	GCACCCCGACGAGCTTTCGAGATGACCAAGCGGGGAAAGTATACGGAAGCCGCCCATATCA	1946						
QY	904	gctcgagccggttttcgcgacacggcggaagcgctcggcgagttcgtgtgaacagccggcg	963						
Db	1945	GCTCGGCCGCTTCCGCCGACCGGTGGGAAGATCCGGCCAGTTCGGGTGAGACGCCGCTCCG	1886						
QY	964	cgatcgcgagcgatgcgatactcgcgtctcggccagccggcgcggtgttgaacgcaaggtcgt	1023						
Db	1885	CGATGCGGCGCATGCGATCCGTCCTCGCGGACGCGGCGGGATTGAACGCCGGTGGCGT	1826						
QY	1024	ggatgcgagcgcaagcgcggttggtgctcgcgttcaacggcgagatgagcgttgaacgagca	1083						
Db	1825	GGATCGGCGGACGAGCGCGGTGTCTTCAACCTGTCAACGGCGGATGAGCGTGAACGGGACGGA	1766						

QY 1084 gctccggaacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1143  
|||||  
Db 1765 gctccggaacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1706  
|||||  
QY 1144 cggggtctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1203  
|||||  
Db 1705 cggggtctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1646  
|||||  
QY 1204 tgacacgaaggcggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1263  
|||||  
Db 1645 tgacacgaaggcggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1586  
|||||  
QY 1264 aggcgtcgtcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1323  
|||||  
Db 1585 aggcgtcgtcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1526  
|||||  
QY 1324 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1383  
|||||  
Db 1525 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1466  
|||||  
QY 1384 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1443  
|||||  
Db 1465 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1406  
|||||  
QY 1444 cgtcggcgtcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1503  
|||||  
Db 1405 cgtcggcgtcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1346  
|||||  
QY 1504 cgtcggcgtcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1563  
|||||  
Db 1345 cgtcggcgtcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1286  
|||||  
QY 1564 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1623  
|||||  
Db 1285 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1226  
|||||  
QY 1624 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1683  
|||||  
Db 1225 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1166  
|||||  
QY 1684 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1743  
|||||  
Db 1165 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1106  
|||||  
QY 1744 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1803  
|||||  
Db 1105 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1046  
|||||  
QY 1804 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1863  
|||||  
Db 1045 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 986  
|||||  
QY 1864 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1923  
|||||  
Db 985 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 926  
|||||  
QY 1924 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1983  
|||||  
Db 925 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 866  
|||||  
QY 1984 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2043  
|||||  
Db 865 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 806  
|||||  
QY 2044 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2103  
|||||  
Db 805 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 746  
|||||  
QY 2104 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2163  
|||||  
Db 745 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 686  
|||||

QY 2164 gaacctgctcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2223  
|||||  
Db 685 gaacctgctcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 632  
|||||  
QY 2224 tgacacgaaggcggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2283  
|||||  
Db 633 tgacacgaaggcggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 586  
|||||  
QY 2284 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2343  
|||||  
Db 585 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 526  
|||||  
QY 2344 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2403  
|||||  
Db 525 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 466  
|||||  
QY 2404 actcctcgtcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2463  
|||||  
Db 465 actcctcgtcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 406  
|||||  
QY 2464 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2523  
|||||  
Db 405 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 346  
|||||  
QY 2524 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2583  
|||||  
Db 345 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 286  
|||||  
QY 2584 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2643  
|||||  
Db 285 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 226  
|||||  
QY 2644 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2703  
|||||  
Db 225 gacgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 166  
|||||  
QY 2704 tgacacgaaggcggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2763  
|||||  
Db 165 tgacacgaaggcggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 106  
|||||  
QY 2764 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2823  
|||||  
Db 105 cggcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 46  
|||||  
QY 2824 acatcgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 2888  
|||||  
Db 45 acatcgcgaacacgaggatgctcgaacacgaggatgctcgaacacgctcgcacaccccgcaaggcggcgaggat 1

RESULT 4  
AR083230/c 3196 bp DNA linear PAT 01-SEP-2000  
LOCUS AR083230 Sequence 4 from patent US 5976830.  
DEFINITION AR083230  
ACCESSION AR083230.1 GI:10010020  
VERSION AR083230.1  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 3196)  
AUTHORS Strohl,W.R., Dickens,M.L. and Desanti,C.L.  
TITLE Methods of producing doxorubicin  
JOURNAL Patent: US 5976830-A 4-02-NOV-1999;  
FEATURES  
source 1..3196  
BASE COUNT 475 a 1185 c 1076 g 460 t  
ORIGIN

Query Match 88.6%; Score 2542.2; DB 6; Length 3196;  
Best Local Similarity 93.6%; Pred. No. 1.3e-202;  
Matches 2681; Conservative 0; Mismatches 163; Indels 21; Gaps 2;



[illegible][illegible]



[illegible]

	source
	1..1932 /organism="Streptomyces peucetius subsp. caesiuss" /strain="ATCC 27952" /sub_species="caesiuss" /db_xref="ATCC:27952" /db_xref="taxon:55158" 591..1853 /gene="doxa" /gene="doxa" 591..1853 /gene="doxa" /note="cytochrome P-450 hydroxylase" /codon_start=1 /transl_table=11 /product="daunomycin C-14 hydroxylase" /protein_id="AAK95626.1" /db_xref="GI:1534142" /translation="MSGEAPRVAVADFPACPMNTMORKPEVHDAREAGPYVENAPAGGPAEITDALSRYVLADPRLVLPOLAPAMGGYNGLDIPVELRPFLIIVDGAHRLRHRIHARFNPRLAERTDRILAIAGNLTELADASSRSEPALIGFRAYHPFLVLICELGVPTVPMAKEAVSLAKALSAOSGGSDTDPAGVPTDSALESLLENAVHSARNDTPMTIRLYLXHTQAEFGSSVDNOLVMYIIIFAGHERNSFFGLIAEVLASRAADADEDADEVAEREVEAVRYHPVPYLIMREAATEEVIGVRLLPQPVALIDEGTNFGRRHDDAHAFHPPDRPSMRRLTFEDCGHYHCIGEQLALESRTMGVLSRPREARLAVPYDELDMCRNAOTARLTLEPVMLR"
BASE COUNT	250 a 714 c 690 g 278 t
ORIGIN	
Query Match	60.4%; Score 1732.4; DB 1; Length 1932;
Best Local Similarity	96.3%; Pred. No. 1,7e-135;
Matches 1872; Conservative	0; Mismatches 56; Indels 16; Gaps 9;
OY 1	ggatcgcaccggygtacagcgacagggagccgccacgcgcggtgctgcgttgcgttc 60
DB 1932	GGATCGGACCGGGGTACACGGCACGGGACGCCCAACCGCGGTGCCTCG---C 1876
OY 61	cgtgcggttcgcgcgcgcgcgcgatcaagcgcagcagaaggcagttcgttgacgcgcgcg 120
DB 1875	TGCGCTCCGGCCCCGGCGGGCATCAGCCACGACGGGCGAGTTCCGTTGACCGCGCCG 1816
OY 121	tcttggtcccccttcgcgcaccccgaactcgttgttaaggcaagtcagtctgggtctcg 180
DB 1815	TCTGGGCCCTTCGCGGCACACCGCAACTCTGCTTAGGGACGCGCCAGTGCGGCGCTCGG 1756
OY 181	ggaacctctgcgcagtagtcgcgatcatctcgctgcgcgaattcacgcctgggcctctcc 240
DB 1755	GGAACCTCTCTCGCGCATGCCGCATCATCTGTGCGCGACTCCAAGCTGGGCGAGCTCTCC 1656
OY 241	cgatgcagtagtgcgccgccttcgcgcgaagggtgaagcgcgcgcacagaaggaaagtcgcgt 300
DB 1695	CGATGCAGTAGTGCGGGCCGCTCGCGGAAGGTGAAGCCCGCCACGAGGAGCGTCCGGGT 1636
OY 301	ggaagcgctgcggggcgctcgttgatggcggtccgttcggttgttgacctcgatgtccacca 360
DB 1635	GGAAGCGCTGGGGGCGCGTGAATGGCGGCGCGCTGCTGTGGTGGCCCGATGTCCACACA 1576
OY 361	gcaaccggtctccgcggcgagccgcgaagccgcgcgaatgatacttccttgccagcagaacc 420
DB 1575	GCAACC GGCTCTCCGGGGGCGACCGGACGCGGCCCATGTACTCTCCGTGGCAGCGAACCC 1516
OY 421	tccacaacgtgtlaaggcaaccgcgcgcgtgtgttagcgaagcctctccaagaacccgggaga 480
DB 1515	TCCACAACGTGTAGGGGACCGGGGGGTGTGAAGCGACCGCTCTCTCCAGCAACGGGGAGA 1456
OY 481	cggtgcctctcgtagcatccgcgcgcgaagcgccgcgcagaactcgcgcagcagaagc 540
DB 1455	CGGCTCTCTCTCGCGCAATCCGCCGAGCGCCGCCCGCAGACCTCCGCGGACGAGAACG 1396
OY 541	ccaggaagaagccggttggctgctgcgcgcgcgaagatbaagccggtatcatctgtagaaga 600
DB 1395	CCAGGAAGAGACCGGCTCTCTCTGTGGCCGGGGAAGATATCTCCGGTATCTAGTAGACGA 1336
OY 601	gctgtgctgcgcgaaccgcgaactcgcgccttcgcgcgtctgtacagcagcgtgttca 660



```

QY 503 cgcgagcgccgcgcagagacctccgcgagcaggaagcccgaggaagcggtggtc 562
    |||
Db 849 CGGAGGCGCGCCGCGAGACCTCCGGAGACAGGAAGCCAGGAGCGGTGATGTC 790
QY 563 gtggcgcgagaaatgaagccggtatcatatgaagagctgtcgtcgaagacgagcc 622
    |||
Db 789 GTGGCGCGCGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 730
QY 623 gaactcgccgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg 682
    |||
Db 729 GAACCTGCGCGCTGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 670
QY 683 ggtctgagtgacagctctcgaagagcagctcctcgaagcgaggtgtcgtcgaagcc 742
    |||
    669 GGGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA 610
    743 ggcagaggtcctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg 802
    |||
    609 GGCAGGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCG 550
    |||
QY 803 aagcttgaagcagctcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 862
    |||
    549 AACGCTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 490
    |||
QY 863 gatgacaaacagcgaggtgagtgacgcaagcgagcgagctgagctgagctgagctg 922
    |||
    489 GATGACCAACAGCGGAGAGTACGCGAGAGCGCGCGATGAGCTGAGCTGAGCTGAG 430
    |||
QY 923 cgcgagcgagcgctgagcgagctgagcgagcgagcgagcgagcgagcgagcgagc 982
    |||
    429 CCGGCGGAGAGCGCTGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 370
    |||
QY 983 cgtcgcctgctgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgag 1042
    |||
    369 CGTCCGCTCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 310
    |||
QY 1043 gtggagcctcgcctcgcagcgagtgagcgagtgagcgagtgagcgagtgagcgag 1102
    |||
    309 GTGGGCTCGCGCTCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 250
    |||
QY 1103 gagaagcgtcgcagcccccgagcgagcgagcgagcgagcgagcgagcgagcgag 1162
    |||
    249 GAAACCGCTCTCCACCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 190
    |||
    1163 ggaatcgcgagagcctcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 1222
    |||
    189 GGGATCGCGCGAGACCTCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 130
    |||
    1223 cgcgagcgagctcgcagcgagcgagcgagcgagcgagcgagcgagcgagcgagcg 1282
    |||
    129 CGCGGGGCGCTTACCTCGAGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 70
    |||
QY 1283 ctggcgctgcatgtatcatatgaagcgagcgagcgagcgagcgagcgagcgagc 1342
    |||
    69 CTGGCGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 10
    |||
QY 1343 ggcgcgtcac 1351
    |||
    9 GCCGCTCAC 1
    |||
RESULT 7
LOCUS AR078148 2081 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 7 from patent US 5962293.
ACCESSION AR078148
VERSION AR078148.1 GI:10004894
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2081)

```

```

AUTHORS Strohl, W.R., Dickens, M.L. and Desautel, C.L.
TITLE Methods of producing doxorubicin
JOURNAL Patent: US 5962293-A / 05-OCT-1999
FEATURES
    source 1.2081
    /organism="unknown"
BASE COUNT 380 a 688 c 657 g 356 t
ORIGIN
Query Match 42.6%; Score 1221.6; DB 6; Length 2081;
Best Local Similarity 94.1%; Pred. No. 3.1e-93;
Matches 1280; Conservative 0; Mismatches 79; Indels 1; Gaps 1;
QY 5 cgcgagcggttaacgagcagagcgagcgagcgagcgagcgagcgagcgagcgagcgag 64
    |||
    1730 CCGCACCGGGCGACCGGACGAGGAGCGCCACCGCGGATGGCGGTGGCTCCGCTG 1671
    |||
QY 65 cc-gtgcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagc 123
    |||
    1670 CCGGTCGCGCGTGGCGCCATCAACGAGCGAGCGGCGAGCTGATGAGCGCGCTGCT 1611
    |||
QY 124 ggcgcctcctcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 183
    |||
    1610 GGGCGCCCTTCTGCAACCGACCGCACTCTGTAACGCGACGCGCGAGCTGGGGGA 1551
    |||
QY 184 acctgtgcagtgacgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgag 243
    |||
    1550 ACTGTGCGCACTGACCGCATCTGCTGCGCGATTCACCTGAGCGAGCTGCTCCCGA 1491
    |||
QY 244 ttgagtagtcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgag 303
    |||
    1490 TGCAGTAGTGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1431
    |||
QY 304 aagcggtgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcg 363
    |||
    1430 AAGCGTGGCGGGCGCTGATGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1371
    |||
QY 364 cgcgagcctcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 423
    |||
    1370 CCGGCGCTCGCGGGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG 1311
    |||
QY 424 acacgctgtaggcaacgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcg 483
    |||
    1310 ACAACGAGTAGGGGACCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1251
    |||
QY 484 cgtcctcgtcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 543
    |||
    1250 CGTCCCGCTGGCGCTCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1191
    |||
QY 544 ggaagagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcg 603
    |||
    1190 GGAACGAGCGCGGTGCTGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1131
    |||
QY 604 ggtcgtcgaagacgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagc 663
    |||
    1130 GGTGCTGAGAGACGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAGCG 1071
    |||
QY 664 tcgggtgtcgtcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 723
    |||
    1070 TCGGGGTGCTTTCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1011
    |||
QY 724 aggtgtcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 783
    |||
    1010 ACGTGTCCGCGACGCTCCCGCGAGGCTCCGCTGCGGTACCGCGCGCGCGCGCGCG 951
    |||
QY 784 cgaagcgagtgagcttgagagcgagcgagcgagcgagcgagcgagcgagcgagcgagc 843
    |||
    950 CGAGCGCGAGTGCCTTGAAGACGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 891
    |||
QY 844 gcaacacgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagcgagc 903
    |||
    890 GCAAGCGCGAGCGAGTGCAGATGACCAACAGCGGAGGTGTTACGCGGAAAGCGCGGATCA 831
    |||

```

[illegible]

Search completed: June 11, 2002, 20:01:13  
Job time: 7335 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 11, 2002, 17:59:13 ; Search time 308.46 Seconds

(without alignments)  
15974.663 Million cell updates/sec

Title: US-09-673-254-1

Perfect score: 2870  
1 ggcacgcagccggtacacg.....catcgatgcgcggtacacg 2870

Sequence: IDENTITY-NUC  
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries  
60096/27014=No. 4  
60096/27014=No. 4  
60096/27014=No. 4

Database : N\_Geneseq\_032802.\*

1: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.\*  
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.\*  
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.\*  
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.\*  
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.\*  
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.\*  
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.\*  
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.\*  
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.\*  
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.\*  
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.\*  
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.\*  
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.\*  
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.\*  
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.\*  
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.\*  
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.\*  
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.\*  
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.\*  
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.\*  
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.\*  
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.\*  
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.\*  
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2870	100.0	2870	AA231413	Complementary DNA
2	2558.2	89.1	3196	AAV01453	Streptomyces dauno
3	2342.2	88.6	3196	AAV01447	Daunomycin C-14 hy
4	1269	44.2	1269	AAV01451	DNA gene encoding
5	1224.8	42.7	3013	AAV01451	Plasmid pANT195 in
6	1221.6	42.6	2081	AAV01452	Modified doxa gene
7	1044.4	36.4	1569	AAV34001	DNA fragment conta
8	182	6.3	114955	AAV3401	Human adenosine Al
9	181.2	6.3	125401	AAV17186	Streptomyces nous

C 10	164.4	5.7	114955	20	AAV3491	Human adenosine Al
C 11	154.8	5.4	2919	21	AAZ24486	Streptomyces tende
C 12	152.6	5.3	12249	21	AAZ5840	Complete Mitomycin
C 13	152.6	5.3	18331	21	AAZ5857	Complete nucleotid
C 14	152.2	5.3	2918	21	AAZ43922	S. tendae nikomyc
C 15	142	4.9	65140	22	AAV17184	Streptomyces nous
C 16	139.8	4.9	1257	22	AAE81357	Quorum sensing con
C 17	138.6	4.8	1224	21	AAZ5788	Hydroxylase orf4.1
C 18	137.4	4.8	4257	19	AAV68520	The nucleotide seq
C 19	137.4	4.8	4257	19	AAV68520	Infected cell prot
C 20	137.4	4.8	5970	21	AAV75635	Nucleotide sequenc
C 21	137.4	4.8	5970	21	AAZ56003	Contig 002 from co
C 22	133.2	4.7	1251	21	AAZ87301	S. venezuelae macr
C 23	133.2	4.6	4496	17	AAZ58553	Streptomyces prist
C 24	132.6	4.6	12001	16	AAZ6213	HSV L/SF region.
C 25	130.6	4.6	44377	18	AAZ8508	Platenolide syntha
C 26	130.6	4.6	44377	18	AAZ80414	Sequence soyC and
C 27	128.6	4.5	1700	14	AAQ45569	Streptomyces grise
C 28	127.4	4.4	2795	22	AAV11296	Streptomyces grise
C 29	127.4	4.4	2795	22	AAV11296	Streptomyces grise
C 30	127.2	4.4	27541	22	AAV17185	Streptomyces nous
C 31	123.8	4.3	3957	22	AAV09686	HSV-2 immediate ea
C 32	123.8	4.3	154746	24	AAZ25519	Human herpesvirus
C 33	123.8	4.3	154746	24	AAZ25519	Human herpesvirus
C 34	122.2	4.3	109519	22	AAZ58553	Micromonospora DNA
C 35	122.2	4.3	58857	21	AAZ58471	Nucleotide sequenc
C 36	121.6	4.2	1194	17	AAZ58555	Streptomyces prist
C 37	120.8	4.2	14806	22	AAZ03809	Streptomyces galli
C 38	119	4.1	940	19	AAV63943	Mycobacterium tube
C 39	119	4.1	940	20	AAV63943	Nucleotide sequenc
C 40	117.6	4.1	24379	18	AAV3095	Streptomyces fireo
C 41	117.6	4.1	24379	19	AAV25925	Streptomyces roseo
C 42	117	4.1	50937	21	AAV09469	Streptococcus olea
C 43	115.6	4.0	8438	15	AAV73500	DNA encoding pseud
C 44	114.6	4.0	1998	12	AAQ11127	Sequence encoding
C 45	113.8	4.0	1879	12	AAQ11126	Sequence encoding

## ALIGNMENTS

RESULT 1	
AA231413	
ID AA231413 standard; DNA; 2870 BP.	
XX	
AC AA231413:	
XX	
DT 07-FEB-2000 (first entry)	
XX	
DE Complementary DNA consisting of doxa, dnrv and C-terminal dnrv genes.	
XX	
KW doxa gene: daunorubicin 14-hydroxylase; daunorubicin; doxorubicin;	
KW anticancer agent; dnrv gene; dnrv gene; complementary: ss.	
XX	
OS Streptomyces peucetius.	
XX	
PN NO9955829-A2	
XX	
PD 04-NOV-1999.	
XX	
PF 22-APR-1999; 99WO-US07016.	
XX	
PR 24-APR-1998; 98US-0065606.	
XX	
PA (PHAA) PHARMACIA & UPJOHN SPA.	
XX	
PI Solari A, Zanuso G, Filippini S, Torti F, Otten S, Colombo AL;	
PI Hutchinson CR;	
XX	
DR WPI: 2000-023353/02.	
XX	
PT New DNA containing the gene for daunorubicin-14-hydroxylase and genes	
PT for resistance to anthracyclines, used to prepare the anticancer agent	



[illegible]

21-MAY-1998 (first entry)

Streptomycetes daunomycin biosynthesis gene cluster.

Daunomycin C-14 hydroxylase; doxa gene; doxorubicin; daunomycin; 13-dihydrocarminomycin; carinomycin; anthracycline; anticancer; cytostatic; cancer; therapy; ds.

Streptomycetes sp. strain C5.

Key	Location/Qualifiers
CDS	9..590
FT	/*tag= a
FT	/note= "3' end of orf1 coding region"
FT	653..666
FT	/*tag= b
FT	674..1501
CDS	/*tag= c
FT	/product= daunomycin C-14 hydroxylase
FT	/note= "orf1"
FT	1498..2766
FT	/*tag= d
FT	/note= "doxa"
FT	3038..3041
RBS	/*tag= e
FT	3050..3196
CDS	/*tag= f
FT	/note= "5' end of daul coding region"

MO9744439-A2.

27-NOV-1997

22-MAY-1997: 97WO-US08690.

24-MAY-1996: SDUS-0653650

(OHIS ) UNIV OHIO STATE RES FOUND.

DeSanti, CT, Dickens ML, Strohl WA.

WPI: 1998-018495/02.

P-PSDB; AAW36128, AAW36130 AND AAW36133-34.

Producing doxorubicin from daunomycin by daunomycin C14 hydroxylase  
PT - also hydroxylation and oxidation of other anthracycline(s) with  
the same enzyme

Disclosure; Fig 3; 59pp; English.

This DNA sequence comprises a 3196 bp KpnI-SstI DNA fragment of Streptomycetes sp. strain C5 containing the doxa gene (see also AAW01447) that codes for daunomycin C-14 hydroxylase (see AAW36128) CC The DNA fragment also includes the 3' end of orf1 (see also CC AAW36133), the complete orf1a (see AAW36134) and the 5' end of daul (see 36130), a putative transcriptional activator. Daunomycin C-14 hydroxylase is an enzyme capable of converting daunomycin to the anticancer agent doxorubicin. Host cells, especially Streptomycetes host cells, transformed with plasmids that include the doxa gene can be used in methods for the production of doxorubicin from daunomycin or for the hydroxylation and oxidation of other anthracyclines.

Sequence 3196 BP; 475 A; 1182 C; 1078 G; 461 T; 0 other;

RESULT	2
AAV01453/c	
ID	AAV01453 standard; DNA: 3196 BP.
XX	
AC	AAV01453;

---

Qy	5	ccgcacccgggtacacagcaggagaccgccacccgcggtgtgcgcggttgagcggctcccgtg	64

		Quality Match	97.1%	Score 2230.2	DG 13	Length 3190
		Best Local Similarity	93.9%	Pred. No. 0;		
		Matches 2691;	Conservative	0;	Mismatches 153;	Indels 21;
					Gaps	2.



[illegible]

QY	1144	cgagtgcccttcacgaacccgggagtcgagccagaaacctcggggccggagggcgatcgtgta	1203
Db	1705	CGGGGCTCTTCAcGAACCCGGGATCGGGACAGACTCTGGGGCGAGGGGCTATCGGTGA	1646
QY	1204	tgaaccagaacgggtccggcccgaggggcgctaacctcagacgaacggccgctccgga	1263
Db	1645	TGACCCAGGCGGGTCCGGCCGGGGGGGCTTCACTCTGACAGACGGGGCGCTCTCGGA	1586
QY	1264	aggcgctctgtgaacctcgggcttgcgtcgtatgtcaatcattggagacgcgaaaggttga	1323
Db	1585	ATGCGGCTGTGCACTCTGGGTTTCGCTGATGTATCATATGGGAGACAGGAACGGGTGCA	1526
QY	1324	cggcaacccggaggcgctcgcgcgtcaagaggacaacggcccgcccgagggtataccctc	1383
Db	1525	CGGGCACCCGGGGCGCTCGCGGCTATATAGGACACCGTCCGCCGCCGGGTATGGCTTC	1466
QY	1384	ccgcagttcgaaccaaccagaagacggcccgctgtcgagttcgaacaggtccgcccgcgc	1443
Db	1465	CCGAGATTTCAGACACCGAGAAACCCAGCCCTGCGGGTGTACAGATCCGCCCGCCGCC	1406
QY	1444	ccctggagcgtgtgagggggctgtcttcgaacggagacggccggatctaaagcgcgcgac	1503
Db	1405	CCTGGGGGTGTGACAGGGCTCTTCTTCAGGGAGCGCCGGAATTGTAGCGGCCCGCGGAC	1346
QY	1504	cgtcgcgttcgcagtcgtgtgacagcgagcaacgaacggccagttgcgagcgtataccgcccgt	1563
Db	1345	CGTCCGCTGTGCGAGTGTGTGACAGGAACAGCAGCGCCAGTGTGGGGCCGTAACGCCCGGT	1286
QY	1564	gagcgcccgagctctctgtgtgtgacggcgagacgggtgtgtcaacgatatgtccagacgggtcgt	1623
Db	1285	CGTGCCTCAATTCCCGGGTCCCGGACACCGGGTGTGTATAGGAGTGTCAACACCGGGTCTGGT	1226
QY	1624	gacgcgccttcagctccggtgttcgcgcggagccagacggcgaggtgtcgcgggttagaagctccg	1683
Db	1225	GACGGCCTTGGCTCGGGTGTGTGGCCGGAGACAGGGCCAGGGTGTGACCGTATGAACACACG	1166
QY	1684	ggcgcccccgatgcgctgcgttcaacagctcgaaaccagaccgagaccgggacgacccgt	1743
Db	1165	GGCGGTCTCCGATGTGTGTGTATCACCAGTTTCCACCCAGCGACCGAGCGGGCACGCCGT	1106
QY	1744	caaccctcgcgcctcatatgaacctccttgcgcgaagaccgaaacggcgccggcgaggtc	1803
Db	1105	CACCTCCGGGCTCTCATATAGACGCCCTTTGGCCACACCCCGAAGCGGGCCCCGATGGGTCT	1046
QY	1804	ggcgaagaaccgcatcgcggcgacgagcgagagacgttcaatcgagatcagatgaacctcgc	1863
Db	1045	GCGGAAGACCGCCATCCGGCGAGACCGAGAGCGTTCATCGGGGCTCATGATGACGTGCC	986
QY	1864	ggccgcgcttcgaaccgcttgggttaagtgcgttcgggtcgttcggttgqcgaaagttacaagtt	1923
Db	985	ACCCGCCGCTCTGACCCCTTTGGTATGATGCGCGGCGTGTGGTGGGGGAATACAGT	926
QY	1924	ccaagaatgcgcgcattgcgcgttctgtcttccgcggcccgtaacggttgtaggggt	1983
Db	925	CCAGATGCGCGGCAATCCGCTGTGTCTTCCCGGGGCCCGTACAGGACGCTGTAGGGGCT	866
QY	1984	gtcgatctgtgtgagcgcgacccgagcgagacagcttcccgctcggagctgaacgtctgtla	2043
Db	865	GTCGATCTGATGGCGGGCGACCGGGGACCAAGCTTCCCTGCGGAGCTGAACGTCTGTGA	806
QY	2044	tcccgcgcgcgcgggtgtcgtcgaaccaagttgtagttccagccgcaacacggccgggtgtgaa	2103
Db	805	TCCCCCGGACCCGGGTGTGCTGATCAGCTGTGCGGTTCCAGCGGAAGACCGGGGTATGAA	746
QY	2104	gtcgcgcgaagcgagacatcggcgcaaacccagagttcgaacacatgcgggggagcccgagc	2163
Db	745	GTCGGCGGAGGCGGGAATCGGGGAGACCGAGGTGCAACATCGAGGGGGCCCGCGCGC	686
QY	2164	gaacctgttcaagaatcgtctccttcgatgtatcggcaacagaaagtcgtcgtcgcgcgga	2223
Db	685	GAACCTGTGTACAGATCGTCTCTTTCGACGAGATGGGACACAGACGCTCTGG-----	632



Chr	Start (kb)	End (kb)	Gene	Accession	Length (bp)	GC (%)	GC3 (%)	GC4 (%)	GC5 (%)	GC6 (%)	GC7 (%)	GC8 (%)	GC9 (%)	GC10 (%)	GC11 (%)	GC12 (%)	GC13 (%)	GC14 (%)	GC15 (%)	GC16 (%)	GC17 (%)	GC18 (%)	GC19 (%)	GC20 (%)	GC21 (%)	GC22 (%)	GC23 (%)	GC24 (%)	GC25 (%)	GC26 (%)	GC27 (%)	GC28 (%)	GC29 (%)	GC30 (%)	GC31 (%)	GC32 (%)	GC33 (%)	GC34 (%)	GC35 (%)	GC36 (%)	GC37 (%)	GC38 (%)	GC39 (%)	GC40 (%)	GC41 (%)	GC42 (%)	GC43 (%)	GC44 (%)	GC45 (%)	GC46 (%)	GC47 (%)	GC48 (%)	GC49 (%)	GC50 (%)	GC51 (%)	GC52 (%)	GC53 (%)	GC54 (%)	GC55 (%)	GC56 (%)	GC57 (%)	GC58 (%)	GC59 (%)	GC60 (%)	GC61 (%)	GC62 (%)	GC63 (%)	GC64 (%)	GC65 (%)	GC66 (%)	GC67 (%)	GC68 (%)	GC69 (%)	GC70 (%)	GC71 (%)	GC72 (%)	GC73 (%)	GC74 (%)	GC75 (%)	GC76 (%)	GC77 (%)	GC78 (%)	GC79 (%)	GC80 (%)	GC81 (%)	GC82 (%)	GC83 (%)	GC84 (%)	GC85 (%)	GC86 (%)	GC87 (%)	GC88 (%)	GC89 (%)	GC90 (%)	GC91 (%)	GC92 (%)	GC93 (%)	GC94 (%)	GC95 (%)	GC96 (%)	GC97 (%)	GC98 (%)	GC99 (%)	GC100 (%)	GC101 (%)	GC102 (%)	GC103 (%)	GC104 (%)	GC105 (%)	GC106 (%)	GC107 (%)	GC108 (%)	GC109 (%)	GC110 (%)	GC111 (%)	GC112 (%)	GC113 (%)	GC114 (%)	GC115 (%)	GC116 (%)	GC117 (%)	GC118 (%)	GC119 (%)	GC120 (%)	GC121 (%)	GC122 (%)	GC123 (%)	GC124 (%)	GC125 (%)	GC126 (%)	GC127 (%)	GC128 (%)	GC129 (%)	GC130 (%)	GC131 (%)	GC132 (%)	GC133 (%)	GC134 (%)	GC135 (%)	GC136 (%)	GC137 (%)	GC138 (%)	GC139 (%)	GC140 (%)	GC141 (%)	GC142 (%)	GC143 (%)	GC144 (%)	GC145 (%)	GC146 (%)	GC147 (%)	GC148 (%)	GC149 (%)	GC150 (%)	GC151 (%)	GC152 (%)	GC153 (%)	GC154 (%)	GC155 (%)	GC156 (%)	GC157 (%)	GC158 (%)	GC159 (%)	GC160 (%)	GC161 (%)	GC162 (%)	GC163 (%)	GC164 (%)	GC165 (%)	GC166 (%)	GC167 (%)	GC168 (%)	GC169 (%)	GC170 (%)	GC171 (%)	GC172 (%)	GC173 (%)	GC174 (%)	GC175 (%)	GC176 (%)	GC177 (%)	GC178 (%)	GC179 (%)	GC180 (%)	GC181 (%)	GC182 (%)	GC183 (%)	GC184 (%)	GC185 (%)	GC186 (%)	GC187 (%)	GC188 (%)	GC189 (%)	GC190 (%)	GC191 (%)	GC192 (%)	GC193 (%)	GC194 (%)	GC195 (%)	GC196 (%)	GC197 (%)	GC198 (%)	GC199 (%)	GC200 (%)	GC201 (%)	GC202 (%)	GC203 (%)	GC204 (%)	GC205 (%)	GC206 (%)	GC207 (%)	GC208 (%)	GC209 (%)	GC210 (%)	GC211 (%)	GC212 (%)	GC213 (%)	GC214 (%)	GC215 (%)	GC216 (%)	GC217 (%)	GC218 (%)	GC219 (%)	GC220 (%)	GC221 (%)	GC222 (%)	GC223 (%)	GC224 (%)	GC225 (%)	GC226 (%)	GC227 (%)	GC228 (%)	GC229 (%)	GC230 (%)	GC231 (%)	GC232 (%)	GC233 (%)	GC234 (%)	GC235 (%)	GC236 (%)	GC237 (%)	GC238 (%)	GC239 (%)	GC240 (%)	GC241 (%)	GC242 (%)	GC243 (%)	GC244 (%)	GC245 (%)	GC246 (%)	GC247 (%)	GC248 (%)	GC249 (%)	GC250 (%)	GC251 (%)	GC252 (%)	GC253 (%)	GC254 (%)	GC255 (%)	GC256 (%)	GC257 (%)	GC258 (%)	GC259 (%)	GC260 (%)	GC261 (%)	GC262 (%)	GC263 (%)	GC264 (%)	GC265 (%)	GC266 (%)	GC267 (%)	GC268 (%)	GC269 (%)	GC270 (%)	GC271 (%)	GC272 (%)	GC273 (%)	GC274 (%)	GC275 (%)	GC276 (%)	GC277 (%)	GC278 (%)	GC279 (%)	GC280 (%)	GC281 (%)	GC282 (%)	GC283 (%)	GC284 (%)	GC285 (%)	GC286 (%)	GC287 (%)	GC288 (%)	GC289 (%)	GC290 (%)	GC291 (%)	GC292 (%)	GC293 (%)	GC294 (%)	GC295 (%)	GC296 (%)	GC297 (%)	GC298 (%)	GC299 (%)	GC300 (%)	GC301 (%)	GC302 (%)	GC303 (%)	GC304 (%)	GC305 (%)	GC306 (%)	GC307 (%)	GC308 (%)	GC309 (%)	GC310 (%)	GC311 (%)	GC312 (%)	GC313 (%)	GC314 (%)	GC315 (%)	GC316 (%)	GC317 (%)	GC318 (%)	GC319 (%)	GC320 (%)	GC321 (%)	GC322 (%)	GC323 (%)	GC324 (%)	GC325 (%)	GC326 (%)	GC327 (%)	GC328 (%)	GC329 (%)	GC330 (%)	GC331 (%)	GC332 (%)	GC333 (%)	GC334 (%)	GC335 (%)	GC336 (%)	GC337 (%)	GC338 (%)	GC339 (%)	GC340 (%)	GC341 (%)	GC342 (%)	GC343 (%)	GC344 (%)	GC345 (%)	GC346 (%)	GC347 (%)	GC348 (%)	GC349 (%)	GC350 (%)	GC351 (%)	GC352 (%)	GC353 (%)	GC354 (%)	GC355 (%)	GC356 (%)	GC357 (%)	GC358 (%)	GC359 (%)	GC360 (%)	GC361 (%)	GC362 (%)	GC363 (%)	GC364 (%)	GC365 (%)	GC366 (%)	GC367 (%)	GC368 (%)	GC369 (%)	GC370 (%)	GC371 (%)	GC372 (%)	GC373 (%)	GC374 (%)	GC375 (%)	GC376 (%)	GC377 (%)	GC378 (%)	GC379 (%)	GC380 (%)	GC381 (%)	GC382 (%)	GC383 (%)	GC384 (%)	GC385 (%)	GC386 (%)	GC387 (%)	GC388 (%)	GC389 (%)	GC390 (%)	GC391 (%)	GC392 (%)	GC393 (%)	GC394 (%)	GC395 (%)	GC396 (%)	GC397 (%)	GC398 (%)	GC399 (%)	GC400 (%)	GC401 (%)	GC402 (%)	GC403 (%)	GC404 (%)	GC405 (%)	GC406 (%)	GC407 (%)	GC408 (%)	GC409 (%)	GC410 (%)	GC411 (%)	GC412 (%)	GC413 (%)	GC414 (%)	GC415 (%)	GC416 (%)</
-----	------------	----------	------	-----------	-------------	--------	---------	---------	---------	---------	---------	---------	---------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-------------

XX 24-MAY-1996: 3605-065365D  
XX (OHIS ) UNIV OHIO STATE RES FOUND.  
PA  
PI Desanti CL, Dickens ML, Strohl WA  
XX  
XX WPI: 1998-018495/02.  
DR P-PSDB; AAW36128.  
XX  
PT Producing doxorubicin from daunomycin by daunomycin C14 hydroxylase  
PT - also hydroxylation and oxidation of other anthracycline(s) with  
PT the same enzyme  
XX  
PS Claim 11, Page 30-33; 59pp: English.  
XX  
XX This DNA sequence comprises the doxa gene of Streptomyces sp.  
CC strain C5 that codes for daunomycin C-14 hydroxylase (DC14H)  
CC (see AAW36128), a P450-like enzyme useful for the production of  
CC doxorubicin from daunomycin, and for the hydroxylation and  
CC oxidation of other anthracyclines. The gene was identified by  
CC sequencing an approximately 8 kb fragment of the daunomycin  
CC biosynthesis gene cluster from C5 (see AAV01451). The gene has been  
CC incorporated into various vectors, including pANT7195 (see AAV01451)  
CC and pANT7199 (see AAV01452). Claimed methods for production of  
CC doxorubicin include: the use of a host microorganism transformed  
CC with a plasmid which contains the doxa gene; incubating a culture  
CC of Streptomyces sp. strain C5 with daunomycin; and incubating  
CC DC14H with daunomycin. The enzyme can also be used in claimed  
CC methods of producing 13-dihydrodoxorubicin and carminomycin  
CC from 13-deoxycarminomycin, and of producing 13-dihydrodaunomycin  
CC and daunomycin from 13-deoxydaunomycin. The methods preclude the  
CC use of halogens as required in the current chemical methods.  
XX  
XX Sequence 3196 BP; 475 A; 1185 C; 1076 G; 460 T; 0 other;  
XX

Query Match	Similarity	88.6%	Score 2542.2	DB 19	Length 3196
Best Local	Similarity	93.6%	Pred. No. 0		
Matches 2681	Conservative	0	Mismatches 163	Indels 21	Gaps 2
OY	5	ccgcacccgggtacacagcagcagcagcagccacccacccgcbgctgctgcggttggcgcgtccgctg	64		
Db	2845	CCGCACCGGGGACCGCGGACCGGACCGCCACCGCGCATGGGGCGGTCCCGT	2786		
OY	65	cc-ggtcgccgacccgagctcaagcgcagccagacccgagcagttcgattgaacgcgcgctt	123		
Db	2785	CCGGGTCCGGCGCGCCCATCAACGACACCAACGCGGAGGTCAATGAGCCCGCGTGTCT	2726		
OY	124	gggcccccttcgcggaacacacgcgaactcgttgtacgcaacgcgcagctcgagcctcgagg	183		
Db	2725	GGGCCCCCTTCCTCGACACCGCAACTCTCTCGTAGCGCACGGCCAGTCGGGTGGGGGA	2666		
OY	184	acctctcgcagctatgcgcgcatcatctcgtgcgcagctcgaactcggagccagctcctccga	243		
Db	2665	ACCTCTCTCGCAGTACGCCGATCATCTGTGCGGATTCCAGCTGGCGAGCTCTCCCGCA	2606		
OY	244	tcgagtagtgcgcgcctcgcgcgaagtgtgagccgcgcgcacacgagggacgcgtccggttga	303		
Db	2605	TGCATTACTGGCGCCGTCGCCGAGAGTGAGCGCGCGCTCGAAGCGCGTCCGGGTGA	2546		
OY	304	aggcgtctgcgggagcgtctgtatagtcgcgcgttcggttgttgctccctcgatgtccacagca	363		
Db	2545	AAGCTGTGGGGGCGCTCGTGATGCGCGCCGCTCGTGGTGGCTTCGTGATGTCCACAGTA	2486		
OY	364	ccgcgcctccgcgcgggacgacgc	423		
Db	2485	CCGGGCGTCGCCGGGGGACCGGACCGGATACCACTTCCTGTGGAGGAACTTCC	2426		
OY	424	acaaactgttaggcacccgcgcgcgttgttaggcgcgcgcctctccacagcaaccgcgcgcgc	483		
Db	2425	ACAACGATTAAGGACACCGCGGGGTGTGTGGCGAGCGCTCTCTCCACGAACCGGAGATGG	2366		
OY	484	gctcctcgttcgcgcacccgc	543		





Db	129	CGGGGAGCCTTCACCTCGAAGACCAGGCCCGCCCTCCCGAAGGCCTGTGCACCTCGGG	70
Qy	1283	cttgcgctcgtatgcatcatcatcgtagaacacgcgcgaacggatgcagcgccaccggaggcgctc	1342
Dd	69	CTTGGCGCTGCAATGGTGATCATCANGGAACAGCGAAGCGGTGACGCGCACCCCGGCGCCTC	10
Qy	1343	gccgcctcac 1351 	
Db	9	GCGCGCTCAC 1	
RESULT	5		
AAV01451/C			
ID	AAV01451 standard; DNA; 3013 BP.		
XX	AAV01451;		
XX	21-MAY-1998 (first entry)		
DT			
XX	Plasmid pANT195 including the doxa gene.		
Daunomycin C-14 hydroxylase; doxa gene; doxorubicin; daunomycin; 13-dihydrocarminomycin; carminomycin; anthracycline; anticancer; cytostatic; cancer; therapy; Plasmid pANT195; ds.			
Streptomyces sp. strain C5.			
Key	Location/Qualifiers		
CDS	complement (99..1034) /*tag= a		
-10_signal	/note= "snpr activator gene" complement (1043..1047) /*tag= b		
-35_signal	complement (1067..1071) /*tag= c		
protein_bind	1193..1209 /*tag= d		
-35_signal	/note= "proposed Snpr binding site" 1230..1235 /*tag= e		
-10_signal	1252..1257 /*tag= f		
RBS	1262..1265 /*tag= g		
RBS	1302..1305 /*tag= h		
CDS	/note= "engineered RBS site" 1315..2583 /*tag= i		
RBS	/note= "doxa gene" 2855..2858 /*tag= j		
RBS	2867..3013 /*tag= k		
note= "5' end of daui gene"			
M09744439-A2.			
27-NOV-1997.			
22-MAY-1997;	97MO-US08690.		
24-MAY-1996;	26US-0653650.		
(OHIS ) UNIV OHIO STATE RES FOUND.			
Desautl CL, Dickens ML, Strohl WA;			
WPI: 1998-018495/02.			
P-PsDB; AAM36128-30.			
Producing doxorubicin from daunomycin by daunomycin C14 hydroxylase			

[illegible]

Db	1942	ACGTCGTCCGGACGTCCCGCAG666TCCGTCGTCACACCGCCGGCGCTCTGCGGGCCG	1883
Qy	784	CGAGGCGCGATgctcttgaagaacgtctaaagcctctgcggygcaltgcgcggatctgltgaccg	843
Db	1882	CGAAGCCGAGTGGCTTTGAGCAGCCGACCGGCCCTCGCGGGCCATTCCCGGATGGTGAACCG	1822
Qy	844	gcacacgcgaacgtctgcagatgacacaaacgcggagatgfatgacgcgaagccgcgcatca	903
Db	1822	GCACGCCGAGCAGTTCGCAGATATACACACGCGGAAATGATACCGGAAACCGCCGATCA	1763
Qy	904	gctcgcgcggttttgcccgcaacgcggagcgctgcgcgtacgtctgcgttgtagcagccgcgcg	963
Db	1762	GCTCGCGCGGTGTCGCCCGACCGGTCGAGGAGTGGCGGATTCGGTGAACACACCGTCGG	1703
Qy	964	cgatcgcgcggaatgcatctccgtctccgtctgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc	1022
Db	1702	CGATGCGCGGAGTCCGATCCGTCCTCGCTCCGCGCCAGCCGCGCGGGTTGAACGCCGGTGGT	1643
Qy	1024	gaatgcgcgcagcgcgcgcgcttgagcctctgcgcgtccacagcgatgcagctgaacgacga	1083
Db	1642	GGATGCGCGGCAGACGGCGGGTGGTCTCTCAACGTCACAGGCGATGACCGTGAACGGACCA	1583
Qy	1084	gctccggaacggggaatgctcgaagacgctcgtccaccccccgcaagcgcgcgggcgaggt	1143
Db	1582	GCTCCGGAAACGGGGATTCAGACCCGTCTCCACCCCGCCGACAGCGGTGGCGCGAGAT	1522
Qy	1144	cgaggctcttcaacgaacccgggagatctgcgcagacacctctgcgcgcgcgcgcgcgcgcgc	1203
Db	1522	CGGGGCTCTTACAGAACCGGGGATTCGCCACGACCTCGCGGGCGAGCGGTATGGGTGA	1463
Qy	1204	tgaccacgacgagtcgc	1263
Db	1462	TGACCCAGGCGGGGCCCGCCCGCGGGGCGCTTCACTCGACGACGCGGGCCCGCTCTCGGA	1403
Qy	1264	aggagctctgacactgc	1323
Db	1402	ATGGCTGTGTCACCTCGGGTTTTCGCTCATGTGTCTATCTGGGACACGAGACGGGTGGA	1343
Qy	1324	cgaccacccggggcgccctgcgcgcctcagcagcaggaacccgcc	1363
Db	1342	CGGCCACCCCGCGGGCGCTCGCCGCTCATGAGGACACCCCTC	1303
RESULT 6			
AAV01452/c			
AAV01452 standard; DNA; 2081 BP.			
AAV01452:			
XX	21-MAY-1998	(first entry)	
DE	Modified doxa gene encoding daunomycin C-14 hydroxylase.		
XX			
KW	Daunomycin C-14 hydroxylase; doxa gene; doxorubicin; daunomycin; 13-dihydrodaunomycin; carlinomycin; anthracycline; anticancer; cytostatic; cancer; therapy; plasmid pANT19; ds.		
KW			
XX			
OS	Chimeric - Streptomyces sp. strain C5.		
OS	Chimeric - synthetic.		
XX			
FT	Key	Location/Qualifiers	
FT	-35_signal	3..8	
FT	/*tag-	a	
FT	-10_signal	26..31	
FT	/*tag-	b	
FT	misc_signal	38..58	
FT	/*tag-	c	
FT	/note-	"lac operator"	
FT	misc_signal	74..142	
FT	/*tag-	d	
FT	/note-	"rnb antiterminator"	
FT	enhancer	159..168	
FT	/*tag-	e	

[illegible]









Query Match : 88.6%; Score 2542.2; DB 2; Length 3196;

Best Local Similarity 93.6%; Pred. No. 0;  
Matches 2681; Conservative 0; Mismatches 163; Indels 21; Gaps 2;

[illegible]

Db	1825	GGATGCGGCGCAGACGCCGGTGTGCTTACCGCTCACCGCCGATGAGCTGAACGGAGCGCA	1766
QY	1084	gtctccggaacgaggatgtctcgaagacctgtctcaaccccccgcaagcgcggggagtg	1143
Db	1765	gcttcggaaacggggatgctcgaagacctgtctcaaccccccgcaagcgcggggagtg	1706
QY	1144	gggggtctcttaagaaacggggatcggccgaagacctctcgggcgaggggtatcatcgtgtga	1203
Db	1705	CGGGTCCCTTCACGAACCGGGGATGCGGCACACACTCTCGCGGGGAGGGGCTATGCGTGA	1648
QY	1204	tgaccacagcgagttccggcccgcggttcctcaacctcgaagacccgggcccgcgtcccgga	1263
Db	1645	TCACCCAGGCGGGGTCCGCGCGGGGGCGTTCACTCGAAGAGGGGCCCGCTCTCGGA	1588
QY	1264	agggctgtatgaacctcgggtctgcgtgtcatatgtatcatatgaaacgacgaaaggtgtga	1323
Db	1585	ATGCGCTCTGTGACCTCCGGGTTTGGCGTGCATGTGCTATGTGGACACGAGAACGGGGTGA	1526
QY	1324	cgggcaaccggggcgccctcgcgtctcagaagaccgcgcgcgcgcgcgcgcgcgcgcgc	1383
Db	1525	CGGGCACCCCGGGGCGCTCGCGCTCATGAGGACCGTCCGCGCGGGGATAGCGCTTC	1466
QY	1384	ccgcaagttcgaaccaacgaaagccggcccgctgcggttcgagcaagttccgcccgcgc	1443
Db	1465	CGGCAATTGACACACGAGAAAGCGCGCCCGCTCGGGTGAAGAGAGTCCGCCCGCGCC	1406
QY	1444	ccgtggcggtctcggcgaggtctgtctctgaagagcccgccgaattcaagcgcgccgcgc	1503
Db	1405	CCTGGGGGTGTGCAGCGGGCTGTCTTCGACGAGACCGCGCATTTGCACGCGCCCGCGAC	1346
QY	1504	cgctcgctcgcagatcgtgtcagacgagcaagcaacgcccagttccgacctgaccgcgcgt	1563
Db	1345	CGTCCGTCGCGACGTGTGCAGCGGAGAACACACGCGCCCAATGGGGCCGTAACCGCCCGT	1286
QY	1564	gacgcgcagctccctgggtgtccggcgagaccggtgtgtacccgatgtgtccagaccgggtcgt	1623
Db	1285	CGTGCACGATTCGCCGGGGCGCGGGACCGGATGTGTCAATGATGTGCAAAACCGGGTGGT	1226
QY	1624	gacgcacctcagttccggtgtgtcggcgagaccgagccgaggtctgcgcggttgaagaatccgc	1683
Db	1225	GACGCGCTTGTGCGTCCGGTGTGCGCGGAGCCAGGCCGAGGGGTGCGACGGTAAACACAG	1166
QY	1684	ggcgagccccgatgtccgtctcgttcaacagctcgaaccagccgaaccgagccgagcccgct	1733
Db	1165	GGCGGTCCCGATGTGTGTGCTGACCAATTCACACCGACCGACCGACCGCGCACCCCGT	1106
QY	1744	caacctcgcgcgccctcaatgaacctcttgcgcgaagccgagcaacgcgcgcgcgcgcgcgtc	1803
Db	1105	CACCTCCGCGCCCTTCATGAGCGCCCTTGGCGCACACCGCGAAGCGCGCCCGCATGGGTC	1046
QY	1804	ggcgaagacgcacatccggccgcgaagccgaagacgtlccatcagtagtcatatgatccttcgc	1863
Db	1045	GCGGAGAACCCGCATTCGCGCGCGAGACCGAGAGAGTGCATATCGGGTGCATGATGACCTGCC	986
QY	1864	gccccgcgctcagaaccgcgttgttaagttgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	1923
Db	985	ACCGCGCCCTTCGACCCGCTTGTGTGATGTGCTGTGGGTGTGTGTGTGTGTGTGTGTGTGT	926
QY	1924	ccagatggcgcgacatgcgcgtgtctgtctgtctccgggcccgtacgcgcggttgttlaaggggt	1983
Db	925	CCAGATGGCGGGCATGCCGCTGT	866
QY	1984	gtcgatctgt	2043
Db	865	GTGATGT	806
QY	2044	tcccccgcgccgggtgtcgtctgaacacggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	2103
Db	805	TCCCCCGGACCCGGGTGCTGTGAACACAGGTGTGGGGTTCACGCGGAAGAGGCGGTGTAGAA	746
QY	2104	gtcggcgcgagcgcgacatcgt	2163
Db	745	GTTCGCGAGCGCGCGCATTCGGGCGACCCGAGGTTGTGAACCATATGGGGGGCGCGCGGCGC	686

[illegible]

Query Match	Best Local Similarity	Score	DB 2;	Length
Matches 2681; Conservative	0;	Mismatches 163; Indels 21; Gaps 2;		
<p>APPLICATION NUMBER: US/08/653,650A</p> <p>FILING DATE:</p> <p>CLASSIFICATION: 435</p> <p>ATTORNEY/AGENT INFORMATION:</p> <p>NAME: Golrick, Mary E.</p> <p>REGISTRATION NUMBER: 34829</p> <p>REFERENCE/DOCKET NUMBER: 22727/00131</p> <p>TELECOMMUNICATION INFORMATION:</p> <p>TELEPHONE: 216-622-8458</p> <p>TELEFAX: 216-241-0816</p> <p>INFORMATION FOR SEQ ID NO: 4:</p> <p>SEQUENCE CHARACTERISTICS:</p> <p>LENGTH: 3196 base pairs</p> <p>TYPE: nucleic acid</p> <p>STRANDEDNESS: double</p> <p>TOPOLOGY: linear</p> <p>MOLECULE TYPE: DNA (genomic)</p> <p>FEATURE:</p> <p>NAME/KEY: mat_peptide</p> <p>LOCATION: 1498..2764</p> <p>FEATURE:</p> <p>NAME/KEY: CDS</p> <p>LOCATION: 1498..2764</p> <p>US-08-653-650A-4</p>				
Query Match	88.6%	Score 2542.2;	DB 2;	Length 3196;
Best Local Similarity	93.6%	Pred. No. 0;		
Matches 2681; Conservative	0;	Mismatches 163; Indels 21; Gaps 2;		
5	ccgcagcgggtatcacgcgacgggagccgcgcacccgcgcggtgctgaggtggtccgtg	64		
2845	ccgcacacccggccacacggccacggcaccggccacccgcgcgcatggcggtggccgtcccg	2786		
65	cc-ggtcggcgccggcggtatcagcgacgacgagggcgagctcgtgtgaacggcgccgtt	123		
2785	ccgggtcggcggtggcgccatfcaacgacgacgacggcgagtgatgagacccgcgtgt	2726		
124	gggaccccttcgcggacacacgcgaactcgtctgacgacggcgacgtcggtccgcggg	183		
2725	ggggcccttcttcgacacacacgcgaactcgtctgacgacggcgacgtcggtccgcggg	2666		
184	accgtctgcgacgtacgcgcgtatcgttgcgcgactcagcttggcgagctgtcccca	243		
2665	acctcgtgcgacgtacgcgcgtatcgttgcgcgactcagcttggcgagctgtcccca	2606		
244	tgcagtagtgcggccgttgcgcgaagtgtgacgcgcgcacgagagggacgttcggttga	303		
2605	tgcagtagtgcggccgttgcgcgaagtgtgacgcgcgcacgagagggacgttcggttga	2546		
304	aggcgtgcggggcgtctgtatgtgcggcgctcggttltgttgccctcgtatgtccacaga	363		
2545	aggcgtgcggggcgtctgtatgtgcggcgctcggttltgttgccctcgtatgtccacaga	2486		
364	ccgcgccttcgcggggacgcgcgacgcgcgcgtatgtlcaactcgttgcgagcgaactcc	423		
2485	ccgcgccttcgcggggacgcgcgacgcgcgcgtatgtlcaactcgttgcgagcgaactcc	2426		
424	acaagctgtatgagcaccggcggtgtgtatgcgacgcgtctctccacgaaacgggagag	483		
2425	acaagctgtatgagcaccggcggtgtgtatgcgacgcgtctctccacgaaacgggagag	2366		
484	cgctctgtctgcacatccgcgcgcgagggcgggccgcgcgcgcgcgcgcgcgcgcgcgc	543		
2365	cgctctgtctgcacatccgcgcgcgagggcgggccgcgcgcgcgcgcgcgcgcgcgcgc	2306		
544	ggaaagagccggctgtgtctgtgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc	603		
2205	ggaaagagccggctgtgtctgtgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc	2246		
604	ggtcgttcggagacgagccgaactcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc	663		
2245	ggtcgttcggagacgagccgaactcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc	2186		

[illegible]













```

Db      410 CGGCCACCCGGCGGCGCTGCAGCATGAGGACCCTC 371
RESULT          7
US-09-096-982-6/c
Sequence & Application US/09096982
Patent No. 5962293
GENERAL INFORMATION:
APPLICANT: Strohl, William R.
APPLICANT: Dickens, Michael L.
APPLICANT: Desanti, Charles L.
TITLE OF INVENTION: METHOD OF PRODUCING DOXORUBICIN
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESSES:
ADDRESSEE: CALFEY, HALTER & GRISWOLD
STREET: 800 Superior Avenue, Suite 1400
City: Cleveland
STATE: Ohio
COUNTRY: USA
ZIP: 44114-2688
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/096,982
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Goltick, Mary E.
REGISTRATION NUMBER: 34829
REFERENCE/DOCKET NUMBER: 22727/00131
TELECOMMUNICATION INFORMATION:
TELEPHONE: 216-622-8458
TELEFAX: 216-241-0816
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 3013 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-09-096-982-6
RY Match 38.4%; Score 1102.2; DB 2; Length 3013;
t Local Similarity 94.4%; Pred. No. 3.8e-165;
ches 1154; Conservative 0; Mismatches 66; Indels 1; Gaps 1;

```

[illegible]

Search completed: June 11, 2002, 17:59:11  
Job time: 3998 sec

---



```

|||||
17 tmetThrMetGlnArgProGluValHisAspAlaPheArgGluVal 34
1251 GCCCGGTCGAGAGTGAACGCCCCCGCGGAGACCCCGCTGGGTATC 1202
34 lYProValValGluValAsnAlaProAlaGlyGlyProAlaTyrValIle 50
1201 ACCGATGACCCCTCGCCGCGAGAGTGTGGCGATCCCGGTTCGTGAA 1152
51 ThrAspAlaLeuAlaIleArgGluValLeuAlaAspProArgPheValIly 67
1151 GGACCCCGACCTGCCCCCGCGCTGGCGGGGGGTGACGAGCTGTCG 1102
67 sAspProAspLeuAlaProAlaIleTyrArgGlyValAspAspIlyLeuA 84
1101 ACATCCCGCTCCGAGCTGCGCTCCGTCACGCTCATCGCTGAGAGGC 1052
84 splleProValProGluLeuArgProPheThrLeuIleAlaValAspGly 100
1051 GAGGCCACCGCGCCCTCGCCGCGATCCAGCACGACCTGCTCAACCGCG 1002
101 GluAlaHisArgArgLeuArgArgIleHisAlaProAlaPheAsnProAr 117
117 gArgLeuAlaGluArgThrAspArgIleAlaAlaIleAlaGlyArgLeuL 134
1001 CCGCGTGGCGGAGCGAGATGGCATCGCCGCGATCGCCGCGCTGTC 952
117 gArgLeuAlaGluArgThrAspArgIleAlaAlaIleAlaGlyArgLeuL 134
951 TCACCGNACTCGCCGAGCCTCGCGCGTGGGGAACCGCGCGAGCTG 902
134 euhArgLeuLeuAlaAspAlaSerGlyArgSerGlyLysProAlaGluLeu 150
901 ATGCGCGCTTCGCGTACCACTTCGCGCTGTGTGTCATCGAGCTGCT 852
151 lIleGlyGlyPheAlaTyrHisPheProLeuLeuValIleGlyGluLeuLe 167
851 CGGTGGCGGTCACCGATCCGGCGATGGCCCGCGAGCGCGCTGAGGTTTC 802
167 uGlyValProValThrAspProAlaMetAlaArgGluAlaValSerValI 184
801 TCAAGCACTCGGCTCGCGCGCCGCGAGAGCGCGGGGTGACGAGCAG 752
184 eulysAlaLeuGlyLeuGlyGlyProGlnSerGlyGlyGlyAspGlyThr 200
751 GACCTGCGCGGGGCGTCCGAGACCTGCGCCCTGAGAGCTGCTGCT 702
201 AspProAlaGlyGlyValProAspThrSerAlaLeuGluSerLeuLeu 217
701 CGAAGCCGTCGACTACGCGCGGAGACGACCGGACCGATGACCGCGG 652
217 uGluAlaValHisSerAlaArgArgAsnAspThrProThrMetThrArgY 234
651 TGGTGTACGAGCGCGGAGCGAGCTGCGCTGCTCGAGCAGCAG 602
234 alLeuTyrGluArgAlaGlnAlaGluPheGlySerValSerAspAspGln 250
601 CTGCTATCATGATCACCGGCGTCATCTCGCGCGCAGACACCGCG 552
251 lLeuValTyrMetIleThrGlyLeuIlePheAlaGlyHisAspThrThrG 267
551 CTGCTCTGCGGCTCTGCTGCGGAGGTCCTGGCGGGCGCGCTGGCG 502
267 ySerPheLeuGlyPheLeuLeuAlaGluValLeuAlaGlyArgLeuAlaA 284
501 CGGATGCCGAGAGAGCGCGTCTCCCGGTCTGAGAGAGCGGCTGCC 452
284 lAspAlaAspGluAspAlaValSerArgPheValGluGluAlaLeuArg 300
451 TACACCGCGCGGTGCTTACGCTGTGAGGTTGCTGCCAGGAGGT 402
301 TyrHisProProValProTyrThrLeuTyrArgPheAlaAlaThrGluVa 317
401 GACGATCGCGGCGTCCGCGCGGAGCGCGGCTGCTGTGAGCA 352
|||||

```

```

317 lThrIleGlyGlyValArgLeuProArgGlyAlaProValLeuValAspI 334
351 TCGAGGCGACCAACACCGAGCGCCGCGATCAGACGCCCCGACGCTTC 302
334 lGluGlyThrAsnThrAspGlyArgHisHisAspAlaProHisAlaPhe 350
301 CACCGGACCGCTCCGTCGGCGGCGCTCACCTTGGGCGAGCGCGCA 252
351 HisProAspArgProSerThrArgArgLeuThrPheGlyAspIlyProH 367
251 CTACTGCATCGGAGAGAGCTCGCCAGCTGAGAGTGGCGCGCATGATCG 202
367 sTyrCysIleGlyGluGlnLeuAlaGlnLeuGlnSerArgThrMetIleG 384
201 GCCTACTGCGACAGAGTTCCCGGAGCGCGACTGGCGCTGCCGTACGAC 152
384 lValLeuArgSerArgPheProGluAlaArgLeuAlaValProTyrAsp 400
151 GAGTTCGCTGTCGCGGAGGCGCCAGAGCGCGGCTCACGAGACT 102
401 GluLeuArgTyrCysArgGlyGlyAlaGlnThrAlaArgLeuThrGlu 417
101 GCCCGTCTGGCTGGC 86
417 uProValTyrPheuArg 422

```

seq\_name: /SIDSL/gcdata/geneseq/geneseq-emb1/AA1998.DAT:AAW36132

seq\_documentation\_block:

ID AAW36132 standard; Protein: 474 AA.

AAW36132;

21-MAY-1998 (first entry)

N-terminal modified daunomycin C-14 hydroxylase.

Dauomycin C-14 hydroxylase; doxa gene; doxorubicin; daunomycin;

13-dihydrocarminomycin; carminomycin; anthracycline;

anticancer; cytostatic; cancer; therapy; plasmid pAN199.

OS Chimeric - Streptomycetes sp. strain C5.

XX Chimeric - synthetic.

Key Location/Qualifiers

FT Cleavage-site 31 /note- "enterokinase cleavage site"

FT Protein 53..474 /note- "native daunomycin C-14 hydroxylase"

XX W09744439-A2.

PD 27-NOV-1997.

PF 22-MAY-1997; 97WO-US08690.

PR 24-MAY-1996; 96US-0653650.

PA (OHIS ) UNIV OHIO STATE. RES FOUND.

PI Desanti CL, Dickens ML, Strohl WA;

XX WPI: 1998-018495/02.

DR N-PSDB; AAV01452.

XX Producing doxorubicin from daunomycin by daunomycin C14 hydroxylase

PT - also hydroxylation and oxidation of other anthracycline(s) with

PS the same enzyme

XX Disclosure; Fig 9; 59pp; English.

CC This protein comprises an N-terminal modified enzyme derived from

the daunomycin C-14 hydroxylase (see AAW36128) of Streptomycetes sp.

CC strain C5. It is encoded by a gene construct (see AAV01452) in  
 CC plasmid pAM199. In this plasmid, the doxa gene (see AAV01447) is  
 CC translationally fused with a leader sequence encoding 6  
 CC histidine residues so that the fusion protein can be affinity  
 CC purified on a nickel agarose gel. Daunomycin C-14 hydroxylase  
 CC is a P450-like enzyme capable of converting daunomycin to the  
 CC anticancer agent doxorubicin. Host cells, especially Streptomyces  
 CC host cells, transformed with pAM199 can be used in methods for  
 CC the production of doxorubicin from daunomycin or for the  
 CC hydroxylation and oxidation of other anthracyclines.

XX Sequence 474 AA:

Alignment\_scores:

Quality: 2093.50 Length: 432  
 Ratio: 4.973 Gaps: 1  
 Percent Similarity: 97.454 Percent Identity: 93.056

Alignment\_block:

US-09-673-254-1/rev x AAW36132

Align seg 1/1 to: AAW36132 from: 1 to: 474

1378 GTACCCCGCGGCGGCGGCGG...TGCTCGTGAAGCGGCGGCGG 1332  
 ||||| |||||:|||||:|||||:|||||:|||||:|||||:|||||  
 43 ValProTyrGlyAsnSerGlyCysLeuMetSerGlyGluAlaProAr 59  
 1331 GGTGGCGCTGCAGCCGCTGCGGTGCCATGATGACATGACAGCGCAAGC 1282  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 59 gValAlaValAspProPheSerCysProMetMetMetGlnArgLysP 76  
 1281 CGAGAGTCAGAGAGCCCTTCGCGGAGGCGGCGGCGGCTGCTGAGGTGAC 1232  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 76 ToglValAlaHisPheAlaPheArgGluAlaGlyProValAlaGluValAsn 92  
 1231 GCCCGCGGCGGCGGCGGCGGCGGCTGAGTATCACCGATGACGCCCTGCGCG 1182  
 . 93 AlaProAlaGlyGlyProAlaTPrValIleThrAspAlaLeuAlaAr 109  
 1181 CGAGGTGCTGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1132  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 109 gGluValAlaLeuAlaAspProArgPheValLysGlyProAspLeuAlaProT 126  
 1131 CGCGCTGCGGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1082  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 126 hAlaTPrArgGlyAlaLysAspGlyLeuAspIleProValProGluLeu 142  
 1081 GGTGCGTTCAGCGCTCATGCGCGTGCAGCGGCGGCGGCGGCGGCTGCG 1032  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 143 ArgProPheThrLeuIleAlaValAspGlyLysAspHisArgArgLeuAr 159  
 1031 CGGATTCACGACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 982  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 159 gArgIleHisAlaProAlaPheAsnProArgArgLeuAlaGluArgThrA 176  
 981 ATGCGATGCGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTG 932  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 176 sPArgIleAlaIleAlaIleAlaAspArgLeuLeuThrGluLeuAlaAspSer 192  
 931 TCCGCGCGGCGGCGGCGGCGGCGGCGGCTGATCGCGGCTGCTGCTGCTGCTG 882  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 193 SerAspArgSerGlyGluProAlaGluLeuIleGlyGlyPheAlaTyrHI 209  
 881 CTTCGCGCTGTGTGCTATGCTGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTG 832  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 209 sPheProLeuLeuValIleCysGluLeuLeuGlyValProValThrAspP 226  
 831 CGGCGATGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 782  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 226 rAlaMetAlaArgGluAlaValAlaGlyValLeuLysAlaLeuGlyLeuGly 242  
 781 GCCCGCGAGAGCGGCGGCGGCTGACGCGACGCCCTGCGGCGGCGGCTGCC 732

|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 243 GlyProGlnSerAlaGlyGlyAlaAspGlyThrAspProAlaGlyAspValPr 259  
 731 GGACACCTCGGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTG 682  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 259 oAspThrSerAlaLeuGluSerLeuLeuLeuGluAlaValaHisAlaAla 276  
 681 GCGCGACAGCACCGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTG 632  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 276 rGArgLysAspThrArgThrMetThrArgValLeuTyrGluAlaArgAlaGln 292  
 631 GCCGAGTTCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 582  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 293 AlaGluPheGlySerValSerAspAspGlnLeuValTyrMetIleThrG1 309  
 581 GCTATCTTCGCGGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTG 532  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 309 yLeuIlePheAlaGlyHisAspThrThrGlySerPheLeuGlyPheLeuL 326  
 531 TCGCGAGAGTCTGCGGCGGCGGCGGCGGCGGATGCCGAGAGAGAGCGCC 482  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 326 euAlaGluValAlaLeuAlaGlyArgLeuAlaAlaAspAlaAspGlyAspAla 342  
 481 GTCTCCCGCTGCTGAGAGAGCGGCTGCGCTACACACCGCGGCTGCCCTA 432  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 343 lIleSerArgPheValGluGluAlaLeuArgHisProProValProTyl 359  
 431 CACGTTGTGAGAGTTCGCTGCCACGAGAGTGCACATCGCGGCGGCTGCCGC 382  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 359 rSerLeuThrPArgPheAlaAlaThrGluValAlaIleArgGlyAlaArgL 376  
 381 TGCCCGCGGAGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 332  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 376 euProArgGlyAlaProValAlaLeuValAspIleGlyGlyThrAsnThrAsp 392  
 331 GCCCGCATCACAGAGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTG 282  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 393 GlyArgHisHisAspAlaProHisAlaPheHisProAspArgProSerAr 409  
 281 CGCGGCGCTCACCTGCGGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTG 232  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 409 gArgArgLeuThrPheGlyAspGlyProHisTyrGlyIleGlyGluGlnL 426  
 231 TCGCCACAGCTGAGTGCAGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTG 182  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 426 euAlaGlnLeuGluSerArgThrMetIleGlyValLeuAlaArgSerArgPhe 442  
 181 CCGGAGCGGCGGCGGCGGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTG 132  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 443 ProGlnAlaArgLeuAlaValProTyrGluGluLeuAlaArgTyrPcysArgLy 459  
 131 GGGGCGGCGGAGCGGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 86  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
 459 sGlyAlaGlnThrAlaArgLeuThrAspLeuProValIleThrLeuArg 474

seq\_name: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:AAW36128

seq\_documentation\_block:

ID AAW36128 standard: Protein: 422 AA.

AC AAW36128:

DT 21-MAY-1998 (first entry)

XX Daunomycin C-14 hydroxylase.

XX Daunomycin C-14 hydroxylase; doxa gene; doxorubicin; daunomycin;

KW 13-dihydrocarminomycin; carminomycin; anthracycline;

KW anticancer; cytostatic; cancer; therapy.

OS Streptomyces sp. strain C5.

XX WO9744439-A2.

XX 27-NOV-1997.  
 PD 22-MAY-1997; 97WO-US08690.  
 XX 24-MAY-1996; 96US-0653650.  
 XX (OHS ) UNIV OHIO STATE. RES FOUND.  
 PA Desanti CL, Dickens ML, Strohl WA;  
 XX WPI: 1998-018495/02.  
 DR N-PSDB; AAV01447, AAV01451-53.  
 XX

PT Producing doxorubicin from daunomycin by daunomycin C14 hydroxylase  
 PT - also hydroxylation and oxidation of other anthracycline(s) with  
 PT the same enzyme

PS Claim 9; Page 31-33; 59pp; English.

This protein comprises the daunomycin C-14 hydroxylase (DC14H) of Streptomyces sp. strain C5. DC14H is a P450-like enzyme useful for the production of doxorubicin from daunomycin, and for the hydroxylation and oxidation of other anthracyclines. Its amino acid sequence was deduced from the doxa gene (see AAV01447) identified in the daunomycin biosynthesis gene cluster from C5 (see AAV01453). Plasmid vectors (see AAV01451-52) have been constructed for use in the recombinant production of DC14H in transformed host cells. Claimed methods for production of doxorubicin include: the use of a host microorganism transformed with a plasmid which contains the doxa gene; incubating a culture of Streptomyces sp. strain C5 with daunomycin; and incubating DC14H with daunomycin. DC14H can also be used in claimed methods of producing 13-dihydrodoxorubicin and carminomycin from 13-deoxydoxorubicin, and of producing 13-dihydrodaunomycin and daunomycin from 13-deoxydaunomycin. The methods preclude the use of halogens as required in the current chemical methods.

Sequence 422 AA:

alignment\_scores:  
 Quality: 2076.00 Length: 422  
 Ratio: 5.027 Gaps: 0  
 Percent Similarity: 97.867 Percent Identity: 94.076

alignment\_block:

US-09-673-254-1/rev x AAW36128 ..

Align seg 1/1 to: AAW36128 from: 1 to: 422

```

351 GTGAGCGGCGAGCGCCCGGGGTGGCCGTGACCCGTTGCGTGCCTCAT 1302
      ::::::::::::::::::::::::::::::::::::::::::::::::::::
1  MetSerGIgLuAlaProArgValAlaValaAspProPheSerCysProkoe 17
1301 GATGACCATGCGAGCGCAAGCCGAGGTGCAGCAGCCCTTCGGGAGCGG 1252
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
17 TwethrMetGlnArgLysProGluValHisAspAlaPheArgGluAlaG 34
1251 GCCCGGTGTGAGGTGAAGCGCCCGCGGGGAGCGCCGCTGGGGTCATC 1202
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
34 LyrProValValGluValaHisAlaProAlaGlyGlyProAlaTrpValIle 50
1201 ACCGATGACGCCCTGCGCCGCGAGGTGCTGGCCGATCCCGGGTTCGTGA 1152
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
51 ThrAspAspAlaLeuAlaArgGluValLeuAlaAspProArgPheValIle 67
1151 GGACCGCCGACCTCGCCCGCGCGCTGGCGGGGGGTGAGCAGCGTTCG 1102
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
67 SelYrProSplLeuAlaProThrAlaTrpArgGlyValaAspAspGlyLeu 84
1101 ACATCCCGTTCGAGAGCTGGCTCGGTACAGCATCGCGCTGAGCGC 1052
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::

```

```

84 spLeProValProGluLeuArgProPheThrLeuAlaValaAspGly 100
1051 GAGGCCACCGGCGCTGCGCGCATCCAGCAGCCCTGCTTAACCCGG 1002
      ||| |::::::::::::::::::::::::::::::::::::::::::::::::::
101 GluAspHisArgArgLeuArgArgGlyLeuHisAlaProAlaPheAsnProArg 117
1001 CCGGCTGGCCGAGCGAGCAGATCGCATCGCCGATCGCGCGCGCGCTTC 952
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
117 GArgLeuAlaGluArgThrAspArgGlyLeuAlaAlaLeuAlaAspArgLeu 134
951 TCACCGAAGCTCGCCGACGCTCGCGCGCTGGGCAACCGCCAGCTG 902
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
134 eutThrGluLeuAlaAspSerSerAspArgSerGlyGluProAlaGluLeu 150
901 ATCGGCGGCTTCGCGTACCATCTCCGCTGTGGTCATCGAGCTGCT 852
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
151 LLeGlyGlyPheAlaTrpHisPheProLeuLeuValIleCysGluLeu 167
851 CGGTGTGCCGCTCACCGATCCGGCGATGGCCCGCGAGGCCGTACGCTTC 802
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
167 uGlyValProValThrAspProAlaMetAlaArgGluAlaValaGlyVal 184
801 TCAGAGCACTCGGCTCGCGCGCGCCGAGCGCGGGGGGTACGGCAG 752
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
184 eulYsAlaLeuGlyLeuGlyGlyProGlnSerAlaGlyAspGlyThr 200
751 GACCTGCGCGGGGGGTGCGCGAGCAGCTCGCGCTGGAGAGCTCTGCT 702
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
201 AspProAlaGlyAspValProAspPheThrSerAlaLeuGluSerLeuLeu 217
701 CGAAGCCGTGCATCAGCCCGCGGAGACAGACCCCGACCATAGACCCGCG 652
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
217 uGluAlaValHisAlaAlaArgArgGlyAspPheArgThrMetThrArgV 234
651 TGCTTAGAGCGCGCGCGAGCGCGAGTTCGCTCGCTCGAGCAGCAG 602
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
234 alLeuTrpGluArgAlaGlnAlaGluPheGlySerValSerAspAspGln 250
601 CTGCTCTACATGATCAGCGGGGCTCATCTTGGCGCGCCAGCACACCGG 552
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
251 LeuValIleTrpMetIleThrGlyLeuIlePheAlaGlyHisAspPheThrG 267
551 CTCTTCTTGGGCTTCCTGCTCGCGAGAGTCTGGCGCGCGCCCTCGCGG 502
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
267 YSerPheLeuGlyPheLeuLeuAlaGluValLeuAlaGlyArgLeuAla 284
501 CGGATCGCGAGAGAGACCGCGCTCCGCTCGGTGCGAGAGCGCTGGCGC 452
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
284 lAAspAlaAspGlyAspAlaIleSerArgPheValGluGluAlaLeuArg 300
451 TACACCGCGCGGTGCTTACACGTTGTGAGAGTTCGCTGCACAGAGAGT 402
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
301 HisHisProProValaProTyrSerLeuTrpArgPheAlaIleThrGluVal 317
401 GACCATGCGGCGCTCGGCTGCGCCCGCGGAGCGCGGCTGTGTGAGCA 352
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
317 lValIleArgGlyValaArgLeuProArgGlyAlaProValLeuValaAsp 334
351 TCGAGGGGACACACAGCGAGCGCGCCATCACAGCGCCCGCCAGCGCTTC 302
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
334 lLeGluGlyThrAsnThrAspGlyArgHisAspAlaProHisAlaPhe 350
301 CACCGGACCGCTCCGCTGCGCGCGGCTCACCTTCGCGCAGCGGCCCA 252
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
351 HisProAspArgProSerArgArgArgLeuThrPheGlyAspGlyProHis 367
251 CTACTGCATCGGGGAGCAGCTCGCCCGCAGCTGGAAGTGCACAGATGATG 202
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
367 sTrpCysIleGlyGluGlnLeuAlaGlnLeuGluSerArgThrMetIleG 384
201 GCGTACTGCGAGCAGAGTTCCCGAGGCGCGCAGTGGCCGCTGACAGAC 152
      ||::::::::::::::::::::::::::::::::::::::::::::::::::::
384 lYalLeuArgSerArgPheProGlnAlaArgLeuAlaValProTyrGlu 400

```

```
151 GAGTTCGGTGTGTCGGAAGGGGCCAGACGGCGGCTCACGCACT 102
|||||
401 GluLeuAArgTrrpCysArgLysGlyAlaGlnThrAlaArgLeuThrAspLe 417
101 GCCCGTCTGGCTGGC 86
|||||
417 uPValATrrpLeuArg 422

seq_name: /SIDSL/gcdata/geneseq/geneseq-emb1/AA1998.DAT.AAW36134
seq_documentation_block:
ID AAW36134 standard; Protein: 275 AA.
XX
AAW36134:
21-MAY-1998 (first entry)
Streptomyces orfa gene product.
XX
Daunomycin C-14 hydroxylase: doxa gene: doxorubicin; daunomycin;
KW 13-dihydrocarbamimycin; carminomycin; anthracycline;
KW anticancer; cytostatic; cancer; therapy.
XX
Streptomyces sp.
OS
PN W09744439-A2.
XX
PD 27-NOV-1997.
XX
PE 22-MAY-1997; 97WO-US08690.
XX
PR 24-MAY-1996; 96US-0653650.
XX
PA (OHIS ) UNIV OHIO STATE. RES FOUND.
XX
PI Desanti CL, Dickens ML, Strohl WA;
XX
DR *WPI: 1998-018495/02.
XX
DR N-PSDB; AAW01453.
XX
PT Producing doxorubicin from daunomycin by daunomycin C14 hydroxylase
PT f, also hydroxylation and oxidation of other anthracycline(s) with
PT the same enzyme
XX
PS Disclosure: Fig 3; 59pp: English.

This protein is the encoded product of the Streptomyces sp. strain
C5 daunomycin biosynthetic gene cluster orfa (see AAW01453). This
gene lies upstream of the doxa (see also AAW01447) gene. The doxa
gene codes for daunomycin C-14 hydroxylase (see AAW36128), an enzyme
capable of converting daunomycin to the anticancer agent doxorubicin.
Host cells, especially Streptomyces host cells, transformed with
CC plasmids (see AAW01451-52) containing the doxa gene can be used in
CC methods for the production of doxorubicin from daunomycin or for the
CC hydroxylation and oxidation of other anthracyclines.
XX
XX
Sequence 275 AA:

alignment_scores:
Quality: 1385.00 Length: 275
Ratio: 5.149 Gaps: 0
Percent Similarity: 97.818 Percent Identity: 94.182

alignment_block:
US-09-673-254-1/rev x AAW36134 ..
Align seg 1/1 to: AAW36134 from: 1 to: 275

2175 GTCACAGAGTTCGGCGCGGCCGATGTTGACCTCGGTCGCC 2126
:::|||||
1 MetThrArgPheAlaProGlyAlaProAlaTrpPheAspLeuGlySerP 17
```

```
2125 CGATGTGCGCGCTCGGCGGACTTCTACACGGGCTGTTCGGGTGAGCG 2076
|||||
17 oAspValAlaAlaSerAlaAspPheTrpThrGlyLeuPheGlyTrpThra 34
2075 CCACCGTGTGACGACCGCGCGCGGGGATACAGACGTTTCACCTCC 2026
|||||
34 larThrValValSerAspProGlyAlaGlyLysTrpThrTrpPheSerSer 50
2025 GACGGGAGAGTGTCCGCGGGGTCCCGCCGACCAAGTGCACACCCCTA 1976
|||||
51 AspGlyLysLeuValAlaAlaValAlaArgHisGlnIleAspThrProTy 67
1975 CCACCGCGCGTACGCGCGCGGCGGAAAGCAGCAGCAGCATCCGCCATCT 1926
|||||
67 rHisArgProTyTrpGlyProGlyAsnAspGlnHisGlyMetProAlaIle 84
1925 GGACCGGTGACTTCGCCACCGACGACGCGGCGGACGCTGACCAAGGGTTC 1876
|||||
84 rPThrValTyrPheAlaThrAsnAspAlaAspAlaLeuThrLysArgVal 100
1875 GAGACGCGCGCGCGGCGAGGTCATCATGACTCCGATGAGCTCTCGGCT 1826
|||||
101 GluThrAlaGlyGlyAspValIleMetThrPrometAspValLeuGlyLe 117
1825 CGCGCGGATGCGGCTCTTCGCGCGACCGCGCGGCGCGGCTGTCT 1776
|||||
117 uGlyArgMetAlaValPheAlaAspProSerGlyAlaAlaPheAlaVal 134
1775 GCGCGAAGGAGTTCATGAGGGCGGAGGTGACGGGCGTCCCGGCTCG 1726
|||||
134 rPArgLysGlyValMetGluGlyAlaGluValThrGlyValProGlySer 150
1725 CTCGCGTGGGTGAGCTGTGACCGACGCGCATCGGCGCGCGCGGCACT 1676
|||||
151 ValGlyTrrpValGluLeuValTrnAspAspIleGlyThrAlaArgGlyPh 167
1675 CTACCGCGGACCGCTCGGCTCGGCTCGGCGGCGACCGGACGATGAGGCG 1626
|||||
167 eTyrrArgAlaThrLeuGlyLeuAlaProAlaAspTrnGlyArgLysGly 184
1625 TCACGACCGCGGTCTGGCACATCGGTGACACACCGGTGCGGCGGACCG 1576
|||||
184 alThrAspProValTrpHisIleHisAspThrProValAlaGlyThrArg 200
1575 GACGTGGCGTCAACCGCGCGGTACGCGGCGGACACTGGGCGGTCTGTCC 1526
|||||
201 GluLeuGlyThrThrGlyAlaValArgProHisTrpAlaValLeuPheSe 217
1525 CGTGACGACTGCGACGCGGCGGTCGCGGCGCGCTTGAACTCGGGGCGT 1476
|||||
217 ValHisAspCysAspAlaThrValAlaArgAlaValGluLeuGlyLys 234
1475 CCGTCGAGAACGACCGCGCGGACGCGGCGGCGGCGGCGGCGGACTG 1426
|||||
234 eValAlaGlnAsnGluProValAspThrProArgGlyLysArgAlaAspLeu 250
1425 CTCGACCGCGGCGGCGCGGCTCTCGGTGTGGAAGTGGGGAAGGGA 1376
|||||
251 LeuAspProHisGlyAlaGlyPheSerValValGluLeuArgGluAlaTy 267
1375 CCCGCGGCGGCGGCGGCGGCTCGC 1351
|||||
267 rProAlaAlaAlaAspGlyAlaSer 275

seq_name: /SIDSL/gcdata/geneseq/geneseq-emb1/AA1998.DAT.AAW68559
seq_documentation_block:
ID AAW68559 standard; Protein: 287 AA.
XX
AAW68559:
25-JAN-1999 (first entry)
```

```

XX DE S. peuceetius dnru gene product.
XX KM dnru; dnru; recombinant; microorganism; doxorubicin; daunorubicin;
XX KM metabolism; baumycin; secretion; anti-tumour compound.
XX OS Streptococcus peuceetius.
XX FH Key Location/Qualifiers
FH FT Misc-difference 59 /note= "encoded by AAC"
FH FT Misc-difference 124 /note= "encoded by AAT"
FH FT Misc-difference 125 /note= "encoded by CAC"
FH FT Misc-difference 167 /note= "encoded by CAC"
FH FT Misc-difference 184 /note= "encoded by CAC"
FH FT Misc-difference 202 /note= "encoded by ATG"
FH FT Misc-difference 202 /note= "encoded by CAC"

W09839458-A1.
11-SEP-1998.
05-MAR-1998; 98WO-US03938.
28-JUL-1997; 97US-0901306.
PR 06-MAR-1997; 97US-0812412.
XX PA (PHAA ) PHARMACIA & UPJOHN SPA.
XX PI Colombo AL, Filippini S, Fonstein L, Hutchinson RC;
PI Lomovskaya N;
XX DR WPI; 1998-506367/43.
XX DR N-PSDB; AAV34001.
XX PT Production of doxorubicin and daunorubicin - using a recombinant
XX PT daunorubicin producing microorganism in which at least one dnru or
XX PT dnru metabolism gene has been inactivated
XX PS Disclosure; Fig 2A-B; 48pp; English.
XX CC This sequence represents the dnru gene product from the microorganism
XX CC Streptomyces peuceetius. The invention relates to a recombinant
XX CC microorganism which produces doxorubicin (DOR), in which at least 1
XX CC daunorubicin (DAR) metabolism gene selected from dnru and dnrx, has been
XX CC inactivated. The microorganism is preferably S. peuceetius WMH1658,
XX CC WMH1654 and WMH1662. The function of the DAR gene is inactivated by
XX CC insertion of a gene (preferably neomycin/kanamycin resistance gene aphII)
XX CC into the daunorubicin metabolism gene. The blocking of the function of
XX CC at least one gene of DAR metabolism can increase DAR and DOR production
XX CC levels and cause the disappearance of baumycin-like products resulting
XX CC in DAR and DOR secretion directly into the culture medium. The products
XX CC can be used in the production of anti-tumour compounds.
XX SO Sequence 287 AA;

alignment_scores:
Quality: 978.00 Length: 196
Ratio: 5.041 Gaps: 0
Percent Similarity: 98.980 Percent Identity: 97.449

alignment_block:
US-09-673-254-1/rev x AAW68559
Align seg 1/1 to: AAW68559 from: 1 to: 287
2869 CGGTACCGCGCATGTCATGTCGACGACGCGCGCGCATGTTCTG 2820
|||||

```

```

92 ArgTyrProArgIleAspValMetAlaSerAsnAlaGlyGlyMetPheTr 108
2819 GTGCGCACACAGACCCAGACGGGTTCCAGGCCACCATTCAGTCAATC 2770
|||||
108 pSerArgThrThrGlnAspIlePheGlnAlaThrIleGlnValMetA 125
2769 ACCTGCAGGCTTCCTGTCGACGGCTGCGGGAGCGGCTCGCGGGC 2720
|||||
125 snLeuAlaGlyPheLeuLeuAlaArgLeuLeuArgGlnValAlaGly 141
2719 GGGCGCTGATCTCACTCACTGTCGACGCGTACACCCAGGCGCATCGA 2670
|||||
142 GlyArgLeuLeuLeuThrSerSerAspAlaTyrThrGlnIleArgIleAs 158
2669 CCGCGACGACCTCAACGCGACCGCTACCGCTACGCGCGCGCGGCGCT 2620
|||||
158 pProAspAspLeuAsnGlyAspArgAsnArgTyrSerAlaGlyGlnAla 175
2619 ACGGCACGTCCAAACAGACCATCATGACGCGCGCGAGCGCGCGCAGG 2570
|||||
175 TyrIleThrSerIleGlnAlaAsnIleAsnThrAlaAlaGlnAlaIleArg 191
2569 CGCTGCGCGGACGTCGTCGCGGTCACTATCACCCGCGTGAGGTCGCGAC 2520
|||||
192 ArgTyrProAspValLeuAlaValSerTyrAsnProGlyGluValArgTh 208
2519 CCGCATTCGACGCGGCGACGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 2470
|||||
208 rArgIleGlyArgGlyThrValAlaSerSerTyrPheAspPheAsnPro 225
2469 TCCTGCGCTCCGCGGCGGAGGCGCGCGCGCGCACACCTCGTGGTGGCTC 2420
|||||
225 heLeuArgSerAlaAlaIleAlaIleAlaIleAlaIleAlaIleAlaIle 241
2419 GCGCGCGCGGAGGAGTTCGACGCGCGGCGCTACTACAGCGACCGCGGCT 2370
|||||
242 AlaProAlaGlnIleLeuThrThrGlyGlyTyrTyrSerAspArgIle 238
2369 GTCCCGGTGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGGCT 2320
|||||
258 UserProValSerGlyProThrAlaAspAlaGlyLeuAlaIleAlaIle 275
2319 GGGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCAC 2282
|||||
275 rPGLuaIleGlyAlaAlaIleAlaIleAlaIleAlaIleAlaIleAla 287

seq_name: /SIDSL/gcgcdata/geneseq/geneseqp-emb1/AA1998.DAT.AAW36133
seq_documentation_block:
ID AAW36133 standard; Protein; 193 AA.
XX AAW36133;
XX AC AAW36133;
XX DT 21-MAY-1998 (first entry)
XX XX Streptomyces orfi gene product.
XX DE Streptomyces orfi gene product.
XX KM Daunomycin C-14 hydroxylase; doxa gene; doxorubicin; daunomycin;
XX KM 13-dihydrocarbamimycin; carminomycin; anthracycline;
XX KM anticancer; cytostatic; cancer; therapy.
XX OS Streptomyces sp.
XX XX WO9744439-A2.
XX PN 27-NOV-1997.
XX PD 22-MAY-1997; 97WO-US08690.
XX PF 24-MAY-1996; 96US-0653650.
XX PR (OHIS ) UNIV OHIO STATE. RES FOUND.
XX PA
XX

```



PI Desanti CL, Dickens ML, Strohl WA;  
 XX  
 DR WPI: 1998-018495/02.  
 N-PSDB: AAV01453.

XX Producing doxorubicin from daunomycin by daunomycin C14 hydroxylase  
 PT - also hydroxylation and oxidation of other anthracycline(s) with  
 PT the same enzyme

XX Disclosure; Fig 3; 59pp; English.

XX This protein is the encoded product of the Streptomyces sp. strain  
 CC C5 daunomycin biosynthetic gene cluster orf1 (see AAV01453). This  
 CC gene lies upstream of orfA and doxa (see also AAV01447). The doxa  
 CC gene codes for daunomycin C-14 hydroxylase (see AAV36128), an enzyme  
 CC capable of converting daunomycin to the anticancer agent doxorubicin.  
 CC Host cells, especially Streptomyces host cells, transformed with  
 CC plasmids (see AAV01451-52) containing the doxa gene can be used in  
 CC methods for the production of doxorubicin from daunomycin or for the  
 CC hydroxylation and oxidation of other anthracyclines.

XX Sequence 193 AA;

alignment\_scores:                   Quality: 961.00           Length: 192  
                                   Ratio: 5.005               Gaps: 0  
 Percent Similarity: 100.000       Percent Identity: 96.354

alignment\_block:  
 US-09-673-254-1/rev x AAW36133

Align seg 1/1 to: AAW36133 from: 1 to: 193

2860 CGCATGATGTCATGGCCAGCAACGCCGGCGCATGTCGTGCGGCAC 2811  
 1 Argilepsylmetalaaglyasnalaaglyglymetpetherargrh 17  
 2810 CACGACCCAGGAGGGGTTCAGAGCCCATCCAGTCATCAATCACTCGGAG 2761  
 17 rtrthrhglaspolyphneglualatrrleuglnvalasnhislsleuadag 34  
 2760 GCTTCCTGTCGCGACGCGCTGCGGAGCGGCTCGCGGCGGCGGCGCTG 2711  
 34 lypheleuleuhalatargyleuleuarglunargleuadaglyglyargleu 50  
 2710 ATCTCTCACTCTGTCGAGCGCTACACCCAGCGCGGATGTCACCCGGACGA 2661  
 51 lleleuthrseraseraspalatrytrthglnglyargileasproaspas 67  
 2660 CCTCAAGCGCGACCGTCACCGCTACAGCGCGGCGGCGGCGTACGCGACGT 2611  
 67 pleuasngelyasparghlsarqytrseralaaglyglnalatryglythr 84  
 2610 CCAACAGCGCCACATCATGACCGCGGCGGAGCGCGGCGGCGGCGGCGG 2561  
 84 erlysglnalaasnllewerthralatrrglnalaalaargargtrpro 100  
 2560 GACGTGCTGGCGGTACCTATACCCCGGAGTCCGCGACCCCGCATCGG 2511  
 101 Aspvallleuthrvalsertrhlsproglylnvalaagtrhrraarglle 117  
 2510 ACGGGGACGGGCGCGCTGCTCTACTTCGGGTCAACCCCTCTCGGCGCT 2461  
 117 yargelythrvalalaserthrtrypheargpheasnrpohleuarg 134  
 2460 CCGCGCGCAAGGGCGCGACACCTCGTGTGCGGCGCTCGCGCGCGCGC 2411  
 134 erAlalalysglvalasprhleuvaltrpleuadalaalalalalal 150  
 2410 GAGGAGTTGACACGCGGCGCTACACGCGCGGCGGCGGTCCCGCGGT 2361  
 151 glngluleuthrthrglyglytyrtyrserasparqargleuSerprova 167

2360 GAGCGGCCGACCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 2311  
 167 lserglyprothrAlaaspalaaglyleuadalaalalalalalalal 184  
 2310 GCGCGCGCGCGCGGTCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 2285  
 184 erAlal 192

seq\_name: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:AAW68560

seq\_documentation\_block:

ID AAW68560 standard; Protein: 117 AA.

AAW68560;

25-JAN-1999 (first entry)

S. peuceitius partial dnrx gene product.

dnrx; dnrx; recombinant; microorganism; doxorubicin; daunorubicin;  
 KM metabolism; daunomycin; secretion; anti-tumour compound.

Streptococcus peuceitius.

Key Location/Qualifiers

FT MISC-difference 13 /note= "encoded by GAG"

FT MISC-difference 14 /note= "encoded by CTC"

FT MISC-difference 68 /note= "encoded by CAC"

FT MISC-difference 78 /note= "encoded by CAC"

FT MISC-difference 80 /note= "encoded by ATG"

FT MISC-difference 88 /note= "encoded by TTC"

WO9839458-A1.

11-SEP-1998.

05-MAR-1998; 98WO-US03938.

28-JUL-1997; 97US-0901306.

06-MAR-1997; 97US-0812412.

(FHAA ) PHARMACIA & UPJOHN SPA.

Colombo AL, Filippi S, Fonstein L, Hutchinson RC;

Lomovskaya N;

WPI: 1998-506367/43.

N-PSDB: AAV34001.

Production of doxorubicin and daunorubicin - using a recombinant  
 daunorubicin producing microorganism in which at least one dnrx or  
 dnrx metabolism gene has been inactivated

Disclosure; Fig 2A-B; 48pp; English.

This sequence represents a partial dnrx gene product from the  
 microorganism Streptomyces peuceitius. The invention relates to a  
 recombinant microorganism which produces doxorubicin (DOR), in which  
 at least 1 daunorubicin (DNR) metabolism gene selected from dnrx and  
 dnrx, has been inactivated. The microorganism is preferably S. peuceitius  
 WMH1658, WMH1654 and WMH1662. The function of the DNR gene is inactivated  
 by insertion of a gene (preferably neomycin/Kanamycin resistance gene  
 aphII) into the daunorubicin metabolism gene. The blocking of the  
 function of at least one gene of DNR metabolism can increase DNR and DOR  
 production levels and cause the disappearance of Daunomycin-like products  
 resulting in DNR and DOR secretion directly into the culture medium.

CC	The products can be used in the production of anti-tumour compounds.
XX	
SQ	Sequence 117 AA;

Sequence 117 AA;

```
alignment_scores:
```

Quality:	593.00
Ratio:	5.202

```
Length: 117
Gaps: 0
```

similarity: 97.436

Identity: 95.726

Percent Similarity: 97.436

Percent Identity: 95.726

```
alignment_block:
```

US-09-673-254-1/rev x AAW68560

Align seg 1/1 to: AAW68560 from: 1 to: 117

2175 GTACCAAGGTTGCGCGCGGCGCCGCCGATGGCTTCGACCTGGTTGGC 2128  
1 ValThrArgPheAlaProIlyAlaProAlaIrrPheAspGlyGlySerPr 17  
2125 CGATGTGCGCGCCTCGCGCGACTTTCACACCGGCTGTTCGGCTGAGCG 2076  
17 oasPvalAlaIalaSerAlaAspPheTyrThcIlyLeuPheGlyTrpThr 34  
2075 CCACCGTGGTCAAGCAACCCGGCGCCGGGGGATACAGCAGCTCACTCC 2026  
34 lathrValValSerAspProGlyAlaGlyGlyTyrThrThPheSerSer 50  
2025 GACGGGAACTGTGTGCGCGCGGTGCGCCGCAACGAGTACGACACCCCTA 1976  
51 AspGlyLysLeuValAlaAlaValAlaIrrgHstgInIleAspThrProTy 67  
1975 CCACCGCGCCGTACGCGCGCCCGGGAGACGACACAGCGCATGCGGCAATC 1926  
67 rAsnArgProIrrTyGlyProGlyYAsnAspGlnAsnGlyYAsnProAlaIrr 84  
1925 GGACGGTACTTGGCCACACGACGACGCGCGACGACACTGACAAAGCGGCT 1876  
84 rPThrValIrrProAlaThrAspAspAlaAspAlaIrrThrLysArgVal 100  
1875 GAGACGGCGCGCGCGAGAGTATATGACTCGATGAGACGCTCGCGCT 1826  
101 GluThrAlaGlyGlyGluValIleMetThrProMetAspValIleuGlyLe 117  
1825 C 1825  
117 1 117

OM of: US-09-673-254-1 to: PIR\_71:\* out\_format : pfs  
Date: Jun 11, 2002 8:10 PM

About: Results were produced by the GenCore software, version 4.5,  
Copyright (c) 1993-2000 Compugen Ltd.

## Command line parameters:

-MODE=frame+np.model -DEV=ylh  
-O=/cgn2\_1/USPTO.spool/US09673254/rnatc\_11062002\_114211\_938/app-query.fasta.1.2973  
-DB=PIR\_71 -QMT=fastan -SUFFIX=np.pir -GAPO=12.000  
-GAPEXT=4.000 -MINMATCH=0.100 -LOOPEXT=0.000 -LOOPEXT=0.000  
-OGAPOP=4.500 -OGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500  
-FGAPOP=6.000 -FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500  
-DELOP=6.000 -DELEXT=7.000 -START=1 -MATRIX=blosum62  
-MNS=human40.csi -LIST=45 -DOCALIGN=200 -THR.SCORE=pct  
-MAX=100 -THR\_MIN=0 -ALIGN=7 -MODE=LOCAL -OUTTEXT=pfs  
-MEXT=HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000  
-SSR=US09673254.@CNC1\_1\_200 -NCPU=6 -ICPU=3 -LONGLOG  
-DEV\_TIMEOUT=120 -WARN\_TIMEOUT=30 -NO\_XLPHY -WAIT -THREADS=1

## Search information block:

Query: US-09-673-254-1  
Query length: 2870  
Database: PIR\_71:\*  
Database sequences: 283138  
Database length: 96089334  
Search time (sec): 86.320000

## score list:

Sequence	Strd	Orig	ZScore	EScore	Len	Documentation
PIR2:J00405	-	625.50	496.99	1.6e-20	1106	hypothetical 119.5K protein (u
PIR2:J00405	-	560.00	443.28	1.2e-17	1106	hypothetical 119.5K protein (u
PIR2:S27923	-	538.00	427.37	1.1e-16	924	gene lrf3 protein - human herpes
PIR2:T02345	-	486.50	381.33	2.1e-14	1791	hypothetical protein K1A0324
PIR2:T02345	-	479.00	372.41	4.4e-14	1791	hypothetical protein K1A0324
PIR1:B45344	-	468.50	367.39	1.3e-13	1733	probable nuclear antigen - sui
PIR1:A35175	-	464.50	366.29	1.9e-13	1344	mucin 1 precursor, repetitive
PIR1:CGH15	-	459.50	364.41	3.1e-13	1042	collagen alpha 1(I) chain - ch
PIR1:CGH15	-	458.00	360.47	3.7e-13	1464	collagen alpha 1(I) chain - ch
PIR2:T43434	-	454.00	353.89	5.6e-13	2232	hypothetical protein K06A9.1a
PIR2:S21626	-	450.00	354.21	8.3e-13	1453	collagen alpha 1(I) chain - pre
PIR2:S59856	-	450.00	354.15	8.3e-13	1464	collagen alpha 1(I) chain - pre
PIR2:S27923	-	448.50	356.70	9.3e-13	924	gene lrf3 protein - human herpes
PIR2:Q08E3	-	442.00	354.30	1.8e-12	660	BHLF protein - human herpesvir
PIR2:CG807S	-	442.00	350.54	1.8e-12	1049	collagen alpha 1(I) chain -
PIR2:CGH2V	-	439.00	345.29	2.5e-12	1496	collagen alpha 2(V) chain - pre
PIR1:B45344	-	437.50	342.91	3.0e-12	1733	probable nuclear antigen - sui
PIR2:HA70933	-	434.50	335.91	3.7e-12	261	hypothetical protein RV0577 - h
PIR2:B40505	-	434.50	335.91	4.0e-12	1958	hypothetical protein - suid he
PIR1:CGH07L	-	430.50	340.32	4.9e-12	1466	collagen alpha 1(I) chain - pr
PIR2:T43481	-	430.50	340.32	5.8e-12	580	probable mucin DKFZP343C196.1
PIR2:TA4382	-	430.50	333.88	6.2e-12	3020	mucin 2 precursor, intestinal
PIR2:T43032	-	429.00	351.50	6.5e-12	263	probable hydroxylase - Streptoc
PIR2:T43032	-	428.00	337.04	7.7e-12	1418	collagen alpha 1(I) chain - pre
PIR2:B40505	-	427.50	334.03	8.2e-12	1958	hypothetical protein - suid he
PIR2:A41182	-	425.50	335.06	9.9e-12	1419	collagen alpha 1(I) chain - pre
PIR2:TA1182	-	419.00	331.63	1.9e-11	1151	high molecular mass nuclear an
PIR2:TA1182	-	419.00	331.63	1.9e-11	1487	collagen alpha 1(I) chain - pre
PIR2:BA1182	-	419.00	332.81	1.9e-11	1843	collagen alpha 1(I) chain - pre
PIR2:SI8803	-	418.00	329.71	2.1e-11	1497	collagen type V alpha 2 - pi
PIR2:T43032	-	418.00	329.71	2.1e-11	1497	collagen type V alpha 2 - pi
PIR1:CGH01V	-	418.00	327.04	2.1e-11	1838	collagen alpha 1(V) chain - pred
PIR1:CGH01V	-	415.00	326.80	2.9e-11	1414	collagen alpha 2(I) chain - hom
PIR2:A50849	-	415.00	320.45	3.1e-11	2944	collagen alpha 1(VI) chain - pr
PIR1:CGH01S	-	413.50	325.33	3.3e-11	1464	collagen alpha 1(I) chain - pred
PIR1:CGH01S	-	413.50	325.33	3.3e-11	1466	collagen alpha 1(I) chain - pred
PIR1:CGH07L	-	412.00	324.02	3.9e-11	1487	collagen alpha 1(I) chain - pre
PIR1:CGH07L	-	411.50	324.02	3.9e-11	1487	collagen alpha 1(I) chain - pre
PIR1:BA4606	-	411.50	323.18	4.5e-11	405	cytochrome P450 CYP11B1 - Saccha
PIR1:CGH02S	-	410.00	323.53	4.5e-11	1366	collagen alpha 2(I) chain - pred
PIR2:T33325	-	410.00	323.44	4.5e-11	265	probable hydroxylase - Streptoc
PIR1:S48478	-	408.00	321.55	5.8e-11	1367	glucan 1,4-alpha-glucosidase (

PIR2:T45025 - 408.00 313.76 6.1e-11 3570 mucin MUC5B, tracheobronchi  
PIR2:S24750 - 406.50 330.09 6.5e-11 412 cytochrome P450 (soy) - Stre  
PIR2:F75518 - 405.50 323.53 7.4e-11 839 hypothetical protein - deino  
PIR2:A40333 - 405.50 318.86 7.5e-11 1492 collagen alpha 1(I) chain  
PIR2:SI59856 + 405.00 318.62 7.9e-11 1464 collagen alpha 1(I) chain  
seq\_name: PIR2:J00405

## seq\_documentation block:

hypothetical 119.5K protein (uvra region) - Micrococcus luteus  
N/Alternate names: ORF 1 protein  
C/Species: Micrococcus luteus, Micrococcus lysodeikticus  
C/Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 04-Feb-2000  
C/Accession: J00405  
R/Shiota, S.; Nakayama, H.  
Mol. Gen. Genet. 217, 332-340, 1989  
A/Title: Micrococcus luteus homolog of the Escherichia coli uvra gene: identification  
A/Reference number: S04781; MUID:89364717  
A/Accession: J00405  
A/Molecule type: DNA  
A/Residues: 1-1106 <SH1>  
A/Cross-references: EMBL:X15867  
A/Note: This reading frame extends between two stop codons and does not begin with a  
C/Note: the gene encoding this protein overlaps uvra gene  
C/Superfamily: collagen alpha 1(I) chain; fibrillar collagen carboxyl-terminal homolo

## alignment\_scores:

Quality: 625.50 Length: 1215  
Ratio: 1.295 Gaps: 69  
Percent Similarity: 39.753 Percent Identity: 29.465

## alignment\_block:

US-09-673-254-1/rev x J00405 ..

Align seg 1/1 to: J00405 from: 1 to: 1106

```
2813 CACCAAGACCCAGGAGGCTGCGAGCCACCAATCATACCTGCTG 2764
      ||||| ||| ||||| ||| ||| |||||
60 H1SH1ARGLEULEUARGARGGLY.....PROARGTRARGPROAR 74
2763 CAGCTTCCTGCTGCGAGCGCTGCTGCGAGCGCTGCGAGCGCG 2714
      ||| ||| ||| |||||
74 GLEUARGPROARGARGARGALAU.....GLARGALAG 86
2713 CTGATCTCACTGCTGCGAGCGCTGACACCGCGGATGACCCGGA 2664
      :: |||||
86 LY...PROHS.....ARGARGPROGLY 92
2663 CGACCTCAACGGGAGCGCTGACCGCTGACAGCGCGGCGGCTACG 2614
      |||||::: |||||
93 ARGPROGLAGLPRO..... 98
2613 CGTCAACAGCGACATCATGATGACCGGAGCGGAGCGGAGCGCTG 2564
      ::||| ||| |||
99 .....GLUGLARGGLYCYGLINLEUPROA 107
2563 CCGGAGCTGCTGCGGCTGACATGACCCGCTGAGTCCGACCCGAT 2514
      |||||
107 LAGLARG.....HIS 110
2513 CGGACGGGAGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2464
      ||||| ::||| ||| |||
111 GLYARGVALHISGLYSERVALARGLEU.....GLYGLINLEUPROGL 125
2463 GCTCCGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCG 2427
      ::||| ||| ||| |||||
125 YLEUARGHISARGLEUARGGLYPROALAALALEUARGVALALAL 142
2426 .....GCGCTCGGCGGCGGCGGAGCGGAGCGGAGCGGAGCG 2406
      ||| ::||| |||||
142 EULEUARGPROHISVALPROGLYPROGLYGLINLEUARGGLY 158
```

```

2405 GTTACACGAGGCGGCTACTACAGACGCGGCGGTTCGCCGCT..... 2361
    ::: :|||
159 LeuHisArgLy.....ProValProGlyArgLy 168
    :GAGCGCGCGCAG.....
2360 :|||||:
168 HisArgProGlyValHisGlyProGlyProAlaLeuHisSerGlyAspH 185
2348 .....CGCGGACGCGCGCTCGCGGCGGAAGCTCTGGAGAGCGCGCGCGG 2304
    ||| :|||: |||||
185 HisHisArgSerLeuArgLeuHisAlaProAlaLeuGlyThrCysArgLy 201
2303 CGCGGTCGCGGACACGCGCGCTACAGCGGCGCGCGCGCGCGCGCAT 2254
    ||||| |||||
202 .....AlaAlaLeuProAla..... 206
2253 GTTCGCTGTATCCGCGAGATGTCCGTGTATCCGCGAGCGACGACGCTCG 2204
    ||| |||: ||| |||:
207 ...ValArgArgAlaGlyGlyProAlaAspProAlaAlaAspArgGlyP 222
2203 TGTGGCGATCCATCGAAGAGAACGATTCGTACACGAGTTCGCGCGCGG 2154
    :|||: ||| ||| |||: |||
222 roAlaArgGlyAlaAlaArgAlaHisProLeuProGlyAlaArg..... 236
2153 CGCGGCGATGTTGACCTCGGTTCCGCGCGATGTCGCGCGCTCGCGCGAC 2104
    :236 .....
2103 TTCTACACGCGCGCTGTCCGCTGGACCGCGCACCGCTGTACGACCGCG 2054
    ::: ||||| ||| :|||:
237 .....AlaArgGlyProArgProGlyArgValArg 248
2053 CGCGGCGGATACAGACGCTTCAGCTCGAGCGGAGCTGGTCGCGCGG 2004
    :||| :|||: |||: |||: ||| |||
248 LPro.....ValGlyLProValHisAlaGlyLeuArg 260
2003 TCGCGCGCGACAGATCGACACCGCTTACCGCGCGCGCTACGCGCGG 1954
    ||| ||||| ||| ||||| |||||: |||
260 gArgLyArgGlyAspArgProAlaLeuGlyProAla...ArgAlaGlyG 276
1953 AAGACGACAGCGGATCGCGCGCATCTGACCGCTACTTCCGCCACGA 1904
    ||| ||| |||||
276 LuAlaGlyLuAlaHis.....HisArg 283
1903 CGACGCGCGACGACTGACCAAGCGGCTCGAGACGCGCGCGCGAGCTCA 1854
    ||||| ||| |||
284 ArgArgArg.....GlyProProArg..... 290
1853 TCATGACTCCGATGACGTCCTCGGCT.....CGGC 1822
    |||: ||| |||
291 HisGlyGlyGlyHisProProAlaProHisArgLeuGlyLysArgP 307
821 GCGATGCGGCTCTCGCGCGACCGCGCGCGCGCGCTTCGCGCTCGCGG 1772
    |||: ||| ||| ||||| ||||| |||||
307 roGlyLuAlaLy...GlyArgProArgGlyArgValArgLy..... 320
1771 CAAGGAGTCATGAGGCGCGGAGTGCAGCGCGCTGCCGCGCTCGCTG 1722
    ||| ||| |||||
321 .....ArgGlyAlaGlyArg..... 325
1721 GCTGGGTGAGCTGTGACCGACGCGCATCGGCG..... 1688
    ||| |||: |||: ||||| |||||
326 .....ArgGlyGlyGlyGlyHisArgGlyValArgArgAlaGlyA 340
1687 .....CGCGCGGAGCTTCATACC 1670
340 rArgGlyGlyInProProValProLeuValLeuArgGlyLuAlaLeuLeuPro 356
1669 GCGGACCGCTCGGCTCGCGCGCGACGCGACT..... 1634
    ||| ||||| ||||| |||||
357 GlnArgAlaArgAlaAspArgGlyArgAspArgAlaAlaLeuValLeuLe 373
1633 ...GAAAGGCTGACGCGACCGCGTCTGGCACATCGGTGACACACCGGTC 1588

```

```

    :||| :|||: |||
373 uGlyGlyInProValArgArgValProArgValHisArg.....H 386
1587 GCGCGACCGCAGAGCTGG.....CGTCACCGCGCG 1556
    :||| ||| |||||
386 IsArgLeuProProAlaGlyGlyProGlyProArgArgArgGlnArgArg 402
1555 GATACGCGCGACCTGGCGCGCTGTCCGCGCGACGACGACGCGCGG 1506
    :|||: ||| ||||| ||||| |||||
403 AlaValProAlaArgGlyArg.....ArgArgAlaValAlaArgGly 417
1505 CGGTCCGCGCGCGCTTGAATCGCGCGCGCTCGCA..... 1469
    :||| ||| |||||
417 nValHisLeuGlyLeuLeuAlaAlaArgAlaArgArgAlaGlyGlyGlyA 434
1468 .....GAA 1466
434 spGlyLeuLeuProGlyHisProValGlyGlyProAspGlyGlyAla 450
1465 CGAGCGCGCGCGACGCGCGCGGCGCGCGGCGA..... 1430
    ||| ||| |||||
451 ArgArgArgProAlaArgGlyGlyLeuGlyGlyGlyAspValProG 467
1429 .CGTCTCGACCC..... 1418
    ||||| |||||
467 nProValArgProArgAlaProLeuHisHisGlyLeuArgGlyArgHisP 484
1417 .....GCACGCGCGCGCTTCGCTGTGCGACCT... 1388
    ||||| ||| |||||
484 roLeuArgAspAlaGlnAlaArgGlyAspArgValGlyArgArgProArg 500
1387 .....GCGGGA.....GGGTCACCGCGG 1368
501 AlaLeuArgValAlaHisAlaGlyAspProValProGlyValProArgG 517
1367 CGCGGCGCGGTG.....CTTCGAGCGCGCGAGCGCGCG.....G 1331
    :|||: |||: ||||| ||||| |||
517 yProGlyInProHisGlyProGlyHisArgAlaArgGlyArgProValHisA 534
1330 TCGCGCGTCCGCGCGCTTCGCGCTCCCATGATGACCATGCGAGCGAAGC 1281
    ||||| |||||
534 rGlyArgHisPro.....ProAlaHisAla 542
1280 CGAGGT.....GCACGACGCGCTTCGCGGAGCG... 1254
    ||||| ||| ||||| |||||
543 ArgGlyHisGlyValLeuLeuGlyAlaAlaAlaAspGlyProGlyAlaAl 559
1253 .....GGCGCGCTGTCGAGGTGACGCGCGCGCGCGCGCGCGCGCG 1211
    ||||| |||: |||: |||
559 aAspArgGlyProGlyAlaGlnGlyAspProGlyProAlaGlyValProA 576
1210 TGGGTATGACCGATGACCGCGCGCGCGCGCGAGTCTGGCGCATCCG 1161
    |||: ||| ||| ||||| ||||| |||||
576 laGlyArgArgProArgValProGlyProArgGlyAlaAlaGlyArgHisP 592
1160 GTT...CGTGAAGACCGCGACCTCGCGCG.....CGCGCGCTGGC 1123
    :|||: |||: ||||| ||||| |||||
593 LeuArgArgArgGlyProAlaHisProProGlyHisHisArgArgLeuArg 609
1122 GGGGGTGCAGACGCTTCGACATCCCGCTTCCGAGCTGCGCTCGCTG 1073
    :||| ||||| |||||
609 g...AlaGlyArgArgProLeuArgProArgArgAla..... 620
1072 AGCGTCATGCGCGTGGACGCGCGCGCGCGCGCGCGCTGCGCGCATCCA 1023
    :||| ||| ||| ||| |||
621 ..ValHisArgProAlaProAlaGlyGlyInProProHisArgAspPro 636
1022 CGACCTGCTTCAACCGCGCGCGCTGCGCGCGAGCGAGCATCGCATCG 973
    ||||| ||||| ||||| |||||
637 .....ProAlaProAlaGlyProArgGlnHisProHisArg 648
972 CGGC.....GATCGC..... 963
    |||||

```



```

122 1LeuProGlyLeuArgHisAspLeuArgGlyProAlaAlaLeuArgA 139
      |||
      |||
80  GGATGAGCG.....CAGCCAGAGCGGCACT 105
      |||
139  rGValAlaLeuLeuLeuArgProHisValProGlyProGlyGlnAla 155
      |||
106  CGGTAGAGCGCGCGTCTGGGCGCCCTTCGGCAGCAGCGCAATCGTGG 155
      |||
155  aGlyArgGlyLeuHisArgGlyProValProGlyArg.....V 168
      |||
156  TAGGCGACGCGCAATCGCGCGCTGGGGAACGTCTGCGCAGTACGCCAT 205
      |||
168  aHisArgProGlyValHisGlnProGlnProAlaLeuHisSerGlyAsp 184
      |||
206  CATCGTGGCGGCACTCCAGCTG.....CG 228
      |||
185  HisHisArgAspLeuArgLeuHisAlaProAlaLeuGlyThrCysArgG 201
      |||
229  CGAGCTGTCCCGGATCGAGTAGTCGCGCCGCGCCGAGAGGTGAGCGG 277
      |||
201  yAlaAlaLeuPro...AlaValArgArg.....AlaGlyGlnProA 214
      |||
278  .....CGGCCAGAGGAGCGGTCCGGGTGAA 304
      |||
214  laAspProAlaAlaAspArgGlyProAlaArgGlyValAlaAlaArgAlaHis 230
      |||
305  .....GGCGTGGC 312
      |||
231  ProLeuProGlyAlaArgAlaArgGlyProArgProGlnGlyArgValAr 247
      |||
313  GGGCGTGTGATGGCGCGCGCTGGTGGT..... 343
      |||
247  gGlyProValGlnGlyProValHisAlaGlyLeuArgArgArgGlyArgG 264
      |||
344  .....GCCCTCGATGTC 355
      |||
264  lyAspArgProAlaLeuGlyProAlaArgAlaGlnGlyAlaGlyGlnAla 280
      |||
356  CAGCAGCAGCGCGCGCTCGCGCGGAGCGGAGCGCGCGATGTCACCT 405
      |||
281  His...HisArgArgArgGlyProProArgHisGlnGlyGlnHis... 295
      |||
406  CGGTGGCAGCGAAGCTCCAGCAAGTGTAGGGCAGCGCGGTGTAGCGC 455
      |||
296  .....ProProAlaProHisArgLeuGlyLyAspArg..ProGlnAl 309
      |||
456  AGCGCTCTCTCAGCAGACCGGAGA..... 480
      |||
309  aGlyGlyArgProArgArgGlyArgValArgGlyArgGlyAlaGlyArgA 326
      |||
481  .....CGGCTCTCTCGGCGATCCGCGCGGAGGC 510
      |||
326  rGlnGlnGlnGlnGlnHisArgGlyValArgArgAlaGlyArgArgGly 342
      |||
511  GGGCGCGCAGGACT.....CGCGAGCAGAGAGCGCGAGAGAG 551
      |||
343  GlnProProValProLeuValLeuArgGlnAlaLeuLeuProGlnArgAl 359
      |||
552  CCGGTGTGTCTGTGGCGCGGAGATGAGCC..... 582
      |||
359  aArgAlaAspArgGlyArgAspArgAlaAlaLeuValLeuLeuGlnGlnP 376
      |||
583  .....CGGTGATCATGTAGACGAGCTGCT 606
      |||
376  roValArgArgValProArgValHisArgHisArgLeuProProAlaGly 392
      |||
607  .....CTCGAGAGACCGAGCAACTCGGCGCTCGCGCGGCTGG 644
      |||
393  GlyProGlyProArgArgGlnArgAlaValProAlaArgGlyArg 409
      |||
645  T.....ACAGCAGCGGCGTCACTGTCGGGCTGTCTCTCCGCGC 682
      |||
409  gArgArgAlaValValAlaArgGlnValHisLeuGlyLeu..... 422
      |||
683  GGCTAGTGCACGGCTTCGAGAGCAGAGCTTCACAGGCGCGAGTCTCCG 732
      |||
423  ..LeuAlaAlaArgAlaArgArgAlaGlnGlyAspGlyLeuLeuPro 438
      |||
733  GCAGCGCGCGCGGAGGTCG.....TGCGTCAACCGCG 767
      |||
439  GlnHisProValGlnGlyProAspGlyGlyAlaArgArgArgProAl 455
      |||
768  CGCTCTGCGGCGCGCGAGCGGAGTGTGTCAGACGCTACGCGCTC 817
      |||
455  aArgGlnGlyLeuGlnGlyGlyAspValProGlnProValArgProA 472
      |||
818  GCGGCGCATCGCGGATCGGTGAGCGGCAACCGAGCAGCTCGCAGATGA 867
      |||
472  rGAla.....ProLeuHisHis..... 477
      |||
868  CCAACAGCGGGAAGTGTACGGCAAGCCGCGATCAGTCCGCGGTTTG 917
      |||
478  .....GlyLeuArgGlyArgHisProLeuArgAspAlaG 489
      |||
918  CCCAGCGCGCGAGGCGTGGCGAGTTCGTGACAGCGCGCGCGAT 967
      |||
489  nAlaArgGlyAspArg.....ValGlyArgArgP 499
      |||
968  CGCGCGATCGCATCCGTCGCGCGCGCGCGCGCGGTGACGCGAG 1017
      |||
499  roArg.....AlaLeuArgValValHisAlaGly...AspPro 510
      |||
1018  GTGCTGTGATGCGGCGGAGCGCGCGGTGGCGCTCGCGCTCAGCGGATG 1067
      |||
511  ValProGlyValProArgGlyProProGlnProHisGlyProGlnArg... 526
      |||
1068  AGCGTGAACGGAGCACTCCGGAACGGGATGTGAGACCGCTGTCCAC 1117
      |||
527  .....AlaArgGlyArgProValHisArgGlyArgHisP 538
      |||
1118  CCGCGCGCGCGCGCGGAGGT..... 1143
      |||
538  roProAlaHisAlaArgGlyHisGlyValLeuLeuGlyValAlaAlaAsp 554
      |||
1144  .....CGGGCTCTTCACGACCGGGATCGGCGCAGC 1175
      |||
555  GlyProGlyAlaAlaAspArgGlyProGlyAlaGlnGlyAsp...ProG 570
      |||
1176  ACCTGCGGG.....CGAGGCTCATGCTGATGACCCAGCGGCTCC 1219
      |||
570  yProAlaGlyValProAlaGlyArgArg.....ProArgValProG 584
      |||
1220  GCGCGCGG.....GGCGTTCACCT..CGAGCAGCGGCGCGG..... 1254
      |||
584  lnProArgAlaAlaGlyArgHisProLeuArgArgGlyProAlaHis 600
      |||
1255  CTTCCCGGAAGCGTCTGACCTCGGCTTCGCGTGCATGTCATCATG 1304
      |||
601  ProProGlyHisHisThrAspArgLeuArgAla..... 610
      |||
1305  GGAACAGCGAAGCGGTGACGCGCAACCGGGGCGCTCGCGCTACAGAG 1354
      |||
611  .....GlyArgArgProLeu...ArgProArgArgAla..Va 621
      |||
1355  GCACGCGCGCGCGCGGAGTACCCCTCCGCACTTCGACACCGAGAA 1404
      |||
621  HisArgProAlaProAlaGlyGlnProProHisArgAspPro.... 636
      |||
1405  GCGGCGCGCGTGGGATGAGAGGTCGCGCGCGCGCGCGCGGCGGTG 1454
      |||
637  .....ProAlaProAlaGlyProArgGlnHisProHisArg... 648
      |||
1455  CGCGCGGCTGTCTGACGAGCGCGCA.....GTTCAACGGCGCGC 1498
      |||
649  ArgArgAlaArgArgGlyHisAspArgArgGlyGlyLeuAspArgGlyHis 665
      |||

```

```

1499 CGAGCGTGGCGT.....CGAGTCGTGCACGGCAGACGACGCG 1539
      |||||
665 sargrProserArgGlyArgValArgArgArgGlyArgAlaLeuGlyLeuP 682
      |||||
1540 CCAGTGGC.....GCCGTACCGCGCGGTGACGCCCAAGT 1574
      |||||
682 rGlyArgLeuGlnGlnHisAlaValArgHisArgArgLeuProLeu 698
      |||||
1575 CCTGGGTGGCGGCGGTGTGTACCGATGTGC..... 1610
      |||||
699 .....ArgProLeuHisArgGlyAlaGlyAlaAlaSerAr 711
      |||||
1611 .....AGACGGGTGGTGC 1626
      |||||
711 gProGlyGlnGlyAlaArgAlaAspGlyProArGArProGlyGln...G 727
      |||||
627 GCCCTTCACTCCGGTGGCGCGGACGCGCGAGGGTGGCGCGGTAGA 1676
      |||||
727 InProGlyGlyArgLeuGlyProGlyProAlaArgGlyProHisGlyArg 743
      |||||
1677 AGTCCGGCGGCGCGCGATGCCGT..... 1700
      |||||
744 Asp...GlyArgValArgLeuArgGlnValHisAlaAspGlnArgAspPr 759
      |||||
1701 .....CGGTACCGAGTCCAGCCAGC.....CGACCGAGCGCGGACGCG 1740
      |||||
759 OleuGlnGlyProGlyGlnProAlaGlnArgArgGlnAlaArgAlaArgP 776
      |||||
1741 GGTCACTCCGCGCGCTCCATGACTCCCTTGGCGCAGACCGGCAACGCGG 1790
      |||||
776 rAlaArgPro..... 778
      |||||
1791 CCCCGCGGCGGTGGCGAGACGCCCATCCGCG.....CGAGCGCGAG 1834
      |||||
779 ValArgGlyGlyThrArgAlaProGlyGlnGlyGlyProArgGly...ProG 795
      |||||
1835 AGCTCATCGAGATCATGATGACTCGCGCGCGCGCGCTGC..... 1875
      |||||
795 InProHisArgHisAlaThrLeuGlnProArgHisLeuHisGlyArg 811
      |||||
1876 .....GACCGGCTTGGTCACTGCGT 1895
      |||||
812 ValArgArgAspProGlnAlaLeuArgGlyAspProArgGlyGlnGlyPr 828
      |||||
1896 GGGCGTGGTGGCGGAGTA..... 1917
      |||||
828 OeGlyLeuProAlaGlyProValLeuGlnHisGlnGlyArgAlaLeuA 845
      |||||
1918 .....CACGCT.....CCAGAT 1929
      |||||
845 rGlyValArgGlyArgArgHisAlaGlnAspArgAspGlyLeuProAla 861
      |||||
1930 GCGCGG...CATGCGTGGTGGTGGTCC...GGCGCGTACGCGCG... 1971
      |||||
862 GlyArgLeuArgAlaValArgGlyValProArgGlyProValGlnProGl 878
      |||||
1972 .....GTGGTAGGGGTGTGATCTGGTGGCGGCG... 2001
      |||||
878 yAspAlaArgGlyHisLeuGlnGlyGlnHisArgArgGlyProArgH 895
      |||||
2002 .....GACCGCGCGCAGCATTTCCCGTGGAGCTGACGCTGATATCC 2046
      |||||
895 IsAlaAspArgGlyArg.....GlyLeuLeuInArgValHis 908
      |||||
2047 CCCGGCGCGCGGTGGTGCACGAGTGGCGGTCCAGCGGACGCGCGG 2096
      |||||
909 ProHisLeuAlaValProGlyHisAla...ArgArgArgArgSerGlyLeu 924
      |||||
2097 TGTAGAAGTGGCGCGGAGACATCGGGGAGAACGAGTGCAGACAT 2146
      |||||
925 ArgProSerGlyProAlaArgHisAlaLeuGlyArg..... 937

```

```

2147 GCGGGGCGCGCGGCGGAGAACCTGTCAAGATCGTTCCCTTCATGAT 2196
      |||||
938 Arg.GlyProAlaArgGlnAlaGlyGlyArgAlaProGlnAlaLeuGln 953
      |||||
2197 CGGACACGAGCGGTGCGCTCGCGGATGACAGCAGCATTCGCGGATGA 2246
      |||||
954 Arg.....ProHisLeu..... 958
      |||||
2247 GACGACATCGCGCGGCGGCGCGCGCGCGCGCATGTCGCGGTGCGCC 2296
      |||||
959 .....ArgAlaGlyArgAlaAspHisGlyAlaAla.....LeuA 970
      |||||
2297 GACGCGCGCGCGCGCGCGCTCCAGACTTCG...CCGAGAGCGCGCGT 2343
      |||||
970 rGArgHisProGlnAlaProAlaArgAlaSerValProArgGlyGlnGly 986
      |||||
2344 CGCGGTGGCGCGCTCACCGGGGACAGCGCGCGGTGCTAGTACGGC 2393
      |||||
987 GlnHisGlyAlaHisHisArgAlaGlnPro.....A 997
      |||||
2394 CCGGTGTCACTCTCGCGCGCGCGGACGCGCAGCCACAGCAGGCTGC 2443
      |||||
997 rGArgAspGlnGlyArgGlyProArgAspArg...ProArProGly... 1011
      |||||
2444 GCGCGCTTCCGCGCGCGAGCGCAGAGAGGCTTGAACCGAAGTACGACG 2493
      |||||
1012 GlyArgLeuAlaArg.....Ar 1017
      |||||
2494 AGCGACCGTGGCGCGCTCCAGTCCGGTCCGAGCTCCAGCGGCTATAG 2543
      |||||
1017 gHisAspArgGlyHisGlyHisAlaGlyGly.....GlyArgAlaA 1031
      |||||
2544 CTGACCGCGAGCAGCTCCGCGCGCGCTGCGCGCGCTCCGCGCGCTCAT 2593
      |||||
1031 rGArgArgGlyInProHisGlyProValProArgGly..... 1042
      |||||
2594 GATGTTGGCTTTGGAGCTGCGCTACGCTGCGCGCGCTGTACGCT 2643
      |||||
1043 .....AlaAlaArgValAlaArg 1048
      |||||
2644 GACGTCGCGCTTGAAGCTGTCGCGGTGCATCCGCGCTGGGTGACGG 2693
      |||||
1048 pThr.ProProThrGlnAspGlnAspGlyGlyProThr.ArgArgAr 1064
      |||||
2694 TCGGACGAGGTGAGTACGCGCGCGCGCGCGCGCTCCGCGCGAG 2743
      |||||
1064 gArgProCysAlaGly.....AlaProProArgCysGlySerProH 1079
      |||||
2744 CCGTCCACGACGAGACCTGCGAGTGAATTGACTGATGTTGGCTTCGA 2793
      |||||
1079 lAlaValProArgSer.....AspGlyAlaArgProArg 1090
      |||||
2794 ACCGTCCTGGGTGCTGGTGGCGGACACAGATGCGCG 2832
      |||||
1091 GlnAlaProSerSerSerProProThr...ThrCysArg 1102
      |||||
seq_name: p1r2:S27923
seq_documentation_block:
gene Lf3 protein - human herpesvirus 4
C:Species: human herpesvirus 4, Epstein-Barr virus
C:date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 31-Jan-2000
C:Accession: S27923
R: Parker, B.D.; Bankier, A.; Satchwell, S.; Bartell, B.; Farrell, P.J.
submitted to the EMBL Data Library, August 1990
A:Description: Sequence and transcription of Raj1 Epstein-Barr virus DNA spanning the
A:Reference number: S27923
A:Accession: S27923
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-924 <PAR>
A:Cross-references: EMBL:M35547; NID:9330420; PIDN:AAA5896.1; PID:9330421
C:Superfamily: collagen alpha 1(I) chain; fibrillar collagen carboxyl-terminal homolo

```

alignment\_scores:                   Quality: 538.00                   Length: 1034  
                                       Ratio: 1.231                   Gaps: 63  
 Percent Similarity: 42.263           Percent Identity: 30.077

alignment\_block:  
 US-09-673-254-1/rev x S27923   ..

Align seg 1/1 to: S27923 from: 1 to: 924

```

2804 CAGAGAGGGGTTGAGGCCACCATCGATCACTTCGACGCTTCC 2755
      |||||
      |||||
12 ProGlySerGlyLeuGlyAlaHisPro.....HisProArgArg..... 24
2754 TCGTGGCAGCGCTGCTGCGGGAGCGGCTCGGGGGGGGGCGGATTC 2705
      |||||
      |||||
25 .SerGlyAlaAlaAspProAlaAspProValGlyHisProAlaAlaPro 41
2704 ACCTGCTCGACGCGTACACCGAGCGCGGAT.....CGA 2670
      |||||
      |||||
41 rglAla.....ProGlyProGluProArgThrArgLeuGln 52
2669 CCGGAGCAGACCTACACG.....CGACGTCACCGCTACAGCGCGCC 2626
      |||||
      |||||
53 ProAlaThrProArgArgSerGlyAlaAlaAspProAlaAsp..ProVal 68
2625 AGGGGTGAGCAGCTCCAAACAGCGCAACATCATGACCGCGCGAGGCC 2576
      |||||
      |||||
69 GlnHisProAlaAlaProAlaGlyAlaProGlyProGluProArgThrArg 85
2575 GCCAGGGCGCTGGCGGACGCTGGCGGTGACGTATACCCCGGTGAGGT 2526
      |||||
      |||||
85 uGlnProAla.....ThrProArgArg 93
2525 CCGGACCCCGCATGCGAGCGGCGACGCTGCTGCTCTACTCCGGTCA 2476
      |||||
      |||||
93 er.....GlyAlaAlaAspProAlaAspProValGlyHis 104
2475 ACCCTTCCTGCTCGCGCGGAGGCGCGACACCTCGTGTGCTG 2426
      |||||
      |||||
105 .....ProAlaAlaProArgAlaProGlyProGluProArgThrArg 119
2425 GCGTCCGCGCGCGCGAG.....AGTTGACCAACG..... 2395
      |||||
      |||||
119 uGlnProAlaThrProArgArgSerGlyAlaAlaAspProAlaAspPro 136
2394 .....GCGGCTACTACAGCGACCGCGGCTGCTCCCGGTGAGCG 2356
      |||||
      |||||
136 AlGlyHisProAlaAlaProArgAlaProGlyProGluProArgThrArg 152
2355 GCCGACCGCGCGCGCGCTCGCGCGGAGACTCT..... 2320
      |||||
      |||||
153 LeuGlnProAlaThrPro.....ArgArgSerGlyAlaAlaAspProAl 167
2319 .....GGGAGCGCGGCGCGCGCGCTG..... 2296
      |||||
      |||||
167 AspProValGlyHisProAlaAlaProArgAlaProGlyProGluPro 184
2295 .....GCGACACCGCGCACTGACGCGGCGCGCGCGCGCC 2263
      |||||
      |||||
184 rGlyThrArgLeuGlnProAlaThrProArgArgSerGly..AlaAlaAsp 200
2262 CGCCCGCATGTCGCTCATCGCGAGATGTCGCTCATCCGCGAGCG 2213
      |||||
      |||||
200 oAla.....AspProValGlyHisProAlaAlaProArgAla.. 212
2212 AGACCTGCTGTCGCGATTCATGAAGAGACGATTCGTGACCAAGTTCG 2163
      |||||
      |||||
213 .....ProGlyPro 215
2162 CGCCCGCGCGCCCGCANGTTCGACCTGGTTCCGCCGATGTGCGCGCC 2113

```

```

216 GlnPro.....ArgThrArgLeuGlnProAlaThrProAr 227
      |||||
      |||||
2112 TCGGCGG...ACTTCTACACCGGCTGTTGGCTGACCGCCGACCTGGGT 2066
      |||||
      |||||
227 ArgSerGlyAlaAlaAspProAlaAspProValGlyHisPro.....A 242
2065 CAGGACCCCGCGCGCGGAGTACACGACTTCAGCTCCGACGGGAAAC 2016
      |||||
      |||||
242 IaAlaProArgAlaProGlyPro..... 249
2015 TCGTGGCGGCTGCGCCGCCACGATGACACCCCTACCGAGCGG 1966
      |||||
      |||||
250 .....GlnProArgThrArgLeuGlnProAlaThrProArgAr 262
1965 TACGGCGCCGGGAGACACGACGACGCGCATGC...CGGCATCTGACCGCT 1919
      |||||
      |||||
262 gSerGlyAlaAlaAspProAlaAspProValGlyHisProAlaAlaPro 279
1918 GTACTTGGCACCGGACGAGCGGCGACACTGACCAAGCGGGGTGAGACG 1869
      |||||
      |||||
279 rGAlaProGlyProGluProArgThrArgLeuGlnProAlaThrProArg 295
1868 CCGGCGCGGAGGTCAATGACTCCGATGACGCTCGGCTGCGCGCG 1819
      |||||
      |||||
296 ArgSerGlyAlaAlaAsp.....ProAlaAspProValGly 307
1818 ATGGCGGCTTTCGCGGACCCCGCGGCGCGGCTGCGGCTGCGCGCA 1769
      |||||
      |||||
307 yHisProAlaAlaProAlaGlyAlaProGlyProGluProArgThrArg 324
1768 GGAAGTCATGAGAGCGCGGAGGTGACGCGCTGCGCGCTGCTGCGGCT 1719
      |||||
      |||||
324 InProAlaThrProArgArgSerGlyAlaAlaAspProAlaAspProVal 340
1718 GGGTGAAGCTGTGACCGACGACATGCGGCGCGCGGAGCTTCAACCG 1669
      |||||
      |||||
341 GlnHisProAlaAlaProArgAlaProGlyPro..... 351
1668 GCGACCCCTGCGCTGCTCGCGCGGCGGACCGAGTGAAGCGGTACGSA 1619
      |||||
      |||||
352 .GlnProArgThrArgLeuGlnPro.....AlaThrPro 363
1618 CCGGCTGTGACACATG.....GTGACACACCGGTG..... 1587
      |||||
      |||||
363 rGArgSerGlyAlaAlaAspProAlaAspProValGlyHisProAlaAla 379
1586 .....CCGGACCCCGAGACTGCGGCTGCTACCGCGCGGCTA 1552
380 ProArgAlaProGlyProGluProArgThrArgLeuGlnProAla..... 394
1551 CCGCGCGACGTGGCGCGCTGCTGCGCGCTGCGACGACGCGACGCGT 1502
      |||||
      |||||
395 .....ThrProArgArg 399
1501 CCGGCGCGCGCTGGAACCTGCGCGGCTCGCGAGACGAGCCCGGACA 1452
      |||||
      |||||
399 erGlyAlaAlaAspProAlaAspProValGlyHisProAlaAlaProArg 415
1451 CGGCGAGGGGGCGCGGCGGACCTGCTGACCGCGACGCGGCGCGCTTC 1402
      |||||
      |||||
416 AlaProGlyProGluProArg.....ThrArgLeuGlnProAla.. 428
1401 TCGGTGCTGACACTGCGGGAAGGGGTACCCCGCGGCGCGGCTGCTTC 1352
      |||||
      |||||
429 .....ThrProArg..... 431
1351 GTGAGCGGCGAGCGCGCGGCTGCGCGCTGCGACCGCTGCGCTGCCAT 1302
      |||||
      |||||
432 .....ArgSerGlyAlaAlaAspProAlaAspProVal..... 442
1301 GATGACCATGACGCGCAAGCCGAGGTGACAGACGCTTCGCGAGGCGG 1252
      |||||
      |||||

```



```

443 ...GlyHisProAla.....AlaProAlaProGly.... 452
1251 GCCCGGTCGTCGAGGTGAAGCCGCCCGGGGGGAGACCCGCTGGGTCAATC 1202
453 .....ProGluProAlaGlyThrArgLeu.....G 460
1201 ACCGATGACGCCCTCGCCCGCGAGGTGTCGC..... 1170
460 InProAlaThrProAlaGlySerGlyAlaAlaAspProAlaAspProAla 476
1169 .....CGATCCCGGTTGTCGAGGACCCGACCCCTGGCCCGCGCG 1129
477 GlyHisProAlaAlaProAlaProGlyProGluProAlaGlyThrArgLe 493
1128 CCGGCGGGGGGGTGGAGCAGCGGTCTGACATCCCGTCCGAGCTGGCT 1079
493 uGlnProAlaThrProArg.....ArgSerGlyAlaAlaAla 505
1078 CCGTTCACGCTCATGCGCGTGGAGCGGAGCCCAACCGCGCTGCGCG 1029
505 sProAlaAspProAlaGlyHisProAlaAlaProAlaProAlaProGlyPro 521
1028 CATCAGCAGCACTGGCTCAACCCCGCGCGGTGGCCGAGCGGAGGATC 979
522 GluProAlaGlyThrArgLeuInProAlaThrProAlaGlySerGlyAla 538
978 GCATGCGCGCGAT.....CGCCGGCGCGTCTGACCGCACT..... 942
538 aAspProAlaAspProAlaGlyHisProAlaAlaProAlaProGlyPro 555
941 .....CGCCGACGCTCCGCGCGGTC.....GGCCAAACGCGCGCA 906
555 roGluProAlaGlyThrArgLeuInProAlaThrProAlaGlySerGlyAla 571
905 GGTGATCGCGCGCTCGGTACCACTCCCGTGTGGTCACTTCGCACTCGAC 856
572 AlaAsp.....ProAlaAspProAlaGlyHisProAlaAla 583
855 TGCCTGCTGTGCGGTGACCGATCCGCGGATGCGCGCGAGCGCGTCAAC 806
583 aProArg.....AlaProGlyProGluProAlaGlyThr 594
805 GTTCTCAAGCACTCGCCCTGCGCG.....CCCGACGAG 771
594 rgLeuGlnProAlaThrProAlaGlySerGlyAlaAlaAspProAlaAsp 610
770 CGCGGGGGTGAAGGACGAGACCTGCGCGGGCGTCCGCGGACACTCGG 721
611 ProValGly.....HisProAlaAlaProAlaGlyAla..... 620
720 CCTGGAGAGCTGCTCTCGAAGCGGTGCTACAGCCGCGGAGAACGAC 671
621 ..ProGly..ProGluProAlaGlyThrArg..LeuGlnProAla..... 632
670 ACCCGGACCATGACCCGCGCTGCTGACGAGCGCGGACGCGAGGTTCGG 621
633 .....ThrProArg.....Arg 636
620 CTCGGTCTCCGACGACCACTGCTACATGATCAACCGGCTCATCTTGG 571
637 SerGlyAlaAlaAspProAlaAspProValGlyHisProAlaAlaProAr 653
570 CCGGCA.....CGACACCAACCGGCTCTCTCGGCTTCGCTGC 530
653 gAlaProGlyProGluProAlaGlyThrArgLeuInProAlaThrProAla 670
529 GCGAGGCTCTGCGCGCG.....CCT 507
670 rgSerGlyAlaAlaAspProAlaAspProValGlyHisProAlaAlaPro 686
506 CGC.....GGCGGATGCGGAGAGACCGCTCCCGCTT.....CG 469
687 ArgAlaProGlyProGluProAlaGlyThrArgLeuGlnProAlaThrProAr 703

```

```

468 TGGAGAGCGCTGCGCTACACCCGCGGTCGCTACAGCTTGTGGAG 419
1 ..... 111 ..... 720
703 gArgSerGlyAlaAlaAspProAlaAspProValGlyHisProAlaAla 720
418 TTGCGTCCGAGGAGTGACCATCGCGCGCT.....CGGCTCGCGCG 375
720 roArgAlaProGlyProGluProAlaGlyThrArgLeuInProAlaThrPro 736
374 GCGAGCGCGGTGCTGT.....GCACATCG..... 349
737 ArgArgSerGlyAlaAlaAspProAlaAspProValGlyHisProAlaAl 753
348 ...AGGCAACCAACACGAGCGCGCCATCAACGAGACCCCGACGCTT 303
753 aProAlaProGlyPro.....GluProAlaGlyThrArgL 765
302 CCACCGGACCGTCCCTGCGCGCGGCTCACTTCGCGGACGGGCGCG 253
765 euGlnProAlaThrProAlaGlySerGlyAlaAlaAsp..... 777
252 ACTACTGATCGGGGAGCAGCTGCGCCACCTGAGAGTGGCGGACGATGC 203
778 ..ProAlaAspProValGlyHisProAlaAlaProAlaGlyAla..... 790
202 GCGTACTGCGCAGCAGTTCCCGAGCGCGCACTGGCGCTCCGTAACA 153
791 .....ProGlyProGlu..... 794
152 CGAGTTGCGGTGTCGAGAGGGGCGGACGAGCGCGCTCACCGAAC 103
795 .....ProArgThrArgLeuInProAla 802
102 TGGCGG.....TTCGCTGCGCTGATCGCGCGCGCGGACCGGACGG 59
803 ThrProAlaGlySerGlyAlaAlaAspPro.....AlaAspProValG 817
58 ACCGCGCACCGCGCACCGCGGTGGCGCTCCGCTGCTTACCGCG 10
817 yHisProAlaAlaProAlaGlyAla.....ProGlyProGluProAlaGlyThrArg 832

```

seq\_name: p1r2:T02345

seq\_documentation\_block:

hypothetical protein KIA00324 - human (fragment)

C:Species: Homo sapiens (man)

C>Date: 05-Mar-1999 #sequence\_revision 05-Mar-1999 #text\_change 05-Nov-1999

C:Accession: T02345

R:Rickey, D.O.; Bruce, D.; Mundt, M.; Doggett, N.; Munk, C.; Saunders, E.; Robinson, D.

re, J.; White, S.; Yeng, S.; Fatum, O.; Campbell, C.; Fawcett, J.; Deaven, L.

submitted to the EMBL Data Library, March 1998

A:Description: Sequencing of human chromosome 1p13.3.

A:Reference number: Z1464

A:Accession: T02345

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-1791 <R1C>

A:Map position: 16

A:Introns: 1610/2: 1706/2

A:Note: KIA00324

alignment\_scores:

Quality:	486.50	Length:	1108
Ratio:	0.977	Gaps:	55
Percent Similarity:	44.946	Percent Identity:	27.978

alignment\_block:

us-09-673-254-1/rev x T02345 ..

Align seg 1/1 to: T02345 from: 1 to: 1791

```
2844 CCAGCACCAGCGCG.....GCATGTTCTGCTGGCGCACACGACCGACG 2801
      ||| |||||::: |||||::: |||
464 ProArgThrProSerArgSerArgSerArgSerProGluLeuArg 480
      ||| |||||::: |||||::: |||
2800 GAGCGGTGTGAGCGCACCATCCAGGTCAATCACCCTCGACGCGTTCCTGCT 2751
      ||| |||||::: |||||::: |||
480 GAspGlySerGlyThrProSerArg..... 488
2750 GGCACGCTGCTGCGGAGCGGCTCGCGGCGCGGCTGATCCTCAGCT 2701
      ||| |||||::: |||||::: |||
489 ..HisSerLeu.....SerGlySerSerProGlyMetLysAspLeuPro 502
      ||| |||||::: |||||::: |||
2700 CGTCCACGCGGTACACCCAGGCGCGATGACCGGACGACGACCTCAACGCG 2651
      ||| |||||::: |||||::: |||
503 .....ArgThrProSerArgGlyArgSerGlyLysAspSerSer... 515
      ||| |||||::: |||||::: |||
2650 GACCGTCACCGCTACAGCGCGCGCTACGCGACGTCGAACAGCGC 2601
      ||| |||||::: |||||::: |||
516 .....ProGluProLysAlaLeuProGluThr 525
2600 CAACATCATGACCGCGCGAGCGCCACAGCGCT.....GGCCGG 2560
      ||| |||||::: |||||::: |||
525 roArg.....ProArgSerArgSerProSerSerProGluLeuAsn 539
      ||| |||||::: |||||::: |||
2559 ACGTGCTGGCGGTACGCTATCACCCTGGGTAGTCCGACCCGACATCGGA 2510
      ||| |||||::: |||||::: |||
540 LysCys.....LeuThrProGluArgGluArgSerGlySerGly 552
      ||| |||||::: |||||::: |||
2509 CGGG.....GCACGGTGCCT.....CGTC 2490
      ||| |||||::: |||||::: |||
552 userSerValAspGluThrValAlaArgThrProLeuGlyGluArg 569
      ||| |||||::: |||||::: |||
2489 CTACTTCGGTCAAC.....CCTTCCTCGCTCG 2458
      ||| |||||::: |||||::: |||
569 erArgSerGlySerSerGluLeuAspValLysProSerAlaSerPro 585
      ||| |||||::: |||||::: |||
2457 CGGCGAAGGCGCGACACCTCGTGGTGGCTCGCGCGCGCGCGAG 2408
      ||| |||||::: |||||::: |||
586 GlnGluArgSerGluSerAspSerProAspSerLysAlaLysThr 602
      ||| |||||::: |||||::: |||
2407 GACTTGACACAGGCGCGCTACTACAGCGCGCGGCTGTCCCGGTAG 2358
      ||| |||||::: |||||::: |||
602 gThr..ProLeuArgGluArgSerArgSerGlySerSerProGluVal 618
      ||| |||||::: |||||::: |||
2357 CGGCGCGACCGCG...ACGCGCGCTCGCGCGAAGCTTGGAGGCGCG 2311
      ||| |||||::: |||||::: |||
618 sPerLysSerArgLeuSerProArgArgSerArgSerGlySerSerPro 634
      ||| |||||::: |||||::: |||
2310 .....GCGGCGCGCGTGGGAGACCGCGCATGTGACGCGGCGCGC 2269
      ||| |||||::: |||||::: |||
635 GluValLysAspLysProArgAlaAlaProArgAlaGlnSerGlySer 651
      ||| |||||::: |||||::: |||
268 .....CCGCCCGCGCGCATGCTCGTTCATCCGCGAGATGT 2232
      ||| |||||::: |||||::: |||
651 pSerSerProGluProLysAlaProAlaProArgAlaLeuProArgArg 668
      ||| |||||::: |||||::: |||
2231 CGCTTCATCCGCGAGCGACGCTGCTGCGGATCCATCGAAGGAA 2182
      ||| |||||::: |||||::: |||
668 erArgSerGlySerSerLysGlyArgGlyPro..SerProGluGly 684
      ||| |||||::: |||||::: |||
2181 CGATTGTCAGCAGGTTCGCGCGCGCGCGCATGTGACGCGCGG 2132
      ||| |||||::: |||||::: |||
684 rSerSerThrGluSerSerProGluHisProProLysSerArgThrAla 701
      ||| |||||::: |||||::: |||
2131 TTCGC...CCGATGTCGCGCTCGCGCGACTTCTACACCGCGCTGTTCG 2085
      ||| |||||::: |||||::: |||
701 rArgArgGlySerArgSerSerProGluProLysThrLys.....Ser 714
      ||| |||||::: |||||::: |||
2084 GCTGGACCGCGACCGGTGTGACGCGCGCGCGCGGAGATACAGACG 2035
      ||| |||||::: |||||::: |||
715 ArgThrProProArgArgSerArgSerSerProGluLeuThr 731
      ||| |||||::: |||||::: |||

2034 TTCAGTCCGAGCGGAGCTGAGTCGGCGCGGTCGCCCGCACAGATGCA 1985
      ||| |||||::: |||||::: |||
731 gLysAla.....ArgLeuSerArgArgSerArgSerAlaSerSer 745
      ||| |||||::: |||||::: |||
1984 CACCCCTACACCGCGCGCTACGCGCGCGGAGAACGACGACGCGCATCG 1935
      ||| |||||::: |||||::: |||
745 erProGluThrArgSerArgThrProProArg..... 755
1934 CGGCACTGTGACCGTGTACTTCGCCACCGACGACGCGCGCATGACC 1885
      ||| |||||::: |||||::: |||
756 HisArgArgSerProSerValSerSerProGluProAlaGluLysSer 772
      ||| |||||::: |||||::: |||
1884 AAGCGGTCGACAGCGCGCGCGCGAGTCATCATGACTCCATGAGACT 1835
      ||| |||||::: |||||::: |||
772 gSerSerArgArgArgArgSerAlaSerSerPro.....ArgThrLys 787
      ||| |||||::: |||||::: |||
1834 CTTGCGCTCGCGCGATGCGGCTTTCGCGACCGCGCGCGG...CCG 1788
      ||| |||||::: |||||::: |||
787 hrThrSerArgArgGlyArgSerProSerProLysProArgGlyLeuGln 803
      ||| |||||::: |||||::: |||
1787 CGTTCGCGCT...GGCGAAGGAGTCAATGAGGCGCGGAGTGTAGC 1741
      ||| |||||::: |||||::: |||
804 ArgSerArgSerArgSerArgGlyLysThrArgThrThrArgArg 820
      ||| |||||::: |||||::: |||
1740 GCGGTCCCGCGCTCGGTGCGGTGCGAGCTGTGACCGCGCATTCG 1691
      ||| |||||::: |||||::: |||
820 GAspArgSerGlySerSerGlnSerThrSerArgArgGluArgSer 837
      ||| |||||::: |||||::: |||
1690 GCGCGCGCGGACTTACCGCGCGACCTCGCGCTCGCGCGCGACA 1641
      ||| |||||::: |||||::: |||
837 rSerArgSerArgValThrArgArg..ArgArgGlyLysSerGlyThr 853
      ||| |||||::: |||||::: |||
1640 C.....CGGACTGAAGGCGCTCACC 1621
      ||| |||||::: |||||::: |||
853 sSerArgSerProAlaArgGlnGluSerSerArgThrSerSerArgArg 870
      ||| |||||::: |||||::: |||
1620 GACCCGCTGCGACATCGGTGACACACCGCGTCCGCGGACCC..AGGAC 1572
      ||| |||||::: |||||::: |||
870 rArgGlyArgSerArgThrProThrProThrSerArgLysArgSer 886
      ||| |||||::: |||||::: |||
1571 TGGCGCTACCGCGCGGTACGCGCGACTGGCGCTGCTTCGCGCG 1522
      ||| |||||::: |||||::: |||
887 ArgThrSerProAlaProThrLysArgSerArgSerArgAlaSerPro 903
      ||| |||||::: |||||::: |||
1521 CAGCACTGCGACGCGACGCGCGCGCGCTGACACTCG.....GCGG 1478
      ||| |||||::: |||||::: |||
903 atThrHisArgArgSerArgSerArgThrProLeuLysSerArgArgArg 920
      ||| |||||::: |||||::: |||
1477 CTCCTGCGAAGACGACCGCGCGACGCGCGCGCGCGCGCGGAC 1428
      ||| |||||::: |||||::: |||
920 erArgSerArgThrSerProValSerArgArgArgSerArgThr 936
      ||| |||||::: |||||::: |||
1427 TGCTGACCGCGACGCGCGCGCTTCTCGGTGTCGACCTCGCGGAGG 1378
      ||| |||||::: |||||::: |||
937 SerValThrArgArgArgSerArgSerArgAlaSerProValSerArg 953
      ||| |||||::: |||||::: |||
1377 TACCGCGCGCGCGCGGTGCTCGTAGCGGCGAGG...CGCCCG 1332
      ||| |||||::: |||||::: |||
953 gArgSerArgSerArgThrProProValThrArgArgArgSerArgSer 970
      ||| |||||::: |||||::: |||
1331 GGTGCGCTGACCGCTTTCGCGGTCCATGATGACCATGACGCGACG 1282
      ||| |||||::: |||||::: |||
970 rGThrProThrThrArgArgArg..... 977
      ||| |||||::: |||||::: |||
1281 CCGAGGTGACAGCGCTTCCGAGGCGCGCGCGCTCGCAGGTGAAC 1232
      ||| |||||::: |||||::: |||
978 SerArgSerArgThrProProValThrArgArgArgSerArgSerArg 994
      ||| |||||::: |||||::: |||
1231 GCCCGG.....CGGCGGACCGCGCTGGGTGTCATCAGCATGACG 1191
      ||| |||||::: |||||::: |||
994 rProProValThrArgArgArgSerArgSerArgThrProThr 1011
      ||| |||||::: |||||::: |||
1190 CTTGCGCGCGAGGTGCTGCGCGCATCCCGGTTCGTGAAGGACCGCGAC 1141
      ||| |||||::: |||||::: |||
```

```

1011 rgarargSerArg..SerArgThrSerProValThrArg...ArgArgse 1026
1140 TCGCCCCCGCCCTGGCGGGGGTGAGACGAGTCTCGACATCCCGCT 1091
1026 rArgSerArgThrSerProValThrArgArgArgSer.....ArgS 1040
1090 CCGGAGCTGGCTGCTTACAGCTATACGCGGTCGAGCGGAGCCGACG 1041
1040 eArgThrSerProValThrArgArgArgSerArgSerArgThrPro 1056
1040 GCGGCTGGCGGACATCCAGCGACCTGCTCAACCGCGCGGCTGGCG 991
1057 AlaAlaArgArgSerArgSerArgThrProLeuThrProArgLysAr 1073
990 AGGGAGGAGATCGCATCGCGGATCGCGCGGCTGCTCACCAGATC 941
1073 gSer.....ArgSerArgSerProLeuAlaAlaArgArgA 1085
940 GCGGAGCGCTCGCGCGGCGGCAACCGCGGACGCTGATCGCGGCT 891
1085 rArgSerArgSerArg...ThrProArgThrAlaArgLysArgSerLeu 1100
890 CCGGTACACACTTCCGCTGTGTGATCTGAGAGCTGCTGCTGGTGG 841
1101 ThrArgSerProAlaAlaAlaArgArgSerAlaSerGlySerSer 1117
840 TCACCGATCGCGGATGCGCGGAGCGGCTCAGCGCTTCAAGGACAT 791
1117 rAspArgSer...Arg...SerAlaThrProProAlaThrArgAsnHis 1132
790 GCGCTGCGCGCGCGCGAGACGCGGCGGTGAGCGGACGACCTTGG 741
1132 rGlySer.....ArgThrProProVal 1139
740 GCGCGTCCGCGGACACTCGGCGCTGAGAGCTGCTCTCGAAACCG... 694
1139 alaAlaLeuAsnSerArg.....MetSerCysPheSerArgProSer 1153
693 .....TCGACTCAGCCCGCGCGGAGACGACGACG 668
1154 MetSerProThrProLeuAspArgCysArgSerProGlyMetLeuGluPr 1170
667 CCGGACCATGACCGCGCTGTGACGAGCGCGGCGGAGTTCGGCTC 618
1170 o.....LeuGlySerSerArgThrProMetSerVal 1181
617 GGTCTCCGAGCAGCAGCTGCTACATGATCACCGGCTCATCTTCGCG 568
1181 euGlnGlnAlaGlyGlySerMetMetAspLysProGlyProArgLysPro 1197
568 ..... 568
1198 AspHisGlnArgThrSerValProGluAsnHisAlaGlnSerArgLysAl 1214
567 .....GCCAGCAGCAGCAGCGCTCTCTCTCT 543
1214 alaAlaLeuThrAlaAlaSerLeuGlyThrAlaArgProProProSer 1231
542 GGGCTTCTCTCTCTCGGAGAGTCTCGCGGCGCGCTGCGGAGATCG 493
1231 etSerAlaAlaGly.....LeuAlaAlaArgMetSerGln 1242
492 ACAGAGAGCGCGCTCTCGCGTGTGAGAGAGCGCGCTGCTACCAACG 443
1243 ValProAlaProValPro.....LeuMetSerLeuArg 1253
442 CCGGTGCGCTACACGCTTGTGAGAGTTCGCGCAGGAGGACCATCG 393
1253 gThrAlaPro.....AlaAlaAsnLeuAlaSerArgLysProAla 1267
392 CCGGCTCGCGCTGC.....CCCGCGGAGCGC 367

```

```

1267 laSerAlaAlaAlaMetAsnLeuAlaSerAlaArgThrProAlaLysPro 1283
366 CGGCTGTGTGACATGAGGAGGAGCAACCGGAGCGCGCGC..... 325
1284 ThrAlaValAsnLeuAlaAspSerArgThrProAlaAlaAlaAlaMet 1300
324 .....ATCAGCAGCGCGCGGACG..... 307
1300 taAsnLeuAlaSerProArgThrAlaValAlaProSerAlaValAsnLeu 1317
306 .....CCTTCACCGCGGAGCGCTCT.....CGTGGCGGCGCG 274
1317 laAspProArgThrProThrAlaProAlaValAsnLeuAlaGlyAlaArg 1333
273 TCACCTTCGCGGAGCGGCGGCGGACATGACATCGGAGGAGAGCTGGCC 224
1334 ThrProAlaAlaLeuAlaAlaLeuSerLeuThrGlySerGlyThrPro 1350
223 CTGGAGTCCGCGCAGCATGACGCGCTACTGCGGACGAGTTCGCGGAG 174
1350 oThr.....AlaAlaAsnLysProSerSerSerArgThrPr 1362
173 CCGAGTGGCGGCTGCGCTGACGACGAGTTCGCGT..... 142
1362 roGlnAlaProAlaSerAlaAsnLeuValGlyProArgSerAlaAla 1378
142 ..... 142
1379 ThrAlaProValAsnLeuAlaGlySerArgThrAlaAlaAlaLeuAlaPr 1395
141 .....GTGCGCGGAGGCGCGGCGGAGCGGCGCGC..... 112
1395 oAlaSerLeuThrSerAlaArgMetAlaProAlaLeuSerGlyAlaAsnL 1412
111 .....TCACGAGACTGCGCG.....TGTGGCTGC 88
1412 euThrSerProArgValProLeuSerAlaLysGluArgValSerGlyArg 1428
87 GGTGATTCGCGCG.....GCCGCGACCGGCGGAGCGCGCGC..... 52
1429 ThrSerProProLeuLeuAspArgAlaArgSerArgThrProProSerAl 1445
51 .....ACCGCGCAGCGCGCGGCTGCGCGCTCGC 21
1445 aProSerGlnSerArgMetThrSerGlnArgAla.....ProSerP 1459
20 CGTGTACCGCGTGCGA 4
1459 roSerSerArgMetGly 1464
seq_name: pIR2:T02345
seq_documentation_block:
hypothetical protein KIAA0324 - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 05-Mar-1999 #sequence_revision 05-Mar-1999 #extl_change 05-Nov-1999
C:Accession: T02345
R:Ricke, D.O.; Bruce, D.; Mundt, M.; Doggett, N.; Munk, C.; Saunders, E.; Robinson, D.
re, J.; White, S.; Ueng, S.; Tatum, O.; Campbell, C.; Fawcett, J.; Deaven, L.
submitted to the EMBL Data Library, March 1998
A:Description: Sequencing of human chromosome 16p13.3.
A:Reference number: Z14664
A:Accession: T02345
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-1791 <RIC>
A:Cross-references: EMBL:AC004493; NID:g2996648; PIDN:AA08453.1; PID:g2996650
C:Genetics:
A:Map position: 16
A:introns: 1610/2; 1706/2
A:Note: KIAA0324

```

alignment\_scores:  
 Quality: 479.00 Length: 1056  
 Ratio: 1.028 Gaps: 56  
 Percent Similarity: 44.129 Percent Identity: 29.261

alignment\_block:  
 US-09-673-254-1 x T02345 ..

Align seg 1/1 to: T02345 from: 1 to: 1791

```

133 TCCGCGACACCGCACTGCTGCTAGCGGCGGCAATC.....GG 173
    ||| | | | | | | | | | | | | | | | | | | | | |
426 AAGlyMetSerSerSeraInglInsertSerProValLeuAspAlaYa 442
    ||| | | | | | | | | | | | | | | | | | | |
174 GCGTCGGGGAACCTGCTGCGCAGTACGCCGATCATCTGCGGACTCCAG 223
    ||| | | | | | | | | | | | | | | | | | | |
442 LProArg..ThrProSerArgGluArgSerSerSeraAlaSerProG 458
    ||| | | | | | | | | | | | | | | | | | | |
224 CTGGGCGA...GCTGCTCCCGCATGCACTAGTGGCGCCGCTCGCCGAG 270
    ||| | | | | | | | | | | | | | | | | | | |
458 LuMetLysApLylLeuProArgThrProSerArgArgSerArgSerg 474
    ||| | | | | | | | | | | | | | | | | | | |
271 TGAGCCGCGCGCCAGAGGAGCGTCCGGT..... 300
    ||| | | | | | | | | | | | | | | | | | | |
475 SerSerProGlyLeuArgSerpLysSerGlyThrProSerArgHisSer 491
    ||| | | | | | | | | | | | | | | | | | | |
301 ...GGAAGCGCTGCGGCGCTGCTGATGAGCGCGCGT..... 333
    ||| | | | | | | | | | | | | | | | | | | |
491 uSerGlySerSerProGlyMetLysApLylLeuProArgThrProSerArg 508
    ||| | | | | | | | | | | | | | | | | | | |
334 ..CGGTGTGTGTGCCCTCGATGTCCACAGCAACGCGGCTCCGCGGGGCA 381
    ||| | | | | | | | | | | | | | | | | | | |
508 LArgSerGlyLysAspSerSerProGluProLysAlaLeuProGlnThr 524
    ||| | | | | | | | | | | | | | | | | | | |
382 GCGGAGCGCGCGCGATGCTACCTCCGTGGCAGCACTCCACACGCG 431
    ||| | | | | | | | | | | | | | | | | | | |
525 ProArgProArgSerArgSerProSerSerProGluLeuAsnAsnLys 541
    ||| | | | | | | | | | | | | | | | | | | |
432 TAGGGGACCG.....GCGGCTGTAGCGCAGCGCGCTCTCCAC 469
    ||| | | | | | | | | | | | | | | | | | | |
541 sleuthrProGlnArgGluArgSerGlySerGluSerSerValAspGln 558
    ||| | | | | | | | | | | | | | | | | | | |
470 GAACCGGGAGCGCGCTCTGCTGCGCATCCGCGCGAGCGGC..... 513
    ||| | | | | | | | | | | | | | | | | | | |
558 yethrValAlaArgThrProLeuGlyLnaArgSerArgSergLysSer 574
    ||| | | | | | | | | | | | | | | | | | | |
513 ..... 513
575 GlnGluLeuAspValLysProSerAlaSerProGlnGluArgSerGlu 591
    ||| | | | | | | | | | | | | | | | | | | |
514 .....CCGCCAGACTCCCGGAGCAGAGAGCCGAGAGAGAGCC 553
    ||| | | | | | | | | | | | | | | | | | | |
591 rAspSerSerProAspSerLysAlaLysThrArgThrProLeuArgGln 608
    ||| | | | | | | | | | | | | | | | | | | |
554 GGTGCTGCTGCGCGCGAGATGAGCCCGGTGATCATGTAGACAGCT 603
    ||| | | | | | | | | | | | | | | | | | | |
608 rSerArgSergLysSerSerProGluValAspSerLysSerArgLeuSer 624
    ||| | | | | | | | | | | | | | | | | | | |
604 GGTGCTGCGAGACCGGAGCACTCGGCGCTCG.....CGCGCTCG 644
    ||| | | | | | | | | | | | | | | | | | | |
625 ProArgArgSerArgSerGlySerSerProGluValLysAspLysPro 641
    ||| | | | | | | | | | | | | | | | | | | |
645 TACAGCAGCGCGGTCATGTCGGGCTGCTGCTCCGCGCGGCTAGTGAC 694
    ||| | | | | | | | | | | | | | | | | | | |
641 gAlaAlaProArgAlaGlnSerGlySerAspSer..... 652
    ||| | | | | | | | | | | | | | | | | | | |
695 GCGTTCGAGAGCAGGCTCTCCAGGGCCGAGGTCCGCGAGCCCGCGG 744
    ||| | | | | | | | | | | | | | | | | | | |
653 .....SerProGluProLysAlaProAla...ProArg 662
    ||| | | | | | | | | | | | | | | | | | | |
745 CAGGTCGCGCGCTGACCCCGCGCTGCGCGCGCGCGAGCGAGT 794
    ||| | | | | | | | | | | | | | | | | | | |
663 AlaLeuPro...ArgArgSerArgSergLysSerSerLysGlyArg 678

```

```

795 GCGTTGAGAACGCTGACGGCCTCGCGG.....CCATGCG 829
    ||| | | | | | | | | | | | | | | | | | | |
678 yPro.....SerProGluGlySerSerSerThrGlnSerSerp 691
    ||| | | | | | | | | | | | | | | | | | | |
830 CGGATCGGTGACCGGCACACGAGCAGCTCGCAGATGACCAACAGCGGA 879
    ||| | | | | | | | | | | | | | | | | | | |
691 roGlnHisProProLysSerArgThrAlaArgArg..... 702
    ||| | | | | | | | | | | | | | | | | | | |
880 AGTGTACGCGAAGCCCGCATCGGCGCGGTTCGCCGAGCGCGG 929
    ||| | | | | | | | | | | | | | | | | | | |
703 .....GlySerArgSerSerProGluPro..... 710
    ||| | | | | | | | | | | | | | | | | | | |
930 GAGCGCTGCGCGAGTTCGCTGAGACAGCGCGCGCATCGCGCATGCG 979
    ||| | | | | | | | | | | | | | | | | | | |
711 ...LysThrLysSerArgThrProProArgArgArgSerArgSers 726
    ||| | | | | | | | | | | | | | | | | | | |
980 ATCCGTCCTGCGCGCAGCGCGCGGCTTGAACGAGCTGGTGATGC 1029
    ||| | | | | | | | | | | | | | | | | | | |
726 erProGlu..LeuthrArgLysAlaArgLeuSerArgArgSera 742
    ||| | | | | | | | | | | | | | | | | | | |
1030 GCGCAGCGCGCGGTGGGCTCGCGCTCCACGCGCATGAGCGTGAACGA 1079
    ||| | | | | | | | | | | | | | | | | | | |
742 aSerSerSerPro.....GluThrArgSerArgT 752
    ||| | | | | | | | | | | | | | | | | | | |
1080 GCGAGCTCCGGAACGGGATGTCAGACCGTGT...CCACCCCGCGCC 1125
    ||| | | | | | | | | | | | | | | | | | | |
752 hProProArgHisArgArgSerProSerValSerSerProGluProAla 768
    ||| | | | | | | | | | | | | | | | | | | |
1126 .....AGCGGCGCGGGCGAGCTCGGGGCT..... 1152
    ||| | | | | | | | | | | | | | | | | | | |
769 GlnLysSerArgSerSerArgArgArgSerAlaSerSerProArgThr 785
    ||| | | | | | | | | | | | | | | | | | | |
1153 .....TCAGAACCGGGGATGCGCCACACCTCCGCGGCGAGGCG 1192
    ||| | | | | | | | | | | | | | | | | | | |
785 rLysThrThrSerArgArgGlyArgSerProSerProLysArgGlyL 802
    ||| | | | | | | | | | | | | | | | | | | |
1193 GTCATCGGTGATACCCAGCGGGTTCGCCCGCGGGGCGTTCACCTGCA 1242
    ||| | | | | | | | | | | | | | | | | | | |
802 euGlnArgSerArgSerArgSerArgGluLysThrArgThrArg 818
    ||| | | | | | | | | | | | | | | | | | | |
1243 CAACCGGCGCGCGCTCCGGAAGCGCTGTCGACACTCGGCGCTGCGCTG 1292
    ||| | | | | | | | | | | | | | | | | | | |
819 Arg.....ArgAspArg..... 822
    ||| | | | | | | | | | | | | | | | | | | |
1293 ATGCTCATCATGAGACACGACGAGGCTGACGCGCACCGCGGCGCTTC 1342
    ||| | | | | | | | | | | | | | | | | | | |
823 ...SerGlySerSerGlnSerThrSerArgArgGlnArgSera 838
    ||| | | | | | | | | | | | | | | | | | | |
1343 GCGCTCAGAGGACCGCGCGCGCGCGGG.....TACCCCTC 1383
    ||| | | | | | | | | | | | | | | | | | | |
838 erArgSerArgValThrArgArgArgArg..GlyLysSerGlyThrS 854
    ||| | | | | | | | | | | | | | | | | | | |
1384 CCGC.....AGTTCGACACCGAGAACCGCGCGCT 1415
    ||| | | | | | | | | | | | | | | | | | | |
1416 GCGGCTGAGACAGCTCGCGCGCGCGCGCTGCGGCGGCTGCG 1465
    ||| | | | | | | | | | | | | | | | | | | |
854 rArgSerProAlaArgGlnLysSerArgThrSer..SerArgArg 870
    ||| | | | | | | | | | | | | | | | | | | |
871 ArgGlyArgSerArgThrPro.....ProThrSerArgLysArgSer 885
    ||| | | | | | | | | | | | | | | | | | | |
1466 TTCTCGACGAGC.....CGCCGATTCACAGCGCGCGCGAGC 1503
    ||| | | | | | | | | | | | | | | | | | | |
885 gSerArgThrSerProAlaProThrLysArgSerArgSerArgAlaSer 902
    ||| | | | | | | | | | | | | | | | | | | |
1504 CGTG.....GTCGCACTGTCGACGCGGAGAACAGACGCGCAGTGC 1547
    ||| | | | | | | | | | | | | | | | | | | |
902 roAlaThrHisArgArgSerArgSerArg.....ThrProLeu 915
    ||| | | | | | | | | | | | | | | | | | | |
1548 GCGCTACCGCGC...CGGTGACCGCCAGCTCTGAGTCCGCGGAGCGGT 1594
    ||| | | | | | | | | | | | | | | | | | | |
916 SerArgArgArgSerArgSerArgThrSerProValSerArg..... 929

```

```

1595 GTGTACCGATGTCCAGACCGGGGTGGTACGCCCTTCAGTCCGGTGTTC 1644
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
930 .....ArgArgSerArgSerArgThrSerAlaThrArgA 941
1645 GCGCCGAGCCAGCGCGAGGTCCCG.....GGTAGACTCCCGGG 1685
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
941 rArgSerArgSerArgAlaSerProValSerArgArgSerArgSer 957
1686 CGG...CCCCGATGGCGGTGCACACAGCTCCAGCCAGCCAGCCAGCCG 1732
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
958 ArgThrProValThrArgArgSerArgSerArgThrProThr 974
1733 GCGACCGCCCTGACCTCCGCGCCCTCATGACTCCTTCGCGCAGACCC 1782
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
974 rArgArgArgSerArgSerArgThrPro.....ProVal 985
783 GAACGCGCCCGCGCGGGGTGGCGAAGACCCGATCCGCGCGAGCCGA 1832
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
985 alThrArgArgSerArgSerArgThrProValThrArgArg 1001
1833 GGACGTCCATCGGAGTCATGATGACT.....CGCGCGCCGCGGTTC 1873
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1002 SerArgSerArgThrSer.....ProIleThrArgArgArgSerArg 1016
1874 TCGACCCGCTTGTCAGTCGTCGCGCGTCGTCGTCGCGAAGTACAGGT 1923
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1016 rArgThrSerProValThrArgArgArgSerArgSerArgThrSer... 1031
1924 CCAGATGCCCGGCGATCCGCTGTCGTCCCGCGCGCGCTACGCGCGGT 1973
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1032 .....ProValThrArgArg...ArgSerArgSerArgThrSerPro 1044
1974 GGTAGGGGTTCGATCTGTGGCGGGCGACCGCGCGACACTTCGCCG 2023
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1045 ValThrArgArgSerArgSerArgThrPro.....ProIleThr 1059
2024 T.....CGAGCTGAACGTCTGTATCCCGCGCGCGCGGTCCGT 2064
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1059 gArgArgSerArgSerArgThrProIleuLeuProArgLys..... 1072
2065 GACACGCTGGCGGTCCAGCCAGACGCGCGGTGAAGTCCGCGG... 2111
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1073 .....ArgSerArgSerArgSerPro 1079
2112 .....AGGGGCGACATCGGGCGGACCGGATCGGAACATCGCGGG 2152
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1080 LeuAlaIleArgArgArgSerArgSerArgThrProArgThrAlaArg 1096
2153 GCGCCGCGCGCGAACCCTGTCA.....CGAATCGTTCCTTTCG 2190
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1096 yLysArgSerIleuThrArgSerProProIleArgArgArgSerAla 1113
2191 ATGGATCGGCACACGAGCTTCGCTCCGCGATGACGACGACATTCGC 2240
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1113 erClySerSerSerArgSerArgSerAlaThrProProIleThrArg 1129
2241 GGATGAGACGACATCGGGCGGGCGCGCGCGCTCAGTCCGCGCGG 2289
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1130 AsnHisSerCly.SerArgThrProProValAlaLeuAsnSerSerArg 1146
2290 .....TGTCGCGCAGCG.....CGGCGC 2307
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1146 eSerCysPheSerArgProSerMetSerProThrProIleuAspArgCys 1162
2308 CGCGCGCTCCAGAGCTTCGCGCGAGCGCGCGTCCGCGCGCGCG 2357
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1163 ArgSerProGlyMetLeuGlnProLeuGly.....SerSerArg 1175
2358 CTCACCGGGGACAGCGCGGTGCTGTAGTACCGCGCGTGTCAAC 2407
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1175 gThrProMetSerValLeuGlnGlnAlaGlyGlySerMetMetAspGlyP 1192
2408 CTCGCGCG..... 2415

```

```

1192 rCGLProAlaArgIleProAspHisGlnArgThrSerValProGluAsnHis 1208
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2416 .....GCGCGAGCGCCAGCCACAGAGGTGTG 2444
1209 AlaGlnSerArgIleAlaLeuAlaLeuThrAlaIleSerLeuGlyThrAl 1225
2445 GCGCCCTTCGCGCGGAGCGGAGAGGGGTGAGCCGGAAGTAGACGA 2494
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1225 argProProProSerMetSerAlaIleGlyLeuAlaIleArgMetSerG 1242
2495 GCGCGACGTCGCCCTTCGCG.....ATCGGGGTGGGAGCTACCGGGGTGA 2540
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1242 lValProAlaProValProIleuMetSerLeuArgThrAlaPro..... 1256
2541 TACGTACCGCCACAGACGTCCGCGAGCGCTGGCGCGCTCCCGCGGT 2590
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1257 .....AlaAlaAsnLeuAlaSerArgIleProAlaAlaSerAlaAla 1271
2591 CATGATGTGGCCTGTTTGAGCTGGCGGTACGCTGGCGCGCTGTAGC 2640
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1271 ametAsnLeuAlaSerAlaArgThrPro..... 1280
2641 GGTGACGTCGCGCTGTAGAGTCGTCGCGGTGATCCGCGCTGGTGTAC 2690
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1281 .....AlaIleProThrAlaValAsn 1287
2691 GCGTCGAGAGGTGAGATCAGCCCGCGCGCGCGCGCTCCCGCGAG 2740
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1288 LeuAlaAsp.....SerArgThrProAlaAlaAlaAlaLame 1300
2741 CAGCGCTGCAGCAGAGAGCTGCGAGGTGATGACTGTGATGGTGGCT 2790
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1300 tAsnLeuAlaSerProArgThrAla.....ValAla. 1310
2791 CGAACCCTGCTGTCGTGTCGCGCGACGACAGACATGCGG..... 2831
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1311 .....ProSerAlaValAsnLeuAlaAspProArgThrProThrAlaPro 1325
2832 .....CGGCGTTCCTGGCCATGACATC 2854
1326 AlaValAsnLeuAlaGlyAlaArgThrProAlaAlaLeuAlaLeuSe 1342
2855 GATGCGCGGG 2864
1342 rLeuThrGly 1345
seq_name: p1r1:B45344
seq documentation block:
probable nuclear antigen - suid herpesvirus 1 (strain Kaplan)
C:Species: suid herpesvirus 1
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Jul-1999
C:Accession: B45344
R:Vileck, C.; Kozmik, Z.; Paces, V.; Schirm, S.; Schwyzer, M.
Virology 179, 365-377, 1990
A:Title: Pseudorabies virus immediate-early gene overlaps with an oppositely oriented
A:Reference number: A45344; MUID:91021039
A:Accession: B45344
A:Status: translation not shown
A:Molecule type: DNA
A:Residues: 1-1733 <VIC>
A:Cross-references: GB:M34651; MID:g334070; PIDN:AAA47471.1; PID:g334072
C:Superfamily: pseudorabies virus 1 nuclear antigen
alignment_scores:
    Quality: 469.00      Length: 1226
    Ratio: 0.925         Gaps: 72
    Percent Similarity: 41.354      Percent Identity: 29.364
alignment_block:
us-09-673-254-1 x B45344

```

```
Align seg 1/1 to: B45344 from: 1 to: 1733
2 GATCCGACCGGGTA...CACGACGCGGACCGCCACCGCGGGTCCG 48
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
631 AspGlyAlaIArgValGlnHisGly.....ArgAlaGlnLeuAla 643
49 GGTGGCGGTCCCGTCCGCGGTCCGCGCGGATCAGCCAGCAGACG 98
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
643 AlaProGlyProAlaHisGlyAlaLeuGlyAlaArgValGlnAlaAsp 659
99 GGCAGTTCCGTGACGCGCGCGGTCCGCGCGCGTCCGCGACCGCAA 148
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
660 .....AlaAspValAsp 663
149 CTCGTGTAAGCAGCGCGAGTCCGCGCGTCCGCG..... 181
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
664 ValValAlaProHisGlyAlaArgValAlaArgGlyProValLeuAspGly 680
182 .....GAACCTGTCCGCGATACGCGCGATCATCTGCGCGATCC 221
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
680 GlnHisAspGlnProAlaProAlaArgAlaGlnProAlaGln..... 695
222 AGCTGGCGGACGTCTCCCGATCGATCGATCGCGCGCGCGCGAAGT 271
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
696 .....ValLeuHisGlyAlaGlyAla 703
272 GACGCGCGCGCAGA..... 286
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
704 GlnValAlaProAlaArgGlnGlnGlnHisProLeuGlyValGlnAlaAlaAs 720
287 .....GGAGCGTCCGCGGTGAGAGCGTCCGCGCGCGTCCGTA 323
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
720 PValGlyAlaProGlyProValProGlyProGlyAlaArgValAlaArgAla 737
324 TGGCGCGCGTGTGTTGCGTGTGATGTCCAGCAGCAGCGCGCGTCC 373
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
737 LAGlnAlaValAlaGlyGlnGly.....GlnGlnArgAlaArgGlnAla 750
374 GCGGGGAG.....CCGACGCGCGCGATGTCACCTCGTCCGCGAGCA 417
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
751 AlaAlaAlaAlaArgValProGlyAlaArgAlaArgValAlaLeuGlyLeuG 767
418 ACCTCCACAAGTGAAGCGACCGCGCGGTGTAGCGACGCGCTCC 467
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
767 YAlaGlnLeuLeuValGly...GlnArgValAlaGlnHisHisAlaHis 783
468 AGCAACCGGACGCGCTCC.....GTGCGCATC 499
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
783 IsValLeuGlyValGlyTyrLeuProHisProGlyAlaAlaAlaGln 799
500 CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGAGG 549
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
800 ArgGlyAlaAlaAlaArgGlyAspValArgGln..... 810
550 AGCGCGTGTGTGTCGCGCGCGAGATAGCGCGGTGATCATGTAGAG 599
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
811 ...GlyGlyArgValGlnGlyGlnArgAlaProGlnPheGlnAla 826
600 AGCTGCTC.....GTGCGAGAC 616
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
826 SprLeuValHisGlnGlyAlaGlnHisLeuGlyAlaArgAlaValGlyGly 842
617 CGAGCGAGATCGCGCTGCGCGCGCTGTAACAGCAGCGGATAT..... 661
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
843 GlnGlyArgLeuGlyGlyProAlaArgValGlyLeuAlaGlyAlaArgAspAl 859
662 .....GTGCGGTGTGTCGTCGCGCGGTGAGTCAAGTCAAG 695
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
859 AlaGlnAlaAlaValAlaGlyAlaGlyValLeuGlnHisGlyProGlnArgAla 876
696 GCTTCGAGGACGAGCTTC.....CAG 718
   ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
```

[illegible]





195 roAlaProGlySerThrAlaProProAlaHisGlyValThrSerAlaPro 211  
2586 CGCGGAGCGCCGACAGCGCGTGGCGAGCTGGCGGTCAGTATGAC 2537  
212 AspThrArgPro.....Al 216  
2536 CGCGGTAGCTCCGACCGCATCGAGCGGACGCGTGC.....C 2496  
216 aProGlySerThrAlaProProAlaHisGlyValThrSerAlaProAspT 233  
2495 CTGCTGCTACTCCGCTCAACCCCTTCCTGGCTCCGCGGAGGAGCGG 2446  
233 hrArgProAlaProGlySerThr.....AlaProProAlaHisGly 246  
2445 CGGACACCCCTGTGTGGCTGGCGCGCGCGCGGAGAGGTGACCGAG 2396  
247 ValThrSerAlaProAspThrArgProAlaProGlySerThrAlaProBr 263  
2395 GCGG.....GCTACTAGACGCGCGGCGCTGCCCGGTGAGCGGCC 2352  
263 oAlaHisGlyValThrSerAla..... 270  
2351 GACCGCGGACCGCGCGCTCCGCGGACAGCTGGAGCGCGCGCGCGCG 2302  
271 ..ProAspThrArgProAlaProGlySerThrAlaProProAlaHisGly 286  
2301 CGCTGGCGACACGCGCGACT.....GACGGCGGCGCGCGCGCGCG 2261  
287 ValThrSerAlaProAspThrArgProAlaProGlySerThrAlaProBr 303  
2260 CGCGAGTGCCTGTATCCGCGGAGATGCTCGTCTATCCGCGAGCGAG 2211  
303 oAlaHis GlyValThrSerAla.....ProAspThrArgProAla... 316  
2210 ACGCTGTGTGGCGATCCATCGAAGAGACGATGTGACCGAGTTCGCG 2161  
317 .....ProGlySerThr 320  
2160 CGCGGCGCGCGCGCATGCTGTCAGCTGGTGGCGCGCATGCGCGCTC 2111  
320 ValaProProAlaHisGlyValThrSerAla...ProAspThrArgProAla 336  
2110 GCGCGACTTGTACACCGCGCTGTGGCTGACCGCGACCGCTGTGACGG 2061  
336 LaProGlySerThr.....AlaProProAlaHisGlyVal 347  
2060 ACCGCGGCGCGCGGGGATACAGCA.....GCTTCAGCTCCGAC 2023  
348 ThrSerAlaPro...AspThrArgProAlaProGlySerThrAlaProBr 363  
2022 GGGAGCTGTGCGCGCGGTGGCGCGCGCATGAGACACCCCTACGA 1973  
363 oAlaHisGlyValThrSerAlaProAspThrArgProAlaProGlySerT 380  
1972 CGCGCGGATCGCGCGGAGACAGCAGCAGCGCA...TGCCGCGCATCT 1926  
380 hrAlaProProAlaHisGlyValThrSerAlaProAspThrArgProAla 396  
1925 GACCGCTGACTCCGCGCGACCGGACGCGCGGACGACGACGACGAGGCTC 1876  
397 ProGlySerThrAlaProProAlaHisGlyVal.....ThrSerAlaBr 411  
1875 GAGAGCGCGCGCGGAGGTGATCATCTGATGAGCGATGCTCGCGCT 1826  
411 oAspThrArgProAlaProGlySer.....ThrAlaProProAla 424  
1825 CGCGCGGATCGCGCTTTCGCG...ACCGCGCGGCGCGCGCTTTCGCGG 1779  
424 laHisGlyValThrSerAlaProAspThrArgProAlaProGlySer... 439  
1778 TGTGGCGCAAGGAGTCAATGAGGCGCGGAGGTACGCGCGCTGCCGCGC 1729  
440 .....ThrAlaProProAla 444

1728 TCGGTGCGCTGGGTGACGTGTGACCGACGAGCATCGGCGCGCGGGA 1679  
444 aHisGlyValThrSerAla.....ProAspThrArgProAlaProGly. 458  
1678 CTCTACCGCGGACCTCGCGCTGGCTC.....CGG 1647  
459 ..SerThrAlaProProAlaHisGlyValThrSerAlaProAspThrArg 474  
1646 CGGACACCGGAGTGAAGGCGGTGACCGCGCGTGTGCGACATCGGTGATC 1597  
475 ProAlaProGlySerThrAlaProProAlaHisGlyValThrSerAlaBr 491  
1596 ACACCGGTGCGCGCGGACGAGCGTGGCGGTGACCGCGCGGTACGCGC 1547  
491 oAspThrArgProAlaProGlySerThrAlaProProAlaHisGlyValT 508  
1546 GCATGGCGCGCTGTCTGCGCGTGCAGACTGCGACGCGAGCG... 1503  
508 hrSerAlaProAspThrArgProAlaProGlySerThrAlaProProAla 524  
1502 .....TCCGCGCGCGCTTGACTCGCGCGCTCCGCTGAGACAGAG 1462  
525 HisGlyValThrSerAlaProAspThrArgProAlaProGlySerThrAl 541  
1461 CGCGCG.....ACAGCGCGGCGGCGG 1439  
541 aProProAlaHisGlyValThrSerAlaProAspThrArgProAlaProG 558  
1438 GC.....GGCGGACCTGTCTGACCGCGAGG 1410  
558 lySerThrAlaProProAlaHisGlyValThrSerAlaProAspThrArg 574  
1409 CGCGCTTCTGGGTGATGCGGAGCGGAGCGGTACCGCGCGCGCGCGG 1360  
575 ProAlaPro.....GlySerThrAlaProProAlaHisGly 586  
1359 GGTGCTGCTG.....GAGCGGAGCGCGCGCGGTGCGCGCGCGGAC 1317  
586 yValThrSerAlaProAspThrArgProAlaProGlySerThrAlaProBr 603  
1316 .....GTTGCGGTGCTCCATGATGAC 1296  
603 roAlaHisGlyValThrSerAlaProAspThrArgProAlaProGlySer 619  
1295 CATGAGCGGACCGCGGAGTGCAGCAGCGCTTCGCGGAGCGCGCGG 1246  
620 ThrAlaProProAlaHisGlyValThrSerAlaProAspThrArgProAl 636  
1245 TCGTGAAGTGAAGCGCGCGCGGAGCGCGCGCTGGGTCAATCAGCAT 1196  
636 aProGlySer..ThrAlaProProAlaHisGlyValThrSerAlaProAs 652  
1195 GACG...CCCTCGCGCGGAGGTGCTGGCG..... 1168  
652 rThrArgProAlaProGlySerThrAlaProProAlaHisGlyValThrs 669  
1167 ..ATCCCGGTGCTGTAAGAGCGCGCGCGCGCGCGCGCTGCGCGG 1120  
669 erAlaProAspThrArgProAlaProGlySerThrAlaProProAlaHis 685  
1119 GGGTGAAGCGCGCT.....TCGACATGCC 1094  
686 GlValThrSerAlaProAspThrArgProAlaProGlySerThrAlaBr 702  
1093 G.....TTCGAGCTGCGCTGCTCACTGATGAGCGCGCTGGA 1056  
702 oProAlaHisGlyValThrSerAlaProAspThrArgProAlaProGly 718  
1055 CGCGAGCGCGCGCGCGCTGCGCGCATCGACGACGACGCTGCTGACAC 1006  
719 SerThrAlaProProAlaHisGlyValThrSerAlaProAspThrArgPr 735



---



OM of: US-09-673-254-1 to: SwissProt\_40.\* out-format : pfs

Date: Jun 11, 2002 8:21 PM

About: Results were produced by the Gencore software, version 4.5,  
Copyright (c) 1993-2000 Compugen Ltd.

#### Command line parameters:

-Model=framed\_n2p.model -DEV=x1h  
-O=/cgn21/USPTO.spool/US09673254/runtat\_11062002.114213.1053/app\_query.fasta.1.2973  
-DB=SwissProt\_40 -FORMAT=fastan -SUPER=n2p.rsp -GAPOP=12.000  
-GAPEXT=4.000 -MINMATCH=0.100 -LOOPCL=0.000 -LOOPEXT=0.000  
-OGAPOP=4.500 -OGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500  
-FGAPOP=6.000 -FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500  
-GOP=6.000 -DELEXT=7.000 -START=1 -MATRIX=blonsum62  
-US=human40.cdi -LIST=45 -DOCALLIGN=200 -THR SCORE=pcr  
-MAX=100 -THR MIN=0 -ALIGN=7 -MODE=LOCAL -OUTEMT=pfs  
-HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000  
-USR=US09673254.0CGN1\_1.80 -NCPU=6 -ICPU=3 -LONGLOG  
-DEV\_TIMEOUT=120 -WARN\_TIMEOUT=30 -NO\_XLPPY -WAIT -THREADS=1

#### Search information block:

Query: US-09-673-254-1  
Query length: 2870  
Database: SwissProt\_40.\*  
Database sequences: 105224  
Database length: 38719550  
Search time (sec): 57.220000

#### score\_list:

Sequence	Strid	Orig	ZScore	EScore	len	Documentation
SwissProt_40:VNUA_PRVKA	+	468.50	285.30	1.9e-09	1733	P03485 pseudorabies virus (chick)
SwissProt_40:CA1B_CHICK	-	459.50	281.14	4.0e-09	1453	P02457 gallus gallus (chick)
SwissProt_40:CA11_CANPA	-	457.00	281.11	4.0e-09	1460	P09xj7 canis familiaris (dog)
SwissProt_40:CA11_HUMAN	+	459.00	279.62	4.8e-09	1464	P02452 homo sapiens (human)
SwissProt_40:MOC1_HUMAN	-	455.00	279.73	5.5e-09	1255	P15941 h. mucin 1 precursor
SwissProt_40:CA11_MOUSE	-	450.00	275.55	8.1e-09	1453	P11087 mus musculus (mouse)
SwissProt_40:CA13_MOUSE	-	450.00	275.55	8.1e-09	1464	P08121 mus musculus (mouse)
SwissProt_40:MOC2_HUMAN	-	449.50	267.09	6.7e-09	5179	P00217 homo sapiens (human)
SwissProt_40:YH1L_EBV	-	442.00	275.91	1.7e-08	660	P03181 Epstein-Barr virus (str.)
SwissProt_40:CA13_BOVIN	-	442.00	272.94	1.6e-08	1049	P04258 bos taurus (bovine)
SwissProt_40:CA12_RANCA	-	439.00	269.53	1.9e-08	1355	P04250 rana catesbeiana (bd)
SwissProt_40:CA25_HUMAN	-	439.00	268.89	1.8e-08	1496	P05997 homo sapiens (human)
SwissProt_40:CA13_CHICK	-	437.50	269.10	2.1e-08	1262	P12105 gallus gallus (chick)
SwissProt_40:VNUA_PRVKA	+	437.50	267.07	2.0e-08	1733	P03485 pseudorabies virus (chick)
SwissProt_40:CF30_MYCTU	-	434.50	277.49	3.5e-08	260	P03774 Mycobacterium tuberculosis
SwissProt_40:CA13_HUMAN	+	432.50	265.20	3.0e-08	1466	P02461 homo sapiens (human)
SwissProt_40:CA11_HUMAN	+	418.50	255.98	8.7e-08	1464	P02452 homo sapiens (human)
SwissProt_40:CA17_HUMAN	+	417.00	251.61	8.6e-08	2944	P00238 homo sapiens (human)
SwissProt_40:CA15_HUMAN	+	414.50	253.16	1.1e-07	1838	P20608 homo sapiens (human)
SwissProt_40:CA12_MOUSE	-	413.50	254.06	1.3e-07	1459	P28481 mus musculus (mouse)
SwissProt_40:CA13_HUMAN	+	413.50	254.03	1.3e-07	1466	P02461 homo sapiens (human)
SwissProt_40:CPXK_SACER	-	412.00	253.65	1.4e-07	1356	P093484 onchocerca mykiss
SwissProt_40:CA21_ONCMY	-	411.50	261.12	1.9e-07	405	P33271 saccharopolyspora ery
SwissProt_40:CA17_HUMAN	-	410.50	247.78	1.4e-07	2944	P00238 homo sapiens (human)
SwissProt_40:CA12_HUMAN	-	409.50	251.89	1.7e-07	1418	P02458 homo sapiens (human)
SwissProt_40:CA11_CANPA	+	409.50	251.70	1.7e-07	1460	P09xj7 canis familiaris (dog)
SwissProt_40:AMRH_YEAST	-	408.00	251.24	1.9e-07	1367	P08640 saccharomyces cerevisiae
SwissProt_40:CPXH_STGER	-	406.50	258.07	2.7e-07	412	P26911 streptomyces griseus
SwissProt_40:CA11_HUMAN	+	406.00	250.07	2.3e-07	1366	P08123 homo sapiens (human)
SwissProt_40:CA13_MOUSE	-	405.00	249.04	2.4e-07	1464	P08121 mus musculus (mouse)
SwissProt_40:CA13_BOVIN	-	403.00	250.00	3.0e-07	1049	P04258 bos taurus (bovine)
SwissProt_40:CA15_HUMAN	-	403.00	246.40	2.7e-07	1838	P20908 homo sapiens (human)
SwissProt_40:YH1L_EBV	+	402.50	252.09	3.4e-07	660	P03181 Epstein-Barr virus (str.)
SwissProt_40:CA12_MOUSE	-	402.50	247.98	2.9e-07	1372	P01149 mus musculus (mouse)
SwissProt_40:CPXH_RH1SN	-	401.50	255.31	3.9e-07	400	P55544 rhizobium sp. (strain)
SwissProt_40:CA11_RAT	+	399.00	245.93	3.8e-07	1372	P02466 rattus norvegicus (rat)
SwissProt_40:CA11_MOUSE	-	398.00	244.97	4.1e-07	1453	P11087 mus musculus (mouse)
SwissProt_40:CA21_CANPA	-	397.00	244.78	4.5e-07	1366	P04692 canis familiaris (dog)
SwissProt_40:CA1B_HUMAN	-	397.00	244.98	4.3e-07	1806	P12107 homo sapiens (human)
SwissProt_40:CA11_CHICK	+	396.50	244.09	4.6e-07	1453	P02457 gallus gallus (chick)

SwissProt_40:CA21_HUMAN	+	396.00	244.19	4.8e-07	1366	P08123 homo sapiens (hum
SwissProt_40:CA1B_HUMAN	+	395.00	241.81	4.9e-07	1806	P12107 homo sapiens (hum
SwissProt_40:CA11_BOVIN	-	394.50	246.92	6.0e-07	779	P02453 bos taurus (bovine
SwissProt_40:CA21_BOVIN	-	394.50	243.32	5.4e-07	1364	P02465 bos taurus (bovin
SwissProt_40:CA25_HUMAN	+	394.50	242.72	5.3e-07	1496	P05997 homo sapiens (hum

seq\_name: SwissProt\_40:VNUA\_PRVKA

#### seq\_documentation\_block:

ID	VNUA_PRVKA	STANDARD:	PRT:	1733 AA.
AC	P03485:			
DT	01-FEB-1994 (Rel. 28, Created)			
DT	01-FEB-1994 (Rel. 28, Last sequence update)			
DT	01-FEB-1994 (Rel. 28, Last annotation update)			
DE	Probable nuclear antigen.			
OS	Pseudorabies virus (strain Kaplan) (PRV).			
OC	Viruses; dsDNA viruses, no RNA stage; Herpesviridae;			
CC	Alphaherpesvirinae; Varicellovirus.			
OX	NCBI_TaxID=33703;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RX	MEDLINE=91021039; PubMed=2171211.			
RA	Vleck C., Kozmik Z., Paces V., Schlim S., Schwyzer M.;			
RT	"Pseudorabies virus immediate-early gene overlaps with an oppositely			
RT	oriented open reading frame: characterization of their promoter and			
RT	enhancer regions."			
RL	Virology 179:365-377 (1990).			

-----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb.ch/annouce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR	PIR: B45344; AAA47471.1; -			
FT	DOMAIN 112 117			POLY-THR.
FT	DOMAIN 179 173			GLY-RICH.
FT	DOMAIN 192 196			POLY-SER.
FT	DOMAIN 271 298			POLY-PRO.
FT	DOMAIN 304 308			POLY-ARG.
FT	DOMAIN 883 889			POLY-GLY.
FT	DOMAIN 1398 1405			POLY-GLY.
SO	SEQUENCE 1733 AA; 172166 MW; 0C8CDBDE475B5E2 CRC64;			

#### alignment\_scores:

Quality:	469.00	Length:	1226
Ratio:	0.925	Gaps:	72
Percent Similarity:	41.354	Percent Identity:	29.364

#### alignment\_block:

US-09-673-254-1 x VNUA\_PRVKA ..  
Align seg 1/1 to: VNUA\_PRVKA from: 1 to: 1733

2	GATCCGACCCGGGTA...CACGGACAGGAGCCGCCACCGCGGTGGCC	48
11		
631	ASpGyAlaIArgValGlnHisGly.....ArgAlaIuLeuAl	643
49	GGTGGGCGGTCCCGGCGCGGTGGCGGCGGATCAGGCGGCGAGAG	98
11		
643	aAlaPrGyIProAlaHisGlyAlaLeuGlyAlaArgValGlnAlaAsp.	659
99	GGCAGTTCGGTGGAGCGCGCGCTGGGCGCCCTTCGCGACCCAGCA	148
11		
660	.....AlaSpValAsp	663
149	CTGCTGTCGACGCGACGCGCGCTGGCGG.....	181
11		
664	ValValValProHisGlyArgAlaValArgGlyProValLeuAspGlyVa	680

182 ..... GAACSTGTGGCAGTACGCCGATCATGTCGGCGACTCC 221  
680 LGlnHisAspGluProAlaProArgAlaGluProArgAlaGlu.... 695  
222 AGCTGGGCGAGTGTCCCGGATGAGTGTGGCGCCGCGCGAAGT 271  
696 ..... ValLeuHisGlyAlaGlyGluAla 703  
272 GAGCCGCCGCCAGCA..... 286  
704 GluValProArgArgGluGlnGlnHisProLeuGlyValGluAlaAlaAs 720  
287 ..... GGGACGCTCCGGGTGGGAAGGCGTGGCGGGCGTGTGA 323  
720 pValGlyAlaProGlyProValProGlyProGlyValArgValArgArg 737  
324 TGGCGGCGCTGTGGTGTGGCTGATGTCACACGACGCGCGCTCC 373  
737 LagluAlaValGlyGluGlyGly..... GluGlnArgArgGluAla 750  
374 GCGGGGCGAG..... CCGGACGCCCGCGATGTACCTCCGTGGCAGCGA 417  
751 AlaAlaAlaArgValProGlyArgAlaArgGlyAlaLeuGlyGlyLeuGly 767  
418 ACCTCCACAAGTGTAGGGCAGCGGGGTGTAGGCGACGCGCTCTCC 467  
767 yAlaGluLeuLeuValGly... GlnArgValAlaGluHisHisAlaHis 783  
468 ACGAACCGGAGAGCGGCTCTC..... GTCCGACATC 499  
783 IsValLeuGlyValGlyTyrLeuProHisProGlyAlaAlaAlaGly 799  
500 CGCGCGGAGGCGCGCGCGCGAGACTCCGCGACGAGAGCGCGAAG 549  
800 ArgGlyAlaAlaAlaArgGlyAspValArgGln..... 810  
550 AGCGGAGTGTGTGGCGCGCGAGATGAGCGCGGTGATCATGTAGAG 599  
811 ..... GlyGlyArgValGlyGlyGluArgAlaProGluProHisGlyGlu 826  
600 AGCTGTCTC..... GTCCGAGAC 616  
826 sPLeuLeuValHisGlyGlyAlaGlyHisLeuGlyArgAlaValGlyGly 842  
617 CGAGCGGAGACTCGGCTCGCGCGCTGTACAGCAGCGCGGTAT.... 661  
843 GluGlyArgLeuGlyGlyProArgArgValGlyLeuAlaGlyArgAspAl 859  
662 ..... GGTGGGCTGTCTCGCGCGCGGTGAGTGCAGC 695  
859 aAlaGluAlaAlaValGlyArgGlyValLeuGlyHisGlyProGluArg 876  
696 GCTTCGAGGAGCAGGCTCTC..... CAG 718  
876 lProGluProValValLeuGlyGlyGlyGlyGlyGlnGlnArg 892  
719 GCGCGAGGTCTCGGCAC..... GCGCC 741  
893 GlySerGlyValArgSerGlyProGluSerGlyAlaAlaLeuAlaPro 909  
742 CGGC..... AGGTCTCGTCGCGTACCGCGCGCG 770  
909 oGlyProProValLeuPheValAlaValAlaValAlaValProAla 926  
771 CTCTGGCGCGCGCGAGCGAGTGTGAGAACGCTGACGCGCTCGCG 820  
926 lueGlyArgAlaGlyGluProLeuValLeuAlaValProGlyAlaAla 942  
821 GGCCTTCGCGGATCGGTGACGCGCACCGAGCAGCTCGCAGATGACCA 870  
943 GlyProGlyArg..... 946

871 ACAGCGGAAAGTGTACGCGAAGCGCC..... GATCAGCTCGCC 911  
947 ..... AlaAlaLeuLeuLeuAlaProLeuGlyAla 956  
912 GGTTCGCCGACCGCGGAGCGGCTCGGAGTGTGAGACGCGCGC 961  
956 rGTrpValArgAlaGlyGlyGly..... GlyAlaGlyValAla 968  
962 GCGGATCGCGGATGCGATCCGCTCGCGCACCGCGCGGTGTA 1011  
969 GlyGlyAlaGlyGluAla..... GlyLeuGlyAlaGlyAla.GlyLeuG 983  
1012 ACGCAGCTCGTGTGATCGCGCA... GCGCGCGGTGCGCT..... 1050  
983 lValAlaGlyAla.GlyLeuGlyAlaGlyAlaGlyGlyProGlyAlaGly 999  
1051 ..... CGCGTCCACGCGGATGAGCGTGAACGAGC 1081  
999 yGluAlaGlyGlyGlyAlaAlaArgArgArgArgArgArgTrpAspArg 1016  
1082 CAGCT..... CCGAACGCGGATGTGCGACCGT..... CGT 1113  
1016 lueAlaGlyLeuLeuGlyProGluArgGlyGlnAlaGlyArgGlyLeuArg 1032  
1114 CCACCGCGCGCGAGCGCGGCGAGGCTCGGCGTCTTCACGAAACGG 1163  
1033 .GlyProGlyProArgGlyGly..... LeuGlyGluProG 1044  
1164 GGAATCGCAGCAGCTCGCGGCGAGGCGTCACTCGTATGATGACCGAGC 1213  
1044 lArgGlyHisValGlyArgGlyGlyGlyGlyGlyGlyAlaGlyProGly 1060  
1214 GGGTCCGCGCGCGGCGC... GTTCACCTCGAACGCGCGCGCGCTCC 1260  
1061 GlyLeuAlaGlyAlaGlyProValHis..... 1069  
1261 GGAAGCGTGTGACACTCGGCTGTGCTGATGTCATGAGGACAC 1310  
1070 ..... AlaValAlaHisGlnArgAlaGlnGlyAlaG 1080  
1311 GCGAACGGGTGACGCGCACCGGCGCGCTCGCTCAGACGCGCGC 1360  
1080 lAspGlyGlyAsp.ArgValArgGlyLeuProProLeuGlyArgAlaGly 1096  
1361 CCGCGCGCGCGCGGTACCCCTCCGCACTTGACACCGAGAACGCGG. 1409  
1096 yPro..... GlyAspArgValAlaGlyGluArgGlyGlyArg 1110  
1410 ..... CCGCGCGCGGTGCA... GCAAGTCCGCGC 1436  
1110 lIsLeuLeuGlnAlaGlyGlyProGluGlyGlyArgGlyAlaGlyArg 1126  
1437 GCGCGCGCTGTGGCGTGTGCGCGGCTCTCTCGACGAGCGCGCGAGT 1486  
1127 Gly.GlnProGluArgAlaGlyGlnGlnAlaLeuGlnAspAlaAlaAlaG 1143  
1487 TCACGCGCGCGCGCGACCTCGCGTCTC..... GCACTGTGACAC 1524  
1143 lYelHisPalaGlyAlaArgGlnLeuAlaGlyHisAlaAlaGlyLeuArg 1159  
1525 GCGGACAGCAGCGCGCCAGTGCAGCGGTACCGCGCGGTGAGCGCGAGT 1574  
1160 GlyGlyGlyGlyGlyAlaAspAlaGlyAlaGlyGlyGlyLeuAspGlyArgGly 1176  
1575 CCGTGGTCCCGCGAGCGGTGTGTCAACGATGTCCAGACGCGGTGCTG 1624  
1176 uProGlyAlaGlyValArgGlyAlaAla..... ArgValGlyHis 1189  
1625 ACGCCCTTCAGTCCGCTGTGCGCGGAGCGCAGCC..... CAGGCT 1665  
1189 lSVal..... GlyValGlyProAlaGlyAlaLeuGlnAspGlyGly 1202  
1666 ..... CGCGCGGT 1673

1203 LeuLeuGlyAlaIleValAlaAlaAlaHisGlyHisGlyAlaHisArgVala 1219  
1674 AGAAGTCCCGGGGGCCCGGATGCCGTC.....GTCACCCAGCTC...G 1714  
1219 IArg.....GInGlyProGluArgValLeuGlyGlyHisGlyValProA 1234  
1715 ACCGACCCGACCCGACCCGACCCGACCCGACCCGACCCGACCCGACCCGAC 1764  
1234 sPValArgGlnArgArgGlyHisAla..... 1242  
1755 TCCCTGGCCGACCCGACCCGACCCGACCCGACCCGACCCGACCCGACCCG 1814  
1243 .....AlaGlyAspGlu.....GlyAlaValAlaValGlyArg 1253  
815 C...CATCCGGCCGACCCGACCCGACCCGACCCGACCCGACCCGACCCG 1861  
1253 yValAspProAlaLeuAlaGlyLeuValGlyAlaLeuValGlyGlyLeuH 1270  
1865 CCGCCCGCCGTCGACCCGACCCGACCCGACCCGACCCGACCCGACCCG 1911  
1270 IsProArgValLeuGlnPro...GlyHis.....GlyLeuAlaGlyGly 1283  
1911 ..... 1911  
1284 ProAlaValAspGluAlaHisGlyLeuValLeuLeuProArgValArg 1300  
1912 .....GAAGTACAGGTCACATGCGCGGCATGCC... 1941  
1300 HisLeuArgAspGluAspGlyHisGlyPro...GlyArgGlyAlaValAla 1316  
1942 .....GTCTGTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGT 1971  
1316 IagIyArgGlyLeuAlaAspValAlaLeuValProGluProLeuAlaGly 1332  
1972 GT 2001  
1333 ValProGlyAlaAlaValAlaAspAlaAlaValGlyArgArgValGlyAl 1349  
2002 .....GACCCGCGGACCCGACCCGACCCGACCCGACCCGACCCGACCC 2031  
1349 aGlyProGlyLeuProGluArgGlyGlyGlnArgProValGlyArgArg 1366  
2032 .....GAAGTACAGGTCACATGCGCGGCATGCC... 2064  
1366 yProValGlyHisGlyLeuArgGlyValAlaGlyAlaAlaLeuPro 1382  
2065 GACCAAGGTCGCGGTCGACCCGACCCGACCCGACCCGACCCGACCCGACCC 2114  
1383 AlaArgGlyProGlyLeuArgGlyArgGly...ArgGlyGlyArgGly 1398  
2115 CCGCGACAT.....CGGCGACCCGACCCGACCCGACCCGACCCGACCCG 2151  
1398 yGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyG 1413  
2152 GCG 2201  
1413 yArgArgArgArgArgArgArgArgArgArgArgArgArgArgArgArg 1429  
2202 CACGACGCTGTG.....CGCTCGCGGATGAG 2227  
1430 ProAspSerPheValPhePheSerLeuGlyGlyGlyArgGlyArgGlyGly 1446  
2228 ACGGACATCTCCCGGACCCGACCCGACCCGACCCGACCCGACCCGACCCG 2276  
1446 yArgGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyG 1463  
2277 CGTCAAGTGTGCGGTGTGCGGACCCGACCCGACCCGACCCGACCCGACCCG 2326  
1463 yGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGly 1479  
2327 CCGCGCGGACCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 2376

1480 ArgValAlaAlaAlaAlaAlaGlyAlaAlaGlu..... 1490  
2377 GGTGCTGTAGTACCGCCCGGTCACCTCTCTCGGCGG..... 2416  
1491 .....AlaAlaAlaAlaAlaGlyGlyAlaLeuSerGlyAlaAlaProAlaG 1506  
2417 .....CGCGACGCGCAG.....CCACAGCAG..... 2437  
1506 yLeuSerLeuArgGlyArgProAlaValProGlyGlyAlaGlyLeuSerVal 1522  
2437 ..... 2437  
1523 LeuValLeuLeuGlyAlaAlaGlyAspGlyLeuAspGlyAspGlyGlyG 1539  
2438 .....GGTGTGCGCGCCCTTCCGCGGACGCG..... 2464  
1539 yGlyValGlyValGlyValGlyValGlyValGlyValGlyValGlyValG 1556  
2465 ...CAGGAAGGTTGAAACCGAAGTACGACGAGC..... 2497  
1556 yArgProArgGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyG 1572  
2498 .....GACCGTCCCGCTCCGATCGGCGGTCG 2523  
1573 LeuAlaValLeuValMetValThrThrAlaValProSerGlyGlyGly... 1588  
2524 GGACCTCACCGGGGTATGCTGACCCGACCCGACCCGACCCGACCCGACCC 2573  
1589 .....GlyAlaAlaAlaAlaGlyArgArgArgArgArgArgArgArg 1602  
2574 GCGGC.....CTCCGCGCGGTCATGA. 2595  
1602 yGlyGlyTrpGlySerGlyProProProCysArgArgGlyHisArg 1618  
2596 TGTGTGCTGTTTGACGTCGCGTACGCT..... 2625  
1619 CysTrpLeuCysTrpTrpArgArgGlyProArgProArgArgArgProG 1635  
2626 .....GGCGGCGGCTGA 2638  
1635 yLeuThrAspArgValProProArgGlyGlyProSerProArgGlyCysA 1652  
2639 GCGGTACGTCGCGGTCGAGT..... 2661  
1652 rGlyValAlaArgAlaGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGly 1668  
2662 ...CGTCCGCGTGCATCC...GACCCTGG.....TGAC 2690  
1669 ArgAlaProGlyAlaAlaGlyGlyProGlyLeuCysArgCysGlyCysC 1685  
2691 GCGTCGACGAGTGTGATCACCAGCCCGCCGCGACGCGCTCCCGGAG 2740  
1685 sArgGlyArgArgProGlyProGlyAlaGlyProGlyProGlyProGly 1702  
2741 CAGCCGCTG.....CCACGACGACCTG 2763  
1702 sPGLValThrValLeuGlyAlaLeuMetCysLeuSerProThrGlyGlyPro 1718  
2764 CGAGGTGATGACCTGA 2781  
1719 GlyGlyArgGlyProGly 1724  
seq\_name: SwissProt\_40:CA11\_CHICK  
seq\_documentation\_block:  
ID CA11\_CHICK STANDARD; PRT; 1453 AA.  
AC P02457;  
DT 21-JUL-1986 (Rel. 01, Created)  
DT 01-OCT-1989 (Rel. 12, Last sequence update)  
DT 15-JUL-1999 (Rel. 38, Last annotation update)  
DE Collagen alpha 1(I) chain precursor.  
GN COL1A1.  
OS Gallus gallus (Chicken).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinoptera; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
OC Gallus.  
OC NCBI\_TaxID=9031;  
OC [1]  
RP SEQUENCE OF 1-153 FROM N.A.  
RX MEDLINE=88056316; PubMed=3678834;  
RA Fliner M.H., Boedtker H., Doty P.;  
RT "Construction and characterization of cDNA clones encoding the 5' end  
RL of the chicken pro alpha 1(I) collagen mRNA.";  
RN Gene 56:71-78(1987).  
RP [2]  
RP SEQUENCE OF 1-144 FROM N.A.  
RX MEDLINE=88007542; PubMed=2820966;  
RA Fliner M.H., Aho S., Gerstenfeld L.C., Boedtker H., Doty P.;  
RT "Unusual DNA sequences located within the promoter region and the  
RL first intron of the chicken pro alpha 1(I) collagen gene.";  
RN J. Biol. Chem. 262:13323-13332(1987).  
RP [3]  
RP SEQUENCE OF 152-1187.  
RX MEDLINE=82231995; PubMed=7093229;  
RA Hingoringer J.H., Corbett C., Dixt S.N., Yu W., Seyer J.M.,  
RN Kang A.H., Gross J.;  
RT "Amino acid sequence of chick skin collagen alpha 1(I)-CB8 and the  
RL complete primary structure of the helical portion of the chick skin  
RN collagen alpha 1(I) chain.";  
RX Biochemistry 21:2048-2055(1982).  
RP [4]  
RP SEQUENCE OF 1200-1205.  
RX MEDLINE=72243016; PubMed=5047697;  
RA Eyre D.R., Glimcher M.J.;  
RT "Evidence for a previously undetected sequence at the carboxyterminus  
RL of the alpha 1 chain of chicken bone collagen.";  
RN Biochem. Biophys. Res. Commun. 48:720-726(1972).  
RP [5]  
RP SEQUENCE OF 981-1453 FROM N.A.  
RX MEDLINE=81160715; PubMed=6927845;  
RA Fuller F., Boedtker H.;  
RT "Sequence determination and analysis of the 3' region of chicken pro-  
RL alpha 1(I) and pro-alpha 2(I) collagen messenger ribonucleic acids  
RN including the carboxy-terminal propeptide sequences.";  
RX Biochemistry 20:996-1006(1981).  
RP [6]  
RP SEQUENCE OF 1311-1453 FROM N.A.  
RX MEDLINE=80134546; PubMed=6987088;  
RA Showalter A.M., Pesciotta D.M., Eikenberry E.F., Yamamoto T.,  
RT Pastan I., Decrombrughe B., Fietzek P.P., Olsen B.R.;  
RN "Nucleotide sequence of a collagen cDNA-fragment coding for the  
RL carboxyl end of pro alpha 1(I)-chains.";  
RX FEBS Lett. 111:61-65(1980).  
RP [7]  
RP FUNCTION: TYPE I COLLAGEN IS A MEMBER OF GROUP I COLLAGEN  
RL (FIBRILLAR FORMING COLLAGEN).  
RP [8]  
RP SUBUNIT: TRIMERS OF ONE ALPHA 2(I) AND TWO ALPHA 1(I) CHAINS.  
RX TISSUE SPECIFICITY: FORMS THE FIBRILS OF TENDON, LIGAMENTS AND  
RN BONES. IN BONES THE FIBRILS ARE MINERALIZED WITH CALCIUM  
RX HYDROXYAPATITE.  
RP [9]  
RP -1- PMW: PROLINES AT THE THIRD POSITION OF THE TRIPEPTIDE REPEATING  
RL UNIT (G-X-Y) ARE HYDROXYLATED IN SOME OR ALL OF THE CHAINS.  
RX -1- SIMILARITY: CONTAINS 1 WFC DOMAIN.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL: M17839; AAA48704.1; -.  
DR EMBL: M17838; AAA48704.1; JOINED.  
DR EMBL: Y00401; CAA23695.1; -.  
DR EMBL: M10571; AAA48671.1; ALT. SEQ.  
DR EMBL: M17607; AAA48672.1; -.  
DR

DR	PIR: A02857; CGCH1S.				
DR	PIR: A27179; A27179.				
DR	PIR: A29367; A29367.				
DR	InterPro: IPR000087; Collagen.				
DR	InterPro: IPR000885; Fib.collagen_C.				
DR	InterPro: IPR001007; VWC.				
DR	Pfam: PF01410; COLFI, 1.				
DR	Pfam: PF01391; Collagen; 18.				
DR	Pfam: PF00093; VWC; 1.				
DR	Prodom: PD002078; Fib.collagen_C; 1.				
DR	SMART: SM00038; COLFI, 1.				
DR	SMART: SM00214; VWC; 1.				
DR	PROSITE: PS01208; VWC; 1.				
KW	Extracellular matrix; Connective tissue; Repeat; Hydroxylation;				
KW	Glycoprotein; Collagen; Signal.				
FT	SIGNAL	1	22		
FT	PROPEP	23	151		
FT	CHAIN	152	1205		
FT	PROPEP	1206	1453		
FT	DOMAIN	31	89		
FT	MOD_RES	152	152		
FT	MOD_RES	254	254		
FT	MOD_RES	851	851		
FT	MOD_RES	1081	1081		
FT	MOD_RES	1097	1097		
FT	MOD_RES	1153	1153		
FT	CONFLICT	1187	1187		
FT	CONFLICT	1441	1441		
SO	SEQUENCE	1453 AA; 137789 MW; 3BC6152134271FAD CRC64;			

[illegible]

```
US-09-673-254-1/rev x CALL_CHICK ..
Align seg 1/1 to: CALL_CHICK from: 1 to: 1453
```

```

2844 CCAGAGACGCGCGGCGGCAAGTCT.....GCTCGCGACCAACGAC 2804
2845
211 ProAlaGlyProProGlyLysAsnLysPaspArgLysIleAlaGlyLysPr 227
    ||||| ||| :::: :::: |||||::|||::|||::|||::|||::|||
2803 C...AGGACGGGTTCGAGGCGCCATCCAGGT...CAATCCACTTCGACGG 2760
    | || | |||:::|||| || | ||||| |||::: |||
227 oGlyAlaArgProGlyIAsnArgGlyPro..ProGlyProGlnGlyAlaArgGly 243
    ||||| |||||::|||::|||::|||::|||::|||::|||::|||::|||
2759 GTTCTGCTGAGGACGAGCTTCGCGGAGCGCTGCGGGCGGGCGCGGTGA 2710
    ||||| |||||::|||::|||::|||::|||::|||::|||::|||::|||
244 LeuPro...GlyThrAlaGlyLeuProGlyMetLysIleHisArgGlyPh 259
    ||||| |||||::|||::|||::|||::|||::|||::|||::|||::|||
2709 TCCTCACTCT...GTCCGACGGGTACACCCGAGCGG.....G 2675
    ||| :::: |||::|||::|||::|||::|||::|||::|||::|||
259 eSerGlyLeuAspArgLysAlaLysGlyLysProGlyProAlaGlyProLysG 276
    ||||| |||||::|||::|||::|||::|||::|||::|||::|||::|||
2674 ATCGACCGCGGACGACCTTCACGGCGGACCGGTACCGGCTACAGCGCGGCA 2625
    ::|||::||| ||| ::::: ::||| ||| |||
276 IyGluProGlySerProGlyIAsnGlyAlaProGlyLysMetGlyPro 292
    ||||| |||||::|||::|||::|||::|||::|||::|||::|||::|||
2624 GCGGTACGCGACGTCCAAAACAGCGCAACATCATGACCGCCGCG...GGAGG 2578
    ||||| |||||::|||::|||::|||::|||::|||::|||::|||::|||
293 .....ArgGlyLeuProGlyIAsnArgGlyAlaArgProGly 303
    ||||| |||||::|||::|||::|||::|||::|||::|||::|||::|||
2577 CCGCAGCGCGCTGCGCGGACGTCGTGGCGGTCACTATCACCCGCGTAG 2538
    | ::::: ||||| |||::: |||::: |||:::
303 yProSerGlyProAlaGlyAlaArgGlyAsnAspLysAlaProGlyAlaA 320
    ||||| |||||::|||::|||::|||::|||::|||::|||::|||::|||
2527 GTTCCGACCCGACATCGAGAGCGGCGACGCTGCGCTGTCTCACTTCGCTT 2478
    :: ||| ||||| ||||| |||||::|||::|||::|||::|||::|||

```





```

915 AACCGGCGGAGCTGATCGGCGG.....CTGCGCTACCATCTCCCGCTG 872
      ||||| |||
817 uThrglyAspAlaGlyAlaLysGlyAspAlaGlyProProGlyProAla. 833
      ||||| |||||
871 TTGGTATCTGCGAGTCTGCTGGTGTGGTGCACCGATCCGGCGATGGC 822
      ||| ||| |||||
834 ..GlyProThrglyAlaProGlyProAlaGly**ValGlyAlaProGly 849
      ||| ||| |||||
821 CCGGAGGCGCGTGCAGCTTCTCAAGC..... 795
      ||||| ||| |||
850 ProLyGlyAlaArgGlySerAlaGlyProProGlyAlaThrglyPhePr 866
      ||||| ||| |||
795 ..... 795
866 oglyAlaAlaGlyArgValGlyProProGlyProSerGlyAsnIleGlyL 883
794 ..ACTGGCTCGGCGGCGGAGGCGGCGGTGAGCGGACGAGCGC 747
      ||| ||||| |||||
883 euProGlyProProGlyProAlaGlyLys**Gly...SerLySglyPro 898
      ||||| ||||| |||||
746 TGCCGGGGGCGTCCGAGACACTCGGC...CTGAGAGCGCTGCTCGTGC 700
      ||||| ||||| |||||
899 ...ArgGlyLutThrglyProAlaGlyArgProGlyGlyLutProGlyProAl 914
      ||||| ||||| |||||
699 AACCGCTGCACCTACGCCCGCGGAGACA...CACCCGACCATGAC... 657
      ||||| ||||| |||||
914 aglyProProGlyProProGlyLutLySgLySerProGlyAlaAspGlyP 931
      ||||| ||||| |||||
656 .....CCGGTGTCTGATCAGCGCGCGCA 633
      ||||| ||||| |||||
931 rolleGlyAlaProGlyThrProGlyProGlnGlyIleAlaGlyGlnArg 947
      ||||| ||||| |||||
632 GCGCGATTCGGCTCGGTCCGAGCACAGCTGCTATCATGATCACCG 853
      ||| ||| |||
948 GlyValAlaGlyLeu.....ProGlyGln..... 955
      ||| ||| |||
582 GGCATCACTTCGGCGGCGGACACAGCGGCTCTCTGGGCTGCTG 533
      ||| ||| |||
956 .....ArgGlyGlyAlaArgGlyPheProGlyLeuProG 966
      ||| ||| |||
532 CTCGCGGAGGT...CTGCG.....GGGCGGCTCGGCGGATGCGCA 492
      ||| ||||| |||||
966 LyProSerGlyLutProGlyLysGlnGlyProSerGlyAlaSerGlyGln 982
      ||||| ||||| |||||
491 CGAGAGACCGCTCTCCCGGTTCCGGAGAGAGCGCTCGCTACACCGC 442
      ||||| ||||| |||||
983 ArgGlyProProGlyProMetGlyProProGlyLeuAlaGlyProProG 999
      ||||| ||||| |||||
441 CGGTGCGCTACAGTGTGTGAGAGTTCGCTGCCAGAGAGTACCATCGC 392
      ||| ||| |||
999 yGlyAlaGlyArgGlyLutGlyAlaProGlyAlaGlnGlyAlaProGlyArg 1016
      ||| ||| |||
391 GGCCTCGCGTCCCGCGCGAGC..... 369
      ||||| ||||| |||||
016 spGlyAlaAlaGlyProLySgLySparGlyGlyLutThrglyProAlaGly 1032
      ||||| ||||| |||||
368 .....GC 367
      ||| ||| |||
1033 ProProGlyAlaProGlyAlaProGlyAlaProGlyProValGlyProAl 1049
      ||||| ||||| |||||
366 CGGTGCTGTGATGACATGAGGAGCACAA.....CACCGAGCGC 329
      ||||| ||||| |||||
1049 agLyLysAsnLySparGlyGlyLutThrglyProAlaGlyProAlaGlyP 1066
      ||||| ||||| |||||
1066 roProGlyProAlaGlyAlaArgGlyProAlaGlyProGlnGlyProArg 1082
      ||||| ||||| |||||
282 GCGCGC..... 277
      ||| ||| |||
1083 GlyAspLySgLyGlyLutThrglyGlyLutGlnGlyAspArgGlyMetLySgLyH 1099
      ||||| ||||| |||||
276 .....GGCTCACTTCGGCGAGCG 258

```

```

1099 sArgLyPheSerGlyLeuGlnGlyProProGlyProProGlyAlaProG 1116
      ||| ||||| |||||
257 GCCGCACTACTGCATCGGGAGGAGCACCTGCCAGCTGAGTCGCGCACGA 208
      ||||| ||||| |||||
1116 LyGlnGlnGlyProSerGlyAlaSerGlyProAlaGlyProAlaGlyPro 1132
      ||||| ||||| |||||
207 TGATGGCGCTACTGGCGACAGGTTC.....CCGAG 176
      ||||| ||||| |||||
1133 ProGlySerAlaGlyAlaAlaGlyLysAspGlyLeuAsnGlyLeuProG 1149
      ||||| ||||| |||||
175 GCCGCACTGCGCGTCCGCTACGACGAGTTCGCTGCGCGGAGGCGC 126
      ||| ||| |||
1149 yProIleGlyPro.....ProGlyP 1156
      ||| ||| |||
125 CCAGAGCGCGCGCTCACCGAGACTGCGCTGCTGCTGCTGATCCGCG 76
      ||||| ||| ||| |||||
1156 roArgGlyArgThrglyGlyAlaGlyProValGlyProProGlyProPro 1172
      ||||| ||||| |||||
75 GCCGCGACCGCG...ACGGAGCGCGCGCAC 49
      ||||| ||||| |||||
1173 GlyProProGlyProProGlyProProSer 1182
      ||||| ||||| |||||
seq_name: SwissProt_40:CALL_CANFA
seq_documentation_block:
ID CALL_CANFA STANDARD; PRT; 1460 AA.
AC 09XSJ7;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE Collagen alpha 1(I) chain precursor..
GN COL1A1
OS Canis familiaris (dog)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX NCBI_Taxid=9615;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin;
RA Campbell B.G., Woollon J.A.M., McLeod J.N., Minor R.R.;
RT "Sequence of normal canine COL1A1 cDNA.";
RL Submitted (MAY-1999) to the EMBL/Genbank/DBJ databases
CC -!- FUNCTION: TYPE I COLLAGEN IS A MEMBER OF GROUP I COLLAGEN
CC (FIBRILLAR FORMING COLLAGEN).
CC -!- SUBUNIT: TRIMERS OF ONE ALPHA 2(I) AND TWO ALPHA 1(I) CHAINS.
CC -!- PTM: PROLINES ARE HYDROXYLATED IN SOME OR ALL OF THE CHAINS.
CC -!- SIMILARITY: CONTAINS 1 WFPC DOMAIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL, AF153062; AAD34619.1; -
DR InterPro; IPR000087; Collagen.
DR InterPro; IPR000885; Fib_collagen_C.
DR InterPro; IPR001007; WFPC.
DR Pfam; PF01410; COLF1; 1.
DR Pfam; PF01391; collagen; 18.
DR PRODOM; PD002078; Fib_collagen_C; 1.
DR SMART; SM00038; COLF1; 1.
DR SMART; SM00214; WVC; 1.
DR PROSITE; PS01208; WVC; 1.
KW Extracellular matrix; Connective tissue; Repeat; Hydroxylation;
KW Glycoprotein; Collagen; Signal.
FT SIGNAL 1 22 BY SIMILARITY.
FT PROPEP 23 157 AMINO-TERMINAL PROPEPTIDE.
FT CHAIN 158 1214 COLLAGEN ALPHA 1(I) CHAIN.

```



```

639  lnlglyleuproglproalaglproprogllylunalaaglylserproglly 655
      ::::: ||::: :::::||::: ::::: ||
1433 CGG.....ACGTGCTGACCCCGGAGGGGCGGCTTCTGCTGAGCA 1390
      ::::: ::::: ::::: :::::
656 glungllyalprogllyasplleuglyalaprogllyproserglyalaa 672
      ::::: ::::: ::::: :::::
1389 CTCGGGAGGGGTACCCCGGCGGGCGGGGTG..... 1356
      ::::: ||::: :::::||::: ::::: ||
672 ggllyuaraglylpheroaglylunarglylvalglnglyproprogllyp 689
      ::::: ||::: :::::||::: ::::: ||
1355 .....CCTGTGAGCGGCGAGGCGCGCGGGTGGCGCTGACCCGTT 1314
      ::::: ||::: :::::||::: ::::: ||
689 rolaaglyproarglyalaaanglyalaprogllyasnasp..... 702
      ::::: ||::: :::::||::: ::::: ||
1313 CGCGTGTCCATGATGACCATGACGAGCGCAAGCCCGAGTGCAGACGCT 1264
      ::::: ||::: ||::: ||::: ||::: ||
703 glyalalysglyasplalaglialaprogllyalaprogllyserglngly 719
      ::::: ||::: ||::: ||::: ||::: ||
1263 TCCGGGA.....GGCGGGCGCGGTGTCGAGGTGAACG..... 1230
      ::::: ||::: ||::: ||::: ||::: ||
719 aprogllyleuglnglymetprogllylunarglylalaalaglyleuprog 736
      ::::: ||::: ||::: ||::: ||::: ||
1229 ..CCCCGGCGGAGACCCGCTGGGTATCATCCGATACGCCCTGCGCGG 1182
      ::::: ||::: ||::: ||::: ||::: ||
736 lprolysgly.....Asparglyasplalaglypro 746
      ::::: ||::: ||::: ||::: ||::: ||
1181 CGAGGTGCTGGCGATCCCGGTTGTMGAAGACCCGA..... 1143
      ::::: ||::: ||::: ||::: ||::: ||
747 lysglyalalaspilyserprogllylaspilyalarglyleuthrel 763
      ::::: ||::: ||::: ||::: ||::: ||
1142 .....CTGCGCCCGCGCGCTGCGGGGGGT...GAGCAGC 1109
      ::::: ||::: ||::: ||::: ||::: ||
763 yprolleglyproprogllypro.....Alaglyalaprogllyaspl 777
      ::::: ||::: ||::: ||::: ||::: ||
1108 GGCTGTCGATCCCGTTCGCGAGCTGCTCCGTTACGCTATGCC... 1062
      ::::: ||::: ||::: ||::: ||::: ||
777 ysglylunalaaglyproserglyproalaglyprothrlslyalaaargly 793
      ::::: ||::: ||::: ||::: ||::: ||
1061 .....CGTGGCGGCGAGGCCCGGCGGCGCTGCG..... 1032
      ::::: ||::: ||::: ||::: ||::: ||
794 Alaprogllyasplarglylunprogllyproprogllyproalaglylhea 810
      ::::: ||::: ||::: ||::: ||::: ||
1031 .....CCGATTCACGACACTGCTTCACCCGCGC 1001
      ::::: ||::: ||::: ||::: ||::: ||
810 aglyproprogllyalaspilylunprogllylalatysglylunproglly 827
      ::::: ||::: ||::: ||::: ||::: ||
1000 CGGCTGGCGGAGCGAGATGCGATCGCGGATCGCGGCGGCGCTGCT 951
      ::::: ||::: ||::: ||::: ||::: ||
827 splalaglyAlalysglyaspAlaglyproprogllyproalagly.... 841
      ::::: ||::: ||::: ||::: ||::: ||
950 CACCGAATCGCGGAGCGCTCGGCGGTGCGCAAMCGGCGGAGCTGA 901
      ::::: ||::: ||::: ||::: ||::: ||
842 ..Prothrlglyproprogllyprolellylaspilvalgylalaprogllypro 857
      ::::: ||::: ||::: ||::: ||::: ||
900 TGGGGGCTGCTCGGCTACCACTTCCGCTGTGTCATCTGCGAGCTGTC 851
      ::::: ||::: ||::: ||::: ||::: ||
858 lysglyalaaArgglyseralaglyproprogllylathrglylphero 874
      ::::: ||::: ||::: ||::: ||::: ||
850 GGTGTGCGGTATCCGATCGCGGATCGCGGCGGCGGCTGAGGCTTCT 801
      ::::: ||::: ||::: ||::: ||::: ||
874 lylalalaglylathrglylunprogllyproserglyasnalaaglypro 890
      ::::: ||::: ||::: ||::: ||::: ||
800 CAGGCACTCGGCTCGGCGCGCGAGCGGCGGGGTGACG..... 756
      ::::: ||::: ||::: ||::: ||::: ||
891 Proglly.....Proprogllyproalaglylunarglyllyllysglyal 905
      ::::: ||::: ||::: ||::: ||::: ||
755 .....CACGGACCTCGCGGGGGGTGCTCGGACACTCGGC...C 719
      ::::: ||::: ||::: ||::: ||::: ||
905 aarglylunthrglylproalaa...glylathrglylunvalgyllypro 921
      ::::: ||::: ||::: ||::: ||::: ||
718 CTGAGAGAGCTGCTCTCGAAGCGCTGCACTGAGCCGGCGGAGACGAC 669
      ::::: ||::: ||::: ||::: ||::: ||
921 rogllyproprogllyproalaglylunlyslylserprogllyalaspily 937
      ::::: ||::: ||::: ||::: ||::: ||
668 CCCGACCATACCCCGTGTGACGAGCGCGCAGCGGAGCTTGGCT 619
      ::::: ||::: ||::: ||::: ||::: ||
938 Proalaglyalapro..... 942
      ::::: ||::: ||::: ||::: ||::: ||
618 CGGCTCCGCGAGCACAGCTGCTACATGATCACCGGCGCTCATCTTCCG 569
      ::::: ||::: ||::: ||::: ||::: ||
943 ..glylthnprogllyprogllylilealaglylunarglylvalgyl 959
      ::::: ||::: ||::: ||::: ||::: ||
568 GGCCA.....CGACACACCGGCTCTTCTGAGGTCTCTGCT... 531
      ::::: ||::: ||::: ||::: ||::: ||
959 eubrogllylunarglylunarglylpheroalaglyleuprogllyproser 975
      ::::: ||::: ||::: ||::: ||::: ||
530 .....CGCGAGG 523
      ::::: ||::: ||::: ||::: ||::: ||
976 glylunprogllylsglnglylproserglylthrserylunarglylpr 992
      ::::: ||::: ||::: ||::: ||::: ||
522 TCCTGGC.....GGCGCGCT..... 507
      ::::: ||::: ||::: ||::: ||::: ||
992 oprogllyprometglyproprogllyleualaglylproprogllyluserg 1009
      ::::: ||::: ||::: ||::: ||::: ||
506 ..CGCGCGGATGCCGAGAGAGAGCGCGCTCCCGGTGCGAGGA... 462
      ::::: ||::: ||::: ||::: ||::: ||
1009 lylarglylunlyserprogllyalaglylserprogllylathrglylser 1025
      ::::: ||::: ||::: ||::: ||::: ||
461 .....GGCGTCCGCTACACCCG 442
      ::::: ||::: ||::: ||::: ||::: ||
1026 Progllyprolysglylasparglylunthrglylproalaglylproprogl 1042
      ::::: ||::: ||::: ||::: ||::: ||
441 C.....GTGCCCTACAGTTGTGAGGTGCTGCCACGAGGTGACC 398
      ::::: ||::: ||::: ||::: ||::: ||
1042 yalaprogllyalaa..... 1046
      ::::: ||::: ||::: ||::: ||::: ||
397 ATCGGCGGCTCGGCTCGGCTCCCGGAGCGCGGCTGTCGATGACATGCA 348
      ::::: ||::: ||::: ||::: ||::: ||
1047 .....Progllyalaprogllyprovalglylproalaglylpsan 1059
      ::::: ||::: ||::: ||::: ||::: ||
347 GGGCACCAACAGCGAGCGCGCATGACGAGCGCGGCGGCTTCCAGC 298
      ::::: ||::: ||::: ||::: ||::: ||
1060 glylasparglylunthrglylproalagly.....Proal 1071
      ::::: ||::: ||::: ||::: ||::: ||
297 CGGACCGTCCCTGTTGCGGCGGCTCACCTTGGCGAGCGCGGCTGACTAC 248
      ::::: ||::: ||::: ||::: ||::: ||
1071 aglyprolelleglylprovalglyalaa..... 1079
      ::::: ||::: ||::: ||::: ||::: ||
247 TGCATCGGGGAGCAGTCCGCCACGCTGGAGTCGCCACATATGCGGCT 198
      ::::: ||::: ||::: ||::: ||::: ||
1080 .....Argglylproalaglylunarglylproargglylaspilysglylun 1094
      ::::: ||::: ||::: ||::: ||::: ||
197 ACTGCGCAGCAGTTCCCGGAGCGGAGCTGCG...CGTGGGTACGAGC 151
      ::::: ||::: ||::: ||::: ||::: ||
1095 Thrglylunlunllylasparglylilellysglylthrsarglylpheser 1111
      ::::: ||::: ||::: ||::: ||::: ||
150 AGTTGCGGTGTCGCG.....GAAGGGGCGCCAG 122
      ::::: ||::: ||::: ||::: ||::: ||
1111 yleuglnglylproprogllylserprogllylunlunllylpros 1128
      ::::: ||::: ||::: ||::: ||::: ||
121 AGCGGCGGCTCA.....CGGAAGTCCGCTGCTGCTGCTAT 82
      ::::: ||::: ||::: ||::: ||::: ||
1128 erglylaserllylproalaglylproargglylproprogllylserllyl 1144
      ::::: ||::: ||::: ||::: ||::: ||
81 CCGCGGCGCGGAGCGGCG.....ACGGGACCGGC 53
      ::::: ||::: ||::: ||::: ||::: ||
1145 serprogllylaspilylunasnnglylunprogllylprolellylprobr 1161
      ::::: ||::: ||::: ||::: ||::: ||
52 CACCGCGGACCGCGCGGTGGC.....GTCCCGGTG 22
      ::::: ||::: ||::: ||::: ||::: ||
1161 oglylproathrglylathrglylaspilalaglylproval 1173
      ::::: ||::: ||::: ||::: ||::: ||
seq_name: SwissProt_40:CA11_HUMAN
seq_documentation_block:
```

ID CALL\_HUMAN STANDARD; PRT; 1464 AA.  
AC P02452; Q15176; Q14037;  
DT 21-JUL-1986 (Rel. 01, Created)  
DT 01-MAR-1989 (Rel. 10, Last annotation update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Collagen alpha 1(I) chain precursor.  
GN COL1A1.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE OF 1-472 FROM N.A.  
RX MEDLINE-89025644; PubMed-3178743;  
RT Tromp G., Kuivaniemi H., Stacey A., Shikata H., Baldwin C.T.,  
Jansen R., Prockop D.J.;  
RL "Structure of a full-length cDNA clone for the prepro alpha 1(I)  
chain of human type I procollagen";  
Biochem. J. 253:919-922(1988).  
RN [2]  
RP SEQUENCE OF 1-181 FROM N.A.  
RX MEDLINE-84270697; PubMed-6462220;  
RT Chu M.-L., de Wet W.J., Bernard M.P., Ding J.-F., Morabito M.,  
Myers J., Williams C., Ramirez F.;  
RL "Human pro alpha 1(I) collagen gene structure reveals evolutionary  
conservation of a pattern of introns and exons";  
Nature 310:337-340(1984).  
RN [3]  
RP SEQUENCE OF 162-301.  
RC TISSUE-SKIN;  
RX MEDLINE-71038625; PubMed-5529814;  
RA Click E.M., Bornstein P.;  
RL "Isolation and characterization of the cyanogen bromide peptides from  
the alpha 1 and alpha 2 chains of human skin collagen";  
Biochemistry 9:4699-4706(1970).  
RN [4]  
RP SEQUENCE OF 263-268.  
RC TISSUE-SKIN;  
RX MEDLINE-71001508; PubMed-4319110;  
RA Morgan P.H., Jacobs H.G., Segrest J.P., Cunningham L.W.;  
RL "A comparative study of glycopeptides derived from selected  
vertebrate collagens. A possible role of the carbohydrate in fibril  
formation";  
J. Biol. Chem. 245:5042-5048(1970).  
RN [5]  
RP SEQUENCE OF 425-1464 FROM N.A.  
RX MEDLINE-84060385; PubMed-6689127;  
RA Bernard M.P., Chu M.-L., Myers J.C., Ramirez F., Eikenberry E.F.,  
Prockop D.J.;  
RL "Nucleotide sequences of complementary deoxyribonucleic acids for the  
pro alpha 1 chain of human type I procollagen. Statistical evaluation  
of structures that are conserved during evolution";  
Biochemistry 22:5213-5223(1983).  
RN [6]  
RP SEQUENCE OF 1229-1454 FROM N.A.  
RC TISSUE-BONE;  
RX MEDLINE-88124208; PubMed-3340531;  
RA Meekelae J.K., Raassina M., Virta A., Vuorio E.;  
RL "Human pro alpha 1(I) collagen: cDNA sequence for the C-propeptide  
domain";  
Nucleic Acids Res. 16:349-349(1988).  
RN [7]  
RP SEQUENCE OF 1-34 FROM N.A.  
RX MEDLINE-88097389; PubMed-3480516;  
RA Bornstein P., McKay J., Morishima J.K., Devaratyalu S., Gelinas R.E.;  
RL "Regulatory elements in the first intron contribute to  
transcriptional control of the human alpha 1(I) collagen gene";  
Proc. Natl. Acad. Sci. U.S.A. 84:8869-8873(1987).  
RN [8]  
RP SEQUENCE OF 1-34 FROM N.A.  
RX MEDLINE-85130970; PubMed-2857713;  
RA Chu M.-L., de Wet W.J., Bernard M.P., Ramirez F.;  
RL "Fine structural analysis of the human pro-alpha 1 (I) collagen gene.

RT Promoter structure, AluI repeats, and polymorphic transcripts.";  
J. Biol. Chem. 260:2315-2320(1985).  
RN [9]  
RP SEQUENCE OF 1-44 FROM N.A.  
RX MEDLINE-88033098; PubMed-2822714;  
RA Rossoff C.M.S., Vergeer W.P., du Plooy S.J., Bernard M.P., Ramirez F.,  
de Wet W.J.;  
RL "DNA sequences in the first intron of the human pro-alpha 1(I)  
collagen gene enhance transcription";  
J. Biol. Chem. 262:15151-15157(1987).  
RN [10]  
RP REVIEW ON VARIANTS.  
RX MEDLINE-91184577; PubMed-2010058;  
RA Kuivaniemi H., Tromp G., Prockop D.J.;  
RL "Mutations in collagen genes: causes of rare and some common diseases  
in humans";  
FASEB J. 5:2052-2060(1991).  
RN [11]  
RP REVIEW ON VARIANTS.  
RX MEDLINE-91374476; PubMed-1895312;  
RA Byers P.H., Wallis G.A., Willing M.C.;  
RL "Osteogenesis imperfecta: translation of mutation to phenotype";  
J. Med. Genet. 28:433-442(1991).  
RN [13]  
RP REVIEW ON VARIANTS.  
RX MEDLINE-97169389; PubMed-9016532;  
RA Dalgleish R.;  
RL "The human type I collagen mutation database";  
Nucleic Acids Res. 25:181-187(1997).  
RN [14]  
RP VARIANT OF II CYS-1166.  
RX MEDLINE-86287390; PubMed-3016737;  
RA Conn D.H., Byers P.H., Steinmann B., Gelinas R.E.;  
RL "Lethal osteogenesis imperfecta resulting from a single nucleotide  
change in one human pro alpha 1(I) collagen allele";  
Proc. Natl. Acad. Sci. U.S.A. 83:6045-6047(1986).  
RN [15]  
RP VARIANT OF II ARG-569.  
RX MEDLINE-87222295; PubMed-3108247;  
RA Bateman J.F., Chan D., Walkers I.D., Rogers J.G., Cole W.G.;  
RL "Lethal perinatal osteogenesis imperfecta due to the substitution of  
arginine for glycine at residue 391 of the alpha 1(I) chain of type I  
collagen";  
J. Biol. Chem. 262:7021-7027(1987).  
RN [16]  
RP VARIANT OF II CYS-926.  
RX MEDLINE-88033031; PubMed-3667599;  
RA Vogel B.E., Minor R.R., Freund M., Prockop D.J.;  
RL "A point mutation in a type I procollagen gene converts glycine 748  
of the alpha 1 chain to cysteine and destabilizes the triple helix in  
a lethal variant of osteogenesis imperfecta";  
J. Biol. Chem. 262:14737-14744(1987).  
RN [17]  
RP VARIANT OF II ARG-842.  
RX MEDLINE-88298828; PubMed-3403550;  
RA Bateman J.F., Lemande S.R., Dahl H.H., Chan D., Cole W.G.;  
RL "Substitution of arginine for glycine 664 in the collagen alpha 1(I)  
chain in lethal perinatal osteogenesis imperfecta. Demonstration of  
the peptide defect by in vitro expression of the mutant cDNA";  
J. Biol. Chem. 263:11627-11630(1988).  
RN [18]  
RP VARIANT OF CYS-1195.  
RX MEDLINE-89218628; PubMed-3244312;  
RA Lebbard M.E., Wirtz M.K., Pope F.M., Nicholls A.C., Hollister D.W.;  
RL "A cysteine for glycine substitution at position 1017 in an alpha

RT 1(I) chain of type I collagen in a patient with mild dominantly  
 RT inherited osteogenesis imperfecta.";  
 RL Mol. Biol. Med. 5:197-207(1988).  
 RN [19]  
 RP VARIANT OI-II VAL-434.  
 RX MEDLINE-89255493; PubMed-2470760;  
 RA Paterson E., Smiley E., Bonadio J.;  
 RT "RNA sequence analysis of a perinatal lethal osteogenesis imperfecta  
 mutation.";  
 RL J. Biol. Chem. 264:10083-10087(1989).  
 RN [20]  
 RP VARIANT OI-IV SER-1010.  
 RX MEDLINE-89305591; PubMed-2745420;  
 RA Martin J.C., Grange D.K., Gottesman G.S., Lewis M.B., Koepflin D.A.;  
 RT "Osteogenesis imperfecta type IV. Detection of a point mutation in  
 one alpha 1(I) collagen allele (COL1A1) by RNA/RNA hybrid analysis.";  
 RL J. Biol. Chem. 264:11893-11900(1989).  
 RN [21]  
 RP VARIANTS OI-II ALA-1106; VAL-1151; ARG-1154 AND VAL-1184.  
 RX MEDLINE-89380165; PubMed-2777764;  
 RA Lamande S.R., Dahl H.-H.M., Cole W.G., Bateman J.F.;  
 RT "Characterization of point mutations in the collagen COL1A1 and  
 COL2A1 genes causing lethal perinatal osteogenesis imperfecta.";  
 RL J. Biol. Chem. 264:15809-15812(1989).  
 RN [22]  
 RP VARIANT OI SER-1022.  
 RX MEDLINE-90062068; PubMed-2511192;  
 RA Pack M., Constantinou C.D., Kalia K., Nielsen K.B., Prockop D.J.;  
 RT "Substitution of serine for alpha 1(I)-glycine 844 in a severe  
 variant of osteogenesis imperfecta minimally destabilizes the triple  
 helix of type I procollagen. The effects of glycine substitutions on  
 thermal stability are either position of amino acid specific.";  
 RL J. Biol. Chem. 264:19694-19699(1989).  
 RN [23]  
 RP VARIANT OI-II CYS-1082.  
 RX MEDLINE-89109573; PubMed-2913053;  
 RA Constantinou C.D., Nielsen K.B., Prockop D.J.;  
 RT "A lethal variant of osteogenesis imperfecta has a single base  
 mutation that substitutes cysteine for glycine 904 of the alpha 1(I)  
 chain of type I procollagen. The asymptomatic mother has an  
 unidentified mutation producing an overmodified and unstable type I  
 procollagen.";  
 RL J. Clin. Invest. 83:574-584(1989).  
 RN [24]  
 RP VARIANTS OI CYS-272; CYS-704 AND CYS-896.  
 RX MEDLINE-90009313; PubMed-2794057;  
 RA Starman B.J., Eyre D., Charbonneau H., Harrylock M., Weiss M.A.,  
 RA Weiss L., Graham J.M., Byers P.H.;  
 RT "Osteogenesis imperfecta. The position of substitution for glycine by  
 cysteine in the triple helical domain of the pro alpha 1(I) chains of  
 type I collagen determines the clinical phenotype.";  
 RL J. Clin. Invest. 84:1206-1214(1989).  
 RN [25]  
 RP VARIANT OI-II CYS-422.

alignment\_scores:  
 Quality: 462.00 Length: 1122  
 Ratio: 0.937 Gaps: 62  
 Percent Similarity: 43.939 Percent Identity: 26.560

alignment\_block:  
 US-09-673-254-1/rev x CA11\_HUMAN ..  
 Align seg 1/1 to: CA11\_HUMAN from: 1 to: 1464

2780 CCAGGT.....CAATCACTCGCAGGCTTCTGCTGCGACGCG 2743  
 ||||| .....||| ||||| .....  
 178 ProglyProMetGlyProSerGlyProArgGlyLeuProGlyProGly 194  
 2742 TGCTCTCGGGA.....GCGGCTCGCGGCGGCGGCGTGCATC 2708  
 :||| ||| .....||| .....  
 194 yAlaProGlyProGlnGlyPheGlnGlyProProGlyGlnProGlyGlnP 211

2707 CT.....CACCTGCTCCGACGCGCTACACCGACGCG..... 2676  
 || .....||| ||||| |||||  
 211 roGlyAlaSerGlyProMetGlyProArgGlyProProGlyProProGly 227  
 2675 .....GATCGACCCCGACGACCTCAACGCGG 2650  
 228 LysAsnGlyAspAspGlyGlnAlaGlyLysProGlyArgProGlyGln 244  
 2649 A.....CGGTACCGCTACAGCGCG.....CGAGCGTACGCGACG 2612  
 | .....||| ||||| .....  
 244 gAlProProGlyProGlnGlyAlaArgGlyLeuProGlyThrAlaGlyL 261  
 2611 TCCAAAACAGCCCAACATCATGACCGCGCG.....GGAGCGCG 2574  
 .. .....||| ||||| .....  
 261 eu.....ProGlyMetLysGlyHisArgGlyPheSerGlyLeuAspGlyAla 276  
 2573 CAGGCGCTGCGCGACGCTGCG..... 2550  
 277 LysGlyAspAlaGlyProAlaGlyProLysGlyGlnProGlySerProGly 293  
 2549 .....GCTCACTATACCCCGGTG.....A 2529  
 293 yGlnAsnGlyAlaProGlyGlnMetGlyProArgGlyLeuProGlyGln 310  
 2528 GGTCCGACACCCGATCGACGCGGCGCGCTGCTCTACTTCGGT 2479  
 || .....||| .....||| .....  
 310 rGlyLArProGlyAlaProGlyAlaProGlyAlaArgLysAsnAspGly 326  
 2478 TCACCCCTCTCTGCGCTCGCGCGGAGGCGCGACACCTCGTGG 2429  
 :||| .....||| ||||| .....  
 327 AlArnGlyAlaAlaGlyPro.....ProGlyProThr..... 337  
 2428 CTGGCGTCCGCGCGCGGAGGAGTTCACACGCGCGGTCTACACGCA 2379  
 || .....||| .....||| .....  
 338 .....GlyProAlaGlyProProGlyPheProGlyAlaValGlyAlaLysG 353  
 2378 CCGGCGGCTGTCC..... 2365  
 :|| .....||| .....  
 353 LysLAlaGlyProGlnGlyProArgGlySerGlnGlyProGlnGlyAl 369  
 2364 CGGTAGCGGCGCGACCGCGACCGCGGCTCGCGCGACGACTGGGAG 2315  
 || .....||| .....  
 370 ArgGlyGlnProGlyProProGlyProAlaGly..... 380  
 2314 GCGGCGGCGCGCGCGGCGACACCGCGCACTGACGCG.....GGCG 2271  
 || .....||| .....||| .....  
 381 .....AlaAlaGlyProAlaGlyAsnProGlyAlaAspGlyGlnProGly 395  
 2270 GCCCGCCCGCGCGATGCTCTCATCCGCGAGATGCTCTCATCC 2221  
 || .....||| .....||| .....  
 396 AlaLysGlyAlaAsnGlyAlaProGlyLeaGlyAlaProGlyPhePr 412  
 2220 GCGAGCGACGACCTGCTGCGCATTCATCGAAGAAGACATTCGTGAC 2171  
 | .....||| .....  
 412 oGlyAlaArg..... 415  
 2170 CAGTTGCGCGCGCGCGCGCGCGCATGTTGACCTCGGTTGCCCGATG 2121  
 || .....||| .....||| .....  
 416 .....GlyProSerGlyProGlnGly.....ProGly 424  
 2120 TCGCGCGCTCGCGCGCTCTCATACCGCGCTGTCGCTGACCGCACCC 2071  
 :|| .....||| .....||| .....  
 425 GlyProProGlyProLysGly.....AsnSerGlyGlnProG 436  
 2070 GTGTCACGACCGCGCGCGCGCGGAGATACA.....CGAGTTACG 2030  
 :|| .....||| .....||| .....  
 437 .....GlyAlaProGlySerLysGlyAspThrGlyAlaLysGlyGlnProG 452  
 2029 CTCCGACGAGGAGTGTGCGCGCGGTGCGCGCGCG..... 1995  
 :|| .....||| .....||| .....  
 452 LyrValAlaGlyAlaGlnGlyProProGlyProAlaGlyGlnGlyLys 468  
 1994 .....ACCAGATCGACACCCCTACACCGCG..... 1968

```
469 ArgGlyAlaArgGlyLupProGlyProThrGlyLeuProGlyProProG 485
      ::::: |||
1967 ...CGTACGGCGCGGAGAC.....ACCAGACGGCAT 1937
      ||| |||||
485 yGluArgGlyGlyProGlySerArgGlyPheProGlyAlaAspGlyAla 502
      :::::
1936 GCGCGCATGTGACCGGTACTGTGCGCACGCGACGCGCGACGCGCTA 1887
      :: ||:::|||||
502 IaglyProLysGlyProAlaGlyGlyLupArgGlySerProGlyProAlaGly 518
      :: ||:::|||||
1886 CCAAGCGGTGAGAGCGCGCGCGCGAGTCATCATGACTCCGATGAGAC 1837
      ||:::|||||
519 ProLysGlySerProGlyGlyLupArgGlyProGly.....GluAlaG 533
      ::::: |||
836 GTCTCGCGCGCGCGGATGGCGCTTCGCCGACCCCGCGGGCGCG 1787
      ::::: |||
533 yLeuProGlyAlaLysGlyLeuThrGlySerProGlySerProGlyPro 550
      ::::: |||
1786 GTTCGGCGGTGCGCGAGAGTATGAGGGCGCGAGGTGACGGCG 1737
      ::::: |||
550 spGlyLysThrGly..... 554
1736 TCCCCGCTCGGTGCGCTGGTGCAGCTGTGACGCGCATCGGGCC 1687
      ||| |||||
555 ...ProProGlyProAlaGlyGlyLupArgGlyProGlyProProGlyPr 570
1686 GCGCGGACTTACCGCGCGACCTCGCGCTCGCGCGCGACCGG 1637
      |||||
570 oProGlyAla.....ArgGlyLupAlaGlyAlaMetGlyPheProG 584
1636 ACTGAAGGCGTACCGACCGCGTGCACATCGGTGACACACCGGTG 1587
      ::::: |||
584 yProLysGlyAlaAlaGlyLupProGlyLysAlaGlyLupArgGlyAla 600
1586 CCGGACCGGAGAGTGGCGTACCGCG.....CGTACGG 1549
      |||||
601 ProGlyProProGlyAlaAlaGlyProAlaGlyLysAspGlyGlyLupAlaG 617
1548 CCGCACTGGCGCTGCTTCGCCGCGCACGACTGCGACCGACG... 1503
      |||||
617 yAlaGlyLupPro...ProGlyProAlaGlyProAlaGlyLupArgGlyG 633
1502 .....TCGGCGCGCTTGAACCTCGCGCGCTCGCGGAGACG 1464
      ::||::: |||
633 IupGlyLupProAlaGlySerProGlyPheGlyLupProGlyProAla 649
463 AGCCCGCGACACGCCGAGGGGCGCGGCG.....ACCTGCTCGAC 1420
      ::|||
650 GlyProProGlyGlyLupAlaGlyLysProGlyLupGlyLupAlaProGlyAs 666
1419 CCGCACGGGCGGCTTCGCTGTCGACACGCGGAGGGGTACCCCG 1370
      ::|||
666 pLeuGlyAlaProGlyProSerGlyAlaArgGlyLupArgGlyPheProG 683
1369 GCGCGCGCGCGT.....CCTGTCGACGG 1344
      ::|||
683 yGlyLupArgGlyAlaGlyLupProProGlyProAlaGlyProArgGlyAla 699
1343 CGAGCGCGCGCGGTGCGCGTGCACCGCTTCGCTCCATGATGACCA 1294
      ::|||
700 AsnGlyAlaProGlyAsnAsp.....GlyAlaLysGlyAspAlaG 713
1293 TGCAGCGAAGCCGAGTGCACGACGCTTCGGGA.....GGCGGC 1250
      ||| |||
713 yAlaProGlyAlaProGlySerGlyLupAlaProGlyLupGlyLupMetP 730
1249 CGGTCGTGAGGTGAACG.....CCCGCGCGGAGACCCCG 1212
      |||||
730 roGlyLupArgGlyAlaAlaGlyLupProGlyProLysGly..... 743
1211 CTGGGTATACCGATGACGCGCTCGCGGAGGTGTCGGCATCCCG 1162
      ||| |||||
```

```
744 .....AspArgGlyAspAlaGlyProLysGlyAlaAspLysSerPr 757
1161 GGTTCGTGAAGACCCGA.....CTTCGCC 1136
      ::|||
757 oGlyLysAspGlyAlaArgGlyLeuThrGlyProIleGlyProProGlyPr 774
1135 CCGCGCGCGTGGGGGGT.....GGACGAGGTCGTGACATCCCGCTTC 1089
      || |||||
774 ro.....AlaGlyAlaProGlyAspLysGlyLupSerGlyProSer 787
1088 GGAGTCGCTCGTTCACGCTCATCGC.....CTGAGAG 1054
      || |||
788 GlyProAlaGlyProThrGlyAlaArgGlyAlaProGlyAspArgGlyGly 804
1053 GCGAGGCCACCGCGCGCTCGC.....C 1031
      ::|||
804 uProGlyProProGlyProAlaGlyPheAlaGlyProProGlyAlaAspG 821
1030 CGCATTCAGCACCTCGTTCAACCGCGCGCGCTGCGCGAGCGAGCGG 981
      ::|||
821 yGlyLupProGlyAlaLysGlyLupProGlyAspAlaGlyAlaLysGlyAs 837
980 TCGCATCGCGCGATGCGCGCGCGCTGCTCACGAACTCGCGACGCT 931
      |||||
837 pAlaGlyProProGlyProAlaGly.....ProAlaGlyProProGly 851
930 CCGCGCGTGGGCAACCGCGCGAGCTATGCGCGCTTCGCTGACAC 881
      || |||||
852 ProIleGlyAsnAlaGlyAlaProGlyAlaLysGlyAlaArgGlySerA 868
880 TTCGCCGTGTGTCATCGCAGCTGCTCGGTGTCGCGTCCGATCC 831
      |||
868 IaglyProProGlyAlaThrGlyPheProGlyAlaAlaGlyAlaGlyAlaG 884
830 GCGATGCGCGCGAGCGCGCTGCTTCAAGGACCTCGCGCTCGGCG 781
      |||||
885 ProProGlyProSerGlyLysAlaGlyProProGly.....ProProG 899
780 GCGCGAGAGCGCGGGGTGACG.....CAGGACCT 746
      |||||
899 yProAlaGlyLysGlyLupGlyLysGlyProAlaGlyLupThrGlyProA 916
745 GCGGGGCGTGGCGACACCTCGGC.....CTGAGAGCTGCTCTCGCA 699
      ::|||
916 Ia...GlyArgProGlyLupAlaGlyProProGlyProProGlyProAla 931
698 AGCCGTGACACCGCGCGGAGGAGACACCCGACCATGACCGCGTGC 649
      ::|||
932 GlyLupLysGlySerProGlyAlaAspGlyProAlaGlyAlaPro..... 946
648 TGTACGAGCGCGCGAGCGGAGTTCGCTTCGACGACGCTC 599
      |||
947 .....GlyThrProGlyProGlyG 953
598 GTTCATCATCACCGGCTCATCTTCGCGCGCA.....CGACACAC 555
      ::|||
953 yLileAlaGlyLupArgGlyAlaGlyLupProGlyLupAlaArgGlyGly 969
554 CGGCTCTTCGTGGCTCTGCTCGGAGGT...CGTGC.....G 514
      || |||||
970 ArgGlyPheProGlyLupProGlyProSerGlyLupProGlyLysGlyLup 986
513 GCGCGCTCGCGCGGTGCGGAGGAGACCGCTTCGCGGTTCGAGAG 464
      |||
986 yProSerGlyAlaSerGlyLupArgGlyProProGlyProMetGlyProP 1003
463 GAGCGCTGCTTACACCGCGCGGTGCTTACAGCTTGTGAGTTCG 414
      |||
1003 roGlyLupAlaGlyProPro..... 1009
413 TGCACGAGGTGACCATCGCGCGT..... 387
1010 .....GlyLupSerGlyArgGlyLupAlaProGlyAlaGlyLupLys 1023
```

```

386 .CCGGCTGCCCGCGAGCGCCGTGCTGTGACATCGAGCGACCAAC 338
|||||
1023 rProglYAspArglySerProglYAlaLysglYAspArgly..... 1037
337 ACCGAGCGCCGACATCAGACGCCCGACGCCCTCCACCCGAGCGCTCC 288
|||||
1038 .....GluThrnglyProAlaLysglYProProglYAlaProglY 1049
287 CTCGTGGCGCGGCTCACCCTTGGCGAGCGCGGCGCACTACTGATGGGG 238
|||||
1050 AlaProglYAlaPro.....G1 1055
237 AGCAGCTGCGCCAGCTGAGTGGCGACGATGATGCGCTACTGCGCAC 188
|||||
1055 yProValglYProAlaLysSerclYAspArglyglYUthrnglyPro 1072
187 AGGTTCGCCGAGCGCCGACTGCGCGCGCTACGACGAGTTCGGGTGTG 138
|||||
1072 laglyProAlaLysglYProAlaLysglYAlaArglyProAlaLys 1088
137 CCGGAGG..... 129
1089 ProGlnnglyProArglyAspLysglYUthrnglyGlnnglyAsp 1105
|||||
128 .....GGCCGAGCGCGC 117
1105 gGlylleLysglYHisArglyPheSerclYLeuGlnnglyProProglY 1122
|||||
116 C....GGTCACCG.....AACTGCCGCTGTGCTGCGCTATCCGCCG 76
|||||
1122 roProglYSerProglYglnnglyProSerclYAlaSerclYPro... 1137
75 GCGGCGACCGCGACCGCCGACCGCGCGCG..... 37
|||||
1138 ..AlaGlyProArglyProProglYSerAlaGlyAlaProglYLys 1153
36 .....GTGGCGGCTGCCCGCTGCCGTGACCC 12
1153 polyLeuAnsglyLeuProglYProIleGlyProProglYProAlaG 1170
11 GGTGGCGA 4
1170 rGThrgly 1172
seq_name: SwissProt_40:MCU1_HUMAN
seq_documentation_block:
ID MCU1_HUMAN STANDARD; PRT; 1255 AA.
AC P15941; P15942; P15931; P17626; Q14128; Q16442; Q16437; Q9Y4J2;
DT 01-JAN-1990 (Rel. 13, Created)
01-APR-1990 (Rel. 14, Last sequence update)
16-OCT-2001 (Rel. 40, Last annotation update)
Mucin 1 precursor (Polymorphic epithelial mucin) (PEM) (PEMT)
(Epistatin) (Tumor-associated mucin) (Carcinoma associated mucin)
(Tumor associated epithelial membrane antigen) (EMA) (H23A6) (Peanut-
reactive urinary mucin) (PUM) (Breast carcinoma-associated antigen
DF3).
DE (Human)
GN Homo sapiens (Human).
OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OC NCBI_TaxID=9606;
OX 11
RN SEQUENCE FROM N.A.
RP TISSUE=Pancreas;
RX MEDLINE=90368716; PubMed=2394722;
RA Ian M.S., Batra S.K., Qi W.-N., Metzgar R.S., Hollingsworth M.A.;
RT "Cloning and sequencing of a human pancreatic tumor mucin cDNA.";
RL J. Biol. Chem. 265:15294-15299(1990).
RN 12
RP SEQUENCE FROM N.A.
RX MEDLINE=90202794; PubMed=2318825;

```

```

RA Lichtenberg M.J.L., Vos H.L., Gennissen A.M.C., Hilkens J.;
RT "Epistatin, a carcinoma-associated mucin, is generated by a
RT polymorphic gene encoding splice variants with alternative amino
RT termini.";
RL J. Biol. Chem. 265:5573-5578(1990).
RN 13
RP SEQUENCE FROM N.A.
RX TISSUE=Breast carcinoma;
RX MEDLINE=90368715; PubMed=1697589;
RA Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T.,
RA Peat N., Burchell J., Pemberton L., Lalani E.-N., Wilson D.;
RT "Molecular cloning and expression of human tumor-associated
RT polymorphic epithelial mucin.";
RL J. Biol. Chem. 265:15286-15293(1990).
RN 14
RP SEQUENCE FROM N.A.
RX MEDLINE=91097524; PubMed=2268309;
RA Lancaster C.A., Peat N., Duhig T., Wilson D.,
RA Taylor-Papadimitriou J., Gendler S.J.;
RT "Structure and expression of the human polymorphic epithelial mucin
RT gene: an expressed VNTR unit.";
RL Biochem. Biophys. Res. Commun. 173:1019-1029(1990).
RN 15
RP SEQUENCE FROM N.A.
RX TISSUE=Breast carcinoma;
RX MEDLINE=90276413; PubMed=2351132;
RA Wreschener D.H., Hareuveni M., Tsarfaty I., Smorodinsky N.,
RA Horov J., Zaretsky J., Kotkes P., Weiss M., Lathe R., Dion A.,
RA Keydar I.;
RT "Human epithelial tumor antigen cDNA sequences. Differential splicing
RT may generate multiple protein forms.";
RL Eur. J. Biochem. 189:463-473(1990).
RN 16
RP SEQUENCE FROM N.A.
RX TISSUE=Breast carcinoma;
RX MEDLINE=90276414; PubMed=2112460;
RA Hareuveni M., Tsarfaty I., Zaretsky J., Kotkes P., Horev J.,
RA Zrihan S., Weiss M., Green S., Lathe R., Keydar I., Wreschener D.H.;
RT "A transcribed gene, containing a variable number of tandem repeats,
RT codes for a human epithelial tumor antigen. cDNA cloning, expression
RT of the transfected gene and over-expression in breast cancer
RT tissue.";
RL Eur. J. Biochem. 189:475-486(1990).
RN 17
RP SEQUENCE FROM N.A.
RX MEDLINE=91033045; PubMed=1688329;
RA Tsarfaty I., Hareuveni M., Horev J., Zaretsky J., Weiss M.,
RA Jeltsch J.M., Gendler S.J., Lathe R., Keydar I., Wreschener D.H.;
RT "Isolation and characterization of an expressed hypervariable gene
RT coding for a breast-cancer-associated antigen.";
RL Gene 93:313-318(1990).
RN 18
RP PARTIAL SEQUENCE FROM N.A.
RX MEDLINE=88330762; PubMed=3417635;
RA Gendler S.J., Taylor-Papadimitriou J., Duhig T., Rothbard J.,
RA Burchell J.;
RT "A highly immunogenic region of a human polymorphic epithelial mucin
RT expressed by carcinomas is made up of tandem repeats.";
RL J. Biol. Chem. 263:12820-12823(1988).
RN 19
RP SEQUENCE OF 1-169 FROM N.A.
RX MEDLINE=90088473; PubMed=2597151;
RA Abe M., Siddiqui J., Kufe D.;
RT "Sequence analysis of the 5' region of the human DF3 breast
RT carcinoma-associated antigen gene.";
RL Biochem. Biophys. Res. Commun. 165:644-649(1989).
RN 110
RP SEQUENCE OF 1-109 FROM N.A.
RX TISSUE=Thyroid;
RX MEDLINE=96183746; PubMed=8608966;
RA Weiss M., Baruch A., Keydar I., Wreschener D.H.;
RT "Preoperative diagnosis of thyroid papillary carcinoma by reverse
RT transcriptase polymerase chain reaction of the MCU1 gene.";

```







```

756 isglyValThrSerAlaProAspThrArgProAlaProGlySerThrAla 772
669 CCCCACCATGACCCGCG...TGCTGTACGAGCGCGCCAGCGAGTTC 623
773 Pro.....ProAlaHisGlyValThrSerAla.....ProAspThr 784
622 GCGTCGCTCTCCGAGACACAGCTGCTACATGATCACC...GGCT 579
784 ArgProAlaPro.....GlySerThrAlaProProAlaHisGly 798
578 CATCTTCCCGCGCCACGACACACCGGCTCTCTCTGGGCTTCTGTCG 529
798 alThrSerAlaProAspThrArgProAlaProGlySerThrAlaPro 814
528 CGAGAGTCCTGGCGCGCGCTCGCGGGGAGTCCGAGACGACCGCTC 479
715 AlaHisGlyValThrSerAla.....ProAspThrArgProAl 827
478 TCCCGGTCTGTGAGAGAGCGCTGCGGTACACCGCGGTCCTACAC 429
827 aProGlySer.....ThrAlaProProAlaHis 836
428 GTTGTGAGGTTCGCTCCACGAGAGTACATCGCGCGCTCGCGTGC 379
836 isglyValThrSerAlaProAspThrArgProAlaProGlySerThrAla 852
378 CCGCGGAGCGCGCGCTGCTGTGTGAGATCGAGGAGGACACACGCGC 329
853 Pro.....ProAlaHis 856
328 CGCCATCAGACGACCGCCGACGCTTCCACCGGACGCTCCCTCGTGC 279
856 sglyValThrSer.....AlaProAspThrArgProAlaPro...Glys 870
278 CGCGCTCACTTCGCGCGAGCGCGCTACT..... 247
870 erThrAlaProProAlaHisGlyValThrSerAlaProAspThrArgPro 886
246 GCATCGGGGAGAGCTCGCGCCAGCTGTGAGTGGCGACATGATCGGCTA 197
887 AlaProGlySerThrAlaPro.....ProAlaHis 896
196 CTGCGACGACAGTTCCTCCG.....AGCGCGACACTGCGCTCCCTAGA 153
896 sglyValThrSerAlaProAspThrArgProAlaProGlySerThrAlaPro 913
152 CGAGTTCGCGGTGTGCGGAGAGGGGCGCCAGACGCGCGCTCACCGAAC 103
913 roProAlaHisGlyValThrSerAlaProAspThrArgProAlaPro... 928
102 TGCCCGTCTGCTGCGGTGATCCGCGCGCGCGGACCGGACGCGCC 53
929 .....GlySerThrAlaProProAlaHisGlyValThrSerAlaPro 942
52 CACCGCGACCGCGCGGTGCGGCTCCGCGCG 19
942 CaspAsnArgProAlaLeuGlySerThrAlaPro 953

seq_name: SwissProt_40:CA11_MOUSE
seq_documentation_block:
ID CA11_MOUSE STANDARD; PRT; 1453 AA.
AC P11087; 060635;
DT 01-JUN-1989 (Rel. 11, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE Collagen alpha 1(I) chain precursor.
GN COL1A1 OR COLA1.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]

```

```

RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N.
RX MEDLINE=96033240; PubMed=8535610;
RA Li S.W., Khillan J., Prockop D.J.;
RT "The complete cDNA coding sequence for the mouse pro alpha 1(I) chain
of type I procollagen."
RL Matrix Biol. 14:593-595(1995).
RN [2]
RP SEQUENCE OF 518-1128 FROM N.A.
RX MEDLINE=86137403; PubMed=3841523;
RA French B.T., Lee W.-H., Maul G.G.;
RT "Nucleotide sequence of a cDNA clone for mouse pro alpha 1(I)
collagen protein."
RL Gene 39:311-312(1985).
RN [3]
RP SEQUENCE OF 735-1130 FROM N.A.
RX MEDLINE=83141374; PubMed=6298597;
RA Monson J.M., Friedman J., McCarthy B.J.;
RT "DNA sequence analysis of a mouse pro alpha 1 (I) procollagen gene:
evidence for a mouse B1 element within the gene."
RL Mol. Cell. Biol. 2:1362-1371(1982).
RN [4]
RP SEQUENCE OF 735-878 AND 1005-1058 FROM N.A.
RX MEDLINE=83157109; PubMed=6219867;
RA Monson J.M., McCarthy B.J.;
RT "Identification of a Balb/c mouse pro alpha 1(I) procollagen gene:
evidence for insertions or deletions in gene coding sequences."
RL DNA 1:59-69(1981).
RN [5]
RP SEQUENCE OF 1442-1453 FROM N.A.
RX MEDLINE=88124276; PubMed=3340560;
RA Mooslehner K., Harbers K.;
RT "Two mRNAs of mouse pro alpha 1(I) collagen gene differ in the size
of the 3'-untranslated region."
RL Nucleic Acids Res. 16:773-773(1988).
CC -1- FUNCTION: TYPE I COLLAGEN IS A MEMBER OF GROUP I COLLAGEN
(FIBRILLAR FORMING COLLAGEN).
CC -1- SUBUNIT: TRIMERS OF ONE ALPHA 2(I) AND TWO ALPHA 1(I) CHAINS.
CC -1- TISSUE SPECIFICITY: FORMS THE FIBRILS OF TENON, LIGAMENTS AND
BONES. IN BONES THE FIBRILS ARE MINERALIZED WITH CALCIUM
HYDROXYAPATITE.
CC -1- PTM: PROLINES AT THE THIRD POSITION OF THE TRIPEPTIDE REPEATING
UNIT (G-X-Y) ARE HYDROXYLATED IN SOME OR ALL OF THE CHAINS.
CC -1- SIMILARITY: CONTAINS 1 VWF-C DOMAIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: U08020; AAA88912.1; -
DR EMBL: X15896; CAA33904.1; -
DR EMBL: M14423; AAA37333.1; -
DR EMBL: M17491; AAA37334.1; -
DR EMBL: X06753; CAA29227.1; -
DR EMBL: K03029; AAA37332.1; -
DR EMBL: K03030; AAA37332.1; JOINED.
DR EMBL: K03031; AAA37332.1; JOINED.
DR EMBL: K03032; AAA37332.1; JOINED.
DR EMBL: K03033; AAA37332.1; JOINED.
DR EMBL: K03034; AAA37332.1; JOINED.
DR EMBL: K03035; AAA37332.1; JOINED.
DR PIR: A23982; A23982.
DR MGD: MGI:88467; Colla1.
DR InterPro: IPR000087; Collagen.
DR InterPro: IPR000885; Fib-collagen_C.
DR InterPro: IPR001007; VWF_C.
DR Pfam: PF01410; COLF1; 1.
DR Pfam: PF01391; Collagen; 18.

```

DR ProDom; PD002078; Fib.collagen\_C; 1.  
 DR SMART; SM00038; COLFI; 1.  
 DR SMART; SM00214; VMC; 1.  
 DR PROSITE; PS01208; VMEC; 1.  
 KW Extracellular matrix; Connective tissue; Repeat; Hydroxylation;  
 KW Glycoprotein; Collagen; Signal.  
 FT SIGNAL 1 22  
 FT PROPEP 23 151 AMINO-TERMINAL PROPEPTIDE.  
 FT CHAIN 152 1207 COLLAGEN ALPHA 1(I) CHAIN.  
 FT PROPEP 1208 1453 CARBOXYL-TERMINAL PROPEPTIDE.  
 FT DOMAIN 29 87 VMEC.  
 FT DOMAIN 152 167 NONHELICAL REGION (N-TERMINAL).  
 FT DOMAIN 168 1181 TRIPLE-HELICAL REGION.  
 FT DOMAIN 1182 1207 NONHELICAL REGION (C-TERMINAL).  
 FT CARBOHYD 56 56 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 1354 1354 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT SITE 734 736 CELL ATTACHMENT SITE (POTENTIAL).  
 FT SITE 1082 1084 CELL ATTACHMENT SITE (POTENTIAL).  
 FT CONFLICT 1450 1450 A -> V (IN REF. 5).  
 FT SEQUENCE 1453 AA; 137944 MW; 38802E535DF81808 CRC64;

Alignment scores:  
 Quality: 450.00 Length: 1143  
 Ratio: 0.947 Gaps: 62  
 Percent similarity: 41.557 Percent identity: 26.072

alignment block:  
 US-09-673-254-1/rev x CALL\_MOUSE ..

Align seg 1/1 to: CALL\_MOUSE from: 1 to: 1453

2780 CCAGT.....CAATACCTCCAGAGCTTCCTGTCGACGCG 2743  
 ||||| ..... ||||| ||||| .....  
 167 ProGlyProMetGlyProSerGlyProArgGlyLeuProGlyProProGly 183  
 2742 TGCTGCGGA.....GCGGCTGCGGCGCGCGCTGATC 2708  
 ||||| ..... ||||| .....  
 183 yAlaProGlyProGlnGlyPheGlnGlyProProGlyGluProGlyGluP 200  
 2707 CT.....CACCTGCTCCGACGCGGTACACCGAGGCGG..... 2676  
 ||||| ..... ||||| .....  
 200 roGlyGlySerGlyProMetGlyProArgGlyProProGlyProProGly 216  
 2675 .....GATGACCGCGGACGACACTCAACGCGG 2650  
 ||||| ..... ||||| .....  
 217 LysAsnGlyAspAspGlyGluAlaGlyLysProGlyArgProGlyGluAr 233  
 2649 A.....CCGTACCGCTACAGCGCGG.....CCAGCGTACGCGACG 2612  
 ||||| ..... ||||| .....  
 233 gGlyProProGlyProGlnGlyAlaArgGlyLeuProGlyThrAlaGlyL 250  
 611 TCCAACAGAGCCACATCATGACCGCGG.....GGAGGCGCG 2574  
 ||||| ..... ||||| .....  
 250 eu...ProGlyMetLysGlyHisArgGlyPheSerGlyLeuAspGlyAla 265  
 2573 CAGGCGCTGCGCGGACGCTGCG..... 2550  
 ||||| ..... ||||| .....  
 266 LysGlyAspAlaGlyProAlaGlyProLysGlyGluProGlySerProGly 282  
 2549 .....GGTCACTATCACCC..... 2535  
 ||||| ..... ||||| .....  
 282 yGluAsnGlyAlaProGlyGlnMetGlyProArgGlyLeuProGlyGluA 299  
 2534 .....CGGTAGTCCGACCGCATCGAGGCGGACGCGTGC..... 2497  
 ||||| ..... ||||| .....  
 299 rgGlyArgProGlyPro...ProGlyThrAlaGlyAlaArgGlyAsnAspG 315  
 2496 .....CCTGCTCTACTCTCGGCTCAACCCCT 2470  
 ||||| ..... ||||| .....  
 315 yAlaValAlaGlyAlaAlaGlyProProGlyProThrGlyProThrGlyPro 331  
 2469 TCCTGCTCCGCGGCGGAAGGCGCGACACCCCTGCTGTGCTGCGCTGC 2420

||||| ..... ||||| .....  
 332 .ProGlyPhe.....ProGlyAlaValAlaGlyAlaL 341  
 2419 GCGCGCGCGCGAGAGTTCACCGAGGCGGCTTACTACAGGACCGCGCGT 2370  
 ||||| ..... ||||| .....  
 341 yGlyGluAlaGlyProGlnGlyAlaArgGlySerGlyLeuProGlnGly 357  
 2369 GTCCCGGAGTACCGCGCGCGAGCGCGGCGGCTCGCGGGAAGCTCT 2320  
 ||||| ..... ||||| .....  
 358 ValArgGlyGlu...ProGlyProProGlyProAlaGly..... 369  
 2319 GGGAGCGCGCGCGCGCGCGGCTCGCGGACCGCGGACTGACGCG..... 2275  
 ||||| ..... ||||| .....  
 370 .....AlaAlaGlyProAlaGlyAsnProGlyAlaAspGlyGluAr 383  
 2274 .GGCGCGCGCGCGCGCGCGCATGCTGCTCATCCGCGGAGATGCTGCT 2226  
 ||||| ..... ||||| .....  
 383 oGlyAlaLysGlyAlaAsnGlyAlaProGlyLleAlaGlyAlaProGly 399  
 2225 CATCCGCGAGCGGACGAGCTCTGTCGATCATCAAGGAAGCATTC 2176  
 ||||| ..... ||||| .....  
 400 PheProGlyAlaArg..... 404  
 2175 GTACACGAGTTCGCGCGCGCGCGCGCATGTCGACCTGCTGCGC 2126  
 ||||| ..... ||||| .....  
 405 .....GlyProSerGlyProGlnGly.....P 412  
 2125 CGATGTCGCGCGCTCGCGCG.....ACTTTCACACCGGCGCTGTCG 2085  
 ||||| ..... ||||| .....  
 412 roSerGlyProProGlyProLysGlyAsnSerGlyGluProGlyAlaPro 428  
 2084 GCTGACCGCGCACCGTGTGACGACCGCGCGCGGCGGAGATACAGACG 2035  
 ||||| ..... ||||| .....  
 429 GlyAsnLysGlyAspThrGlyAlaLysGlyGluProGlyAlaThrGlyAla 445  
 2034 TTCACCTCCGACGGA..... 2019  
 ||||| ..... ||||| .....  
 445 lGlnGlyProProGlyProAlaGlyGluGlnGlyLysArgGlyAlaArgG 462  
 2018 .....AGCTGTCGCGCGGTCGCGCGCGCGCGCACGATCGACA 1983  
 ||||| ..... ||||| .....  
 462 lYgluProGlyProSerGlyLeuProGlyProProGlyGluArGlyGly 478  
 1982 CCCCTTACC.....ACCGCGCTACGCGG 1960  
 ||||| ..... ||||| .....  
 479 ProGlySerArgGlyPheProGlyAlaAspGlyValAlaGlyProLysG 495  
 1959 CCGGGAACGACGACGACGCGCATCGCGCGCATCTGAGCGGTACTTGC 1910  
 ||||| ..... ||||| .....  
 495 yProSerGlyLysArgGlyAlaProGlyProAlaGlyProLysGlySerP 512  
 1909 CAGCGACGCGCGGACGACGACGACGAGGCGGTGCGAGAGCG..... 1868  
 ||||| ..... ||||| .....  
 512 ro.GlyGluAlaGlyArgProGlyGluAlaGlyLeuProGlyAlaLysG 528  
 1867 .....GGCGCGC 1861  
 ||||| ..... ||||| .....  
 528 yLeuThrGlySerProGlySerProGlyProAspGlyLysThrGlyProp 545  
 1860 GAGGTATCATGATCTCGATGAGCTCTCGGCTCGG..... 1823  
 ||||| ..... ||||| .....  
 545 roGlyProAlaGlyGlnAspGlyArgProGlyProAlaGlyProProGly 561  
 1822 .....CCGATGCGCGCT 1809  
 ||||| ..... ||||| .....  
 562 AlaArgGlyGlnAlaGlyAlaMetGlyPheProGlyProLysGlyThrAl 578  
 1808 TCGCCAGCCCGCGCGGCGCGGCTCGCGGCTGCTG.....GCCAAGGGA 1765  
 ||||| ..... ||||| .....  
 578 aGlyGluProGlyLysAlaGlyGluArgGlyLeuProGlyProProGlyAla 595  
 1764 GTCATGAGAGGCGCGGAGGTACGCGGCTGCCGCGCTC..... 1727  
 ||||| ..... ||||| .....

[illegible][illegible]

```

197 ACTGCGCAGCAGGTTCCCGAGCCGAC.....TGGCCGTCG 160
    ::|||
1135 .....SerIaGlySerProGlyLysAspGlyLeuSnGlyLeuPro... 1148
159 CGTACGACGAGTTGCGGTGTGCGCGA...AGGGGCCAGACGCGCG 113
1149 .....GlyProIleGlyProProGlyProArgIlyrGly 1160
112 CTCACGACAGTCGCGCTGCGCGCGCTAGTCGCGCGCGACGCGG 64
    ::|||
1160 rGlyAspSerGlyProIaGlyProProGlyProProGlyProProGly 1177
63 ..ACGGAGCCGCCACC 49
    |||
1177 rOProGlyProProser 1182

seq_name: SwissProt_40:CA13_MOUSE
seq_documentation_block:
CA13_MOUSE STANDARD; PRT; 1464 AA.
P08121; 061429; O9CRN7;
01-AUG-1988 (Rel. 08, Created)
15-JUL-1999 (Rel. 38, Last sequence update)
16-OCT-2001 (Rel. 40, Last annotation update)
Collagen alpha 1(III) chain precursor.
DE COL3A1.
GN
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
'11'
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL X DBA; TISSUE=Embryo;
RX MEDLINE=95011609; PubMed=7926795;
RA Toman D., de Crombrughe B.,
RT "The mouse type-III procollagen-encoding gene: genomic cloning and
RL complete DNA sequence."
RN Gene 147:161-168(1994).
[12]
RP SEQUENCE OF 1-488 FROM N.A.
RX MEDLINE=88167858; PubMed=3443309;
RA Wood L., Theriault N., Vogeli G.;
RT "Complete nucleotide sequence of the N-terminal domains of the murine
RL alpha-1 type-III collagen chain."
RN Gene 61:225-230(1987).
[13]
RP SEQUENCE OF 1-28 FROM N.A.
RX MEDLINE=85131189; PubMed=3972847;
RA Liu G., Mudryj M., de Crombrughe B.;
RT "Identification of the promoter and first exon of the mouse alpha 1
RT (III) collagen gene."
RN J. Biol. Chem. 260:3773-3777(1985).
[14]
SEQUENCE OF 810-1464 FROM N.A.
STRAIN=C57BL/6J; TISSUE=Embryonic head;
MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shnagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Aikawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Iwawa M., Nishi K., Kiyosawa H., Kondo S., Yamanka I.,
RA Saito T., Okazaki Y., Gojouri T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochava H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Peesle G., Quackenbush J.,
RA Schirral L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Futuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boilelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher R., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamita M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyoka K., Wang K.H., Weltz C., Whitaker C., Wilming L.,
RA Wyshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohlsuki S.,

```

```

RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
RN [5]
RP SEQUENCE OF 1442-1464 FROM N.A.
RC STRAIN=C57BL;
RX MEDLINE=91274355; PubMed=2054384;
RA Metsaeranta M., Toman D., de Crombrughe B., Vuorio E.;
RT "Specific hybridization probes for mouse type I, II, III and IX
RT collagen mRNAs."
RL Biochim. Biophys. Acta 1089:241-243(1991).
CC -1- FUNCTION: COLLAGEN TYPE III OCCURS IN MOST SOFT CONNECTIVE TISSUES
CC ALONG WITH TYPE I COLLAGEN.
CC -1- SUBUNIT: TRIMERS OF IDENTICAL ALPHA 1(III) CHAINS. THE CHAINS ARE
CC LINKED TO EACH OTHER BY INTERCHAIN DISULFIDE BONDS. TRIMERS ARE
CC ALSO CROSS-LINKED VIA HYDROXYLYSINES.
CC -1- PTM: PROLINES AT THE THIRD POSITION OF THE TRIPEPTIDE REPEATING
CC UNIT (G-X-Y) ARE HYDROXYLATED IN SOME OR ALL OF THE CHAINS.
CC O-LINKED GLYCAN CONSISTS OF GLC-GAL DISACCHARIDE (BY SIMILARITY).
CC -1- SIMILARITY: CONTAINS 1 WFMC DOMAIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation-
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X52046; CA36279.1; -.
DR EMBL; M18933; AAA3738.1; -.
DR EMBL; K03037; -. NOT ANNOTATED CDS.
DR EMBL; AK019448; BAB31724.1; -.
DR EMBL; X57983; CAA41048.1; -.
DR PIR; A22287; A22287.
DR PIR; A27353; A27353.
DR PIR; S16373; S16373.
DR MCD; MGI:88453; Col3a1.
DR InterPro; IPR000087; Fib.collagen_C.
DR InterPro; IPR001007; WFMC.
DR Pfam; PF01410; COLF1; 1.
DR Pfam; PF01391; Collagen; 17.
DR ProDom; PD002078; Fib.collagen_C; 1.
DR SMART; SM00038; COLF1; 1.
DR SMART; SM00214; WMC; 1.
DR PROSITE; PS01208; WFMC; 1.
KW Extracellular matrix; Connective tissue; Repeat; Hydroxylation;
KW Glycoprotein; Collagen; Signal.
FT SIGNAL 1 23
FT PROPEP 24 154
FT CHAIN 155 1203
FT PROPEP 1204 1464
FT DOMAIN 31 90
FT DOMAIN 155 169
FT DOMAIN 170 1195
FT DOMAIN 1196 1464
FT CARBOHD 262 262
FT MOD_RES 262 262
FT MOD_RES 283 283
FT MOD_RES 859 859
FT MOD_RES 976 976
FT MOD_RES 1093 1093
FT MOD_RES 1105 1105
FT DISULFD 1195 1195
FT DISULFD 1196 1196
FT SEQUENCE 1464 AA; 138944 MW; 2104EC27A886090B CRC64;
alignment_scores:
Quality: 450.00 Length: 1187
Ratio: 0.911 Gaps: 77
Percent Similarity: 41.618 Percent Identity: 27.043

```



```
1401 TCGGTGTGTAACTCGGGGAGGGGTACCCCGCGGGCGGGCGGTGCTC 1352
      :          ||||| |||          :|||:||||
681 u.....ArgGlyProProGlyThrAlaGlyIleProG 692
1351 GTGAGGCGGAGGCGCC.....CCGGGTGGCCCTCCAGCC 1317
      ||| ||||| ||| ||||| ||| ||||| |||
692 LysAlaArgGlyGlyAlaGlyProProGlyProGlyLysGlyPro 708
1316 GTTCGGGTGTCCCATGATGACATCGACGAGCGCAAGCCGAGTGCAGACG 1267
      :||| :||| :||| :||| :||| :||| :||| :|||
709 AlaGlyProProGlyProProGlyAlaSerGlySerProGlyLeuGlnG 725
1266 CCTTCGGGGA.....GGCGGGCCCGGTCTGAGGTGAAGCCCGCGCG 1223
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
725 yMetProGlyGlyLysArgGlyProGlySerProGly.....ProLysG 740
1222 GGGGAGCCCGCGCTGGGTCAACCATGACGCGCTCGCCCGCGAGGTGCT 1173
      |||:| :|||:| :|||:| :|||:| :|||:| :|||:| :|||:|
740 LysLys.....LysGlyLysProGlyGlyAla 748
1172 GGGCGATCC.....CCGGTTCGTGAAGACCCGA..... 1143
      ||| :||| :||| :|||:||||| ||| :|||:|||||
749 GlyAlaAspGlyAlaProGlyLysAspGlyProArgGlyProAlaGlyPr 765
1142 .....CTCGCCCGCGCGCTGGCGGG.....GTG 1115
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
765 oLleGlyProProGlyProAlaGlyLysProGlyAspLysGlyLys 782
1114 GACGAGGCT.....CGACATCCCGTCCGAGAGTGGGTCC 1077
      || :||| :||| :|||:||||| ||| :|||:|||||
782 LysSerProGlyLeuProGlyIleAlaGlyProArgGlyLysGlyProGly 797
1076 GTTCACGCTCATCGCCGTGACGGCGAGCGCCAGCGCGCTCGCGCGGA 1027
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
798 .....GlyArgGlyGlyHisGlyProProGlyProAlaGlyPh 810
1026 TCCAGCGACACTGCTCAA..... 1008
      ||| :||| :||| :||| :||| :||| :||| :|||
810 eProGlyAlaProGlyGlnAsnGlyLysProGlyAlaLysGlyLysArg 827
1007 .....CCGCGCGCGGTGGCGGA 990
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
827 LysAlaProGlyLysGlyLysGlyLysGlyLysProProGlyProAlaGlyPro 843
989 GCGGACGATCGCATCGCGCGATCGCGCGCTGCTCAACGACATCG 940
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
844 ThrGlySerSer.....GlyProAlaGly..... 851
939 CGGAGCGCTCCGCGCGGTGGGCAAAACCGCGAGCTGATCGCGGCTTC 890
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
852 .....ProProGlyProGlnGlyLysGlyLysArg.... 862
889 GCGTACACTCCCGCTGTGTCACTGACAGCTGCTGGTGGCGGT 840
      :||| :||| :||| :||| :||| :||| :||| :|||
863 .....GlySerProGlyGlyProGlyThrAlaGlyPheProGly 875
839 CACCGATCCGGGATGCCCGGAGCGCGTCAAGCTTCAAGGCACTCG 790
      |||:||||| :|||:||||| :|||:||||| :|||:|||||
876 GlyArgGlyLeuProGlyProProGlyAsnAsnGlyAsnProGly.... 890
769 GCGTGGGGGGCGGAGAGCGGGGGGTGACGACGACGACCTGGCGGG 740
      ||| ||||| ||||| ||||| ||||| ||||| |||||
891 ..ProProGlyProSerGlyAlaProGly...LysAspGlyPro...ProG 905
739 GCGGTGCGGACACTCGGC...CCTGAGAGCTT.....GCTGCT 702
      ||| ||||| :||| :|||:||||| :|||:||||| :|||:|||||
905 LysProAlaGlyLysSerGlySerProGlyAsnProGlyIleAlaGlyPro 921
701 CGAAGCCGTGACTACGCCGCGGAGACGACACCCCGA..... 664
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
922 LysGlyAspAlaGlyLysProGlyLysGlyProProGlyAlaGlnG 938
663 .....CGATGACCC.....GCGTGTGTACGAGCGCG 636
```

```
938 yProProGlySerProGlyProLeuGlyIleAlaGlyLeuThrGlyAla 955
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
635 GCAGGCCGAGTGGCTCGGTCCGACGACGACGCTGCTACATGATCA 586
      || :||| :||| :||| :||| :||| :||| :|||
955 ry.....GlyLeuAlaGlyProProGlyLysProGlyProArgGlySer 969
585 CCGGCG.....TCATCTTCGCGCGGCGACGA... 559
      ||||| :|||:||||| :|||:||||| :|||:|||||
970 ProGlyProGlnGlyLysGlyLysSerGlyLysProGlyAlaSerG 986
558 .....CCACCGGCTCTCTCTGAGCTTCCTGCTGCTCGC 528
      |||||:||||| :|||:||||| :|||:||||| :|||:|||||
986 LysAsnGlyLysArgGlyProProGlyProGln..GlyLeuProGlyLys 1002
527 GAGGTCTCGCGCGCGCT...CGCGCGGTGCGGACGAGGACCGCG 481
      ||| :||| :||| ||| ||| ||| ||| ||| ||| |||
1003 ProGlyThrAlaGlyLysProGlyArgAspGlyAsnProGlySerAsp 1019
480 TCTCCGGTTCGTGAGAGGCGCTGCGCTACCAACCGCGCGTCCCTAC 431
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1019 yGlnProGlyArgAspGlySer.....ProGlyGlyLys.... 1030
430 ACGTTGTGAGGTTCGCTGCACGAGGTGACCATCGCGCGCTCCGCT 381
      ||||| :||| :||| :||| :||| :||| :||| :|||
1031 .....GlyAsp...ArgGlyLysAsnGly 1037
380 GCGCCCGGAGCGCGCTGCTGTGACAT..... 351
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
1038 SerProGlyAlaProGlyAlaProGlyHisProGlyProProGlyProVa 1054
350 .....CGAGGCGACCAACCGAGCGCGCG 326
1054 LysProSerGlyLysSerGlyAspArgGlyLysThrGlyProAlaGlyPr 1071
325 CATCACGACGCGCC.....GCAAGCCTTCACCGCGAGCTGTC. 289
      ||||| ||| ||||| ||||| ||||| ||||| |||||
1071 roSerGlyAlaProGlyProAlaGlyAlaArgGlyAlaProGlyProGln 1087
288 ...CCTGTTGGGCGC..... 277
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
1088 GlyProArgGlyAspLysGlyLysThrGlyLysArgGlySerAsnGlyI 1104
276 .....GGCTCACTT 267
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
1104 eLysGlyHisArgGlyPheProGlyLysnProGlyProProGlySerProG 1121
266 CGCGGAGCGCGCGCACTACTGATCGGGAGGACGACCTGCGCACTGAGCT 217
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
1121 LysAlaAlaGlyHisGlnGlyAlaIleGlySerProGlyProAlaGlyPro 1137
216 CGCGACGATGATCGGCGCTAC.....TGCGAGCGAG 185
      ||||| :||| :||| :||| :||| :||| :||| :|||
1138 ArgGlyProValGlyProHisGlyProProGlyLysAspGlyThrSerG 1154
184 TTCGCCGAGGCCGACGTGCGCGGTACGACGAGTTGCGTGTGCGCG 135
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1154 LysHisProGlyProIleGlyPro..... 1161
134 GAAGGGGCGCCAGA.....CGCGCGGCTCAACGACCTGCGCG 97
      ||||| ||||| :|||:||||| :|||:||||| :|||:|||||
1162 ..ProGlyProArgGlyLysnArgGlyLysArgGlySerLysSerPro 1177
96 TCT.....GGCTGCGCTGATCCGCGCGCGGACGCGGACGAGCGCG 53
      :|||:||||| :|||:||||| :|||:||||| :|||:|||||
1178 GlyHisProGlyGlnProGlyProPro.....GlyProPr 1189
52 CACCGCGACCGCGCGGTGGGCGGTCCGTGCGGTACCGCGGTGCGGA 4
      ||||| ||||| :|||:||||| :|||:||||| :|||:|||||
1189 o.....GlyAlaProGlyProCys.....CysGly 1197
```







OM of: US-09-673-254-1 to: SPTREMBL\_19:\* out\_format: pfs

Date: Jun 11, 2002 8:19 PM

About: Results were produced by the GenCore software, version 4.5,  
Copyright (c) 1993-2000 Compugen Ltd.

#### Command line parameters:

```
-MODEL=framed+n2p.model -DEV=xlh  
-O=/cgml2/USPTO.spool/US09673254/rnatc_11062002.114213.1012/app_query.fasta_1.2973  
-DB=SPTREMBL_19 -OFMT=fasta -SUFFIX=n2p.rspt -GAPOP=12.000  
-GAPEXT=4.000 -MINMATCH=0.100 -LOOPEL=0.000 -LOOPEXT=0.000  
-OGAPOP=4.500 -OGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500  
-FGAPOP=6.000 -FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500  
-OGOP=6.000 -DELEXT=7.000 -START=1 -MATRIX=blonsum62  
-US-human40.cdi -LIST=45 -DOCCALIGN=200 -THR_SCORE=Pct  
-MAX=100 -THR_MIN=0 -ALIGN=7 -MODE=LOCAL -OUTFMT=pfs  
-M-ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000  
-USFR=US09673254.ecgml_1.360 -NCPU=6 -ICPU=3 -LONGLOG  
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -NO_XLPEX -WAIT -THREADS=1
```

#### Search information block:

```
Query: US-09-673-254-1  
Query length: 2870  
Database: SPTREMBL_19:*  
Database sequences: 562222  
Database length: 172994929  
Search time (sec): 134.250000
```

#### score\_list:

Sequence	Strd Orig	ZScore	EScore	Len	Documentation
SP_bacteria:Q9ZAU3	- 2171.00	1722.23	3.3e-88	415	09ZAU3 streptomyces penicellus.
SP_bacteria:Q59971	- 2087.00	1655.77	1.6e-84	422	059971 streptomyces sp. cytocht
SP_bacteria:Q93M12	- 2062.00	1636.07	2.0e-83	420	093M12 streptomyces penicellus
SP_bacteria:Q9ZAU2	- 1465.00	1168.27	3.6e-57	275	09ZAU2 streptomyces penicellus
SP_bacteria:Q55078	- 1385.00	1105.11	1.2e-53	275	055078 streptomyces sp. orfa pt
SP_bacteria:Q9ZAU1	- 1014.00	811.84	2.4e-37	287	09ZAU1 streptomyces penicellus
SP_bacteria:Q53877	- 980.00	785.00	7.6e-36	287	053877 streptomyces sp. c5. ket
SP_bacteria:Q55077	- 975.00	784.27	1.2e-35	195	055077 streptomyces sp. daunom
SP_virus:Q99307	- 538.00	426.28	2.3e-16	924	099307 epstein-barr virus (stra
SP_vertebrate:Q9Y1B4	- 506.00	397.25	6.0e-15	1450	09Y1B4 cynops pyrrhogaster (ja
SP_virus:Q905K9	- 486.50	389.11	4.0e-14	608	0905K9 herpesvirus papio. ntr.
SP_human:Q60382	- 486.50	380.09	4.4e-14	1791	060382 homo sapiens (human). x
SP_human:Q60385	- 484.50	374.93	5.5e-14	2752	090385 homo sapiens (human). x
SP_human:Q15038	- 484.00	378.16	5.6e-14	1783	015038 homo sapiens (human). x
SP_human:Q15038	- 479.00	374.21	9.3e-14	1783	015038 homo sapiens (human). x
SP_human:Q90Q35	- 479.00	374.17	9.3e-14	1791	060382 homo sapiens (human). x
SP_human:Q90Q35	- 479.00	370.59	1.0e-13	2296	090385 homo sapiens (human). x
SP_human:Q90Q35	- 478.00	371.31	1.0e-13	2296	090385 homo sapiens (human). x
SP_vertebrate:Q93251	- 476.50	373.99	1.2e-13	1445	093251 rana catesbeiana (bull)
SP_invertebrate:Q9VPG1	- 475.50	369.38	1.4e-13	2284	09VPG1 drosophila melanogast
SP_human:Q90Q36	- 473.00	372.27	1.7e-13	1275	090Q36 homo sapiens (human). x
SP_bacteria:Q9K9K7	- 472.50	385.05	1.6e-13	263	09K9K7 streptomyces coelicolor
SP_virus:Q41971	- 470.00	374.07	2.2e-13	774	041971 murid herpesvirus 4. hyf
SP_human:Q90Q39	- 468.00	370.73	2.7e-13	956	090Q39 homo sapiens (human). x
SP_bacteria:Q9F200	- 467.00	376.55	2.8e-13	433	09F200 streptomyces coelicolor
SP_virus:Q41971	- 460.50	366.57	2.8e-13	774	041971 murid herpesvirus 4. hyf
SP_human:Q90Q40	- 459.00	361.30	6.9e-13	1262	090Q40 homo sapiens (human). x
SP_vertebrate:Q91B91	- 458.50	359.77	7.3e-13	1447	091B91 xenopus laevis (afrikan
SP_human:Q76045	- 458.00	359.29	7.7e-13	1461	076045 homo sapiens (human). x
SP_vertebrate:Q905K9	- 454.50	356.58	1.1e-12	1453	060379 rattus norvegicus (rat)
SP_invertebrate:Q91365	- 454.00	352.60	1.2e-12	2232	091365 caenorhabditis elegat
SP_human:Q90Q39	- 452.00	351.18	1.4e-12	2296	090Q39 homo sapiens (human). x
SP_virus:Q90Q39	- 452.00	350.09	1.4e-12	956	090Q39 homo sapiens (human). x
SP_virus:Q41972	- 451.50	360.23	1.4e-12	706	041972 murid herpesvirus 4. hyf
SP_virus:Q41973	- 451.00	359.59	1.5e-12	727	041973 murid herpesvirus 4. hyf
SP_human:Q90Q40	- 450.50	354.59	1.6e-12	1262	090Q40 homo sapiens (human). x
SP_human:Q90Q36	- 449.00	353.32	1.9e-12	1275	090Q36 homo sapiens (human). x
SP_virus:Q90307	- 448.50	355.62	2.0e-12	924	090307 epstein-barr virus (stre
SP_bacteria:Q905K9	- 444.50	357.40	2.8e-12	511	052569 amycolatopsis mediterr
SP_virus:Q905K9	- 443.50	359.16	3.1e-12	608	0905K9 herpesvirus papio. ntr.

```
SP_virus:Q41972 + 437.50 349.18 5.8e-12 706 041972 murid herpesvirus 4.  
SP_vertebrate:Q90YJ0 - 436.00 342.57 7.1e-12 1352 090YJ0 brachydanio rerio (z  
SP_virus:Q69340 - 434.50 338.30 8.5e-12 1958 069340 pseudorabies virus.  
SP_human:Q9UF83 - 430.50 345.29 1.2e-11 580 09UF83 homo sapiens (human).  
SP_invertebrate:Q9VE45 - 430.00 340.78 1.3e-11 950 09VE45 drosophila melanoga
```

seq\_name: SP\_bacteria:Q9ZAU3

#### seq\_documentation\_block:

```
ID 09ZAU3 PRELIMINARY; PRT; 415 AA.  
AC 09ZAU3:  
DT 01-MAY-1999 (TREMBLrel. 10, Created)  
DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)  
DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)  
DE CYTOCHROME P450 129A2 (DAUNORUBICIN C-14 HYDROXYLASE).  
GN CYP129A2 OR DOXA.  
OS Streptomyces penicellus.  
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
OC Actinomycetales; Streptomycinae; Streptomycetaceae; Streptomyces.  
OX NCBI_TaxID=1950;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=ATCC 29050;  
RX MEDLINE=99084971; PubMed=9864344;  
RA Lomonoskaya N., Otten S.L., Doi-Katayama Y., Feinstein L., Liu X.-C.,  
RA Takatsu T., Inventi A., Filippi S., Torti F., Colombo A.L.,  
RA Hutchinson C.R.;  
RT "Doxorubicin overproduction in Streptomyces penicellus: cloning and  
RT characterization of the dnru ketoreductase and dnrv genes and the doxa  
RT cytochrome P-450 hydroxylase gene."  
RL J. Bacteriol. 181:305-318(1999).  
CC -1- SIMILARITY: BELONGS TO THE CYTOCHROME P450 FAMILY.  
DR EMBL: U77891; AAD04715.1;  
DR HSSP: 000441; IOXA.  
DR InterPro: IPR001128; Cyt_P450.  
DR Pfam: PF00067; P450. 2.  
DR PRINTS: PR00385; P450.  
DR PROSITE: PS00086; CYTOCHROME_P450; UNKNOWN_1.  
KW Heme; Monooxygenase; Oxidoreductase.  
SQ SEQUENCE 415 AA; 45095 MW; CCF873824BEB6CCF CMC64;
```

#### alignment\_scores:

```
Quality: 2171.00 Length: 415  
Ratio: 5.231 Gaps: 0  
Percent Similarity: 100.000 Percent Identity: 99.759
```

#### alignment\_block:

US-09-673-254-1/rev x Q9ZAU3 ..

Align seg 1/1 to: Q9ZAU3 from: 1 to: 415

```
1330 GTGGCGGTGACCGCTTCGCGTCCATGATACCATGACGCGCAAGC 1281  
:::|||||  
1 MetAlaValAspProPheAlaCysProMetMetThMetInArgLysP 17  
1280 CGAGGTGACGACGACCTCCGAGGAGGCGCGCGTGCAGAGTGAAG 1231  
|||||  
17 OGtUaIHsAsPaLApheArgGtUaAGlYpRoVaIaIGtUaAsn 34  
1230 CCCCCGCGGCGGACCGCGCTGGTCATCAGCATGACGCGCTCGCCGC 1181  
|||||  
34 LpRoLaAGlYgLYpRoLaTrpValIleThrasPaLaLeuAlaArg 50  
1180 GAGGTCTGCGCGATCCCGGTTCGAAAGACCGGACCTGCCCCCGC 1131  
|||||  
51 GlUaIHsAsPaLApheArgGtUaAGlYpRoVaIaIGtUaAsn 67  
1130 CGCGTGGCGGCGGAGTGCAGAGCGTCTCGACATCCCGTTCGAGCTCG 1081  
|||||  
67 aLaTrpPaLpGtYpAlaAsPaSpGtYpLeuAspIlePpRoVaIaIGtUa 84  
1080 GTCCGTTCAAGCTCATCGCGGTGAGCGGAGCGCCACGCGCGCTGCGC 1031
```

```

|||||
84 rgProPheThrLeuIleAlaValAspGlyAlaAlaHisArgArgLeuArg 100
1030 CGCATCCACGACCTGCGTTCACCCGCGCGCGCGCGAGACGAGCA 981
|||||
101 ArgIleHisAlaProAlaPheAsnProArgArgLeuAlaGluArgThrAs 117
980 TCGCATCGCGCGGATCGCGCGCGCGTGTCTACCGCAACTCGCGGACGCT 931
|||||
117 PArgIleAlaAlaIleAlaGlyArgLeuLeuThrIleAlaAlaAspAla 134
930 CGGCGCGGTCGGGCAAAACCGCGGAGCTGATCGCGCGCTTCGCTACAC 881
|||||
134 erGlyArgSerGlyLysProAlaGluLeuIleGlyGlyPheAlaArgHis 150
880 TTCGCGGCTGTCATCGTCGAGCTGCTCGGTCGCGGTCGCGCTACCGCAT 831
|||||
151 PheProLeuIleValIleCysGluLeuLeuGlyValProValThrAspPr 167
830 GCGGATGGCCCGGAGCGCGTCAAGCGTTCAGGCACTCGGCTCGGCG 781
|||||
167 CalMetAlaArgGluAlaValSerValLeuLysAlaLeuGlyLeuGlyG 184
780 GCCGCGACAGCGCGGGGTGACGCGACGAGCCCTGCGCGGGGCGCTGCCG 731
|||||
184 LyrProGlnSerGlyGlyAspGlyThrAspProAlaGlyValPro 200
730 GACACCTCGCGCTGAGAGCTGCTGCTCGCAAGCGCTGACATCGAGCCG 681
|||||
201 AspThrSerAlaLeuGlnSerLeuLeuGlnAlaValHisSerAlaArg 217
680 GCGGAGACGACCCCGACCATGACCCGCGTGTGTAGACGAGCGCGCAG 631
|||||
217 gArgAsnAspThrProThrMetThrArgValLeuArgValAlaGlnA 234
630 CCGAATTCGGCTCGCTCCGACGACGAGCTGCTACATGATCACCGGG 581
|||||
234 IagLuphediLyservalSerAspAspGlnLeuValTyrMetIleThrGly 250
580 CTGATCTTCGCGCGGCGACGACACCGGCTCTTCCTGGGCTCTGCT 531
|||||
251 LeuIlePheAlaGlyHisAspThrThrGlySerPheLeuGlyPheLeu 267
530 CGCGGAGCTCTCGCGCGCGCTCGCGGAGATGCCAGACGAGACCGCG 481
|||||
267 uAlaGluValIleuAlaGlyArgLeuAlaAlaAspAlaAspAlaVal 284
480 TCTCCGGTGTGGAGGAGCGCTGCGCTACACCGCGCGGCTGCCCTAC 431
|||||
284 alSerArgPheValGluGluAlaLeuArgTyrHisProProValProTyr 300
430 ACGTTGTGAGAGTTCGCTGCCACGAGGAGTACCATCGCGCGCTCGGCT 381
|||||
801 ThrLeuThrPargPheAlaIleThrGluValThrIleGlyGlyValArg 317
380 GCCCGCGGAGCGCGGCTCTGTGGACATCGAGGCGACCAACACCGAGC 331
|||||
317 uProArgGlyAlaProValLeuValAspIleGluGlyThrAsnThrAspG 334
330 GCGGCGATACGAGCGCGCGCGCTTCACCGGACCGCTCCCTCGTGG 281
|||||
334 LyrArgHisHisAspAlaProHisAlaPheHisProAspArgProSerTrp 350
280 CGGCGGCTACCTTCGCGGAGCGCGCGCTACTGATCGAGGAGAGAGCT 231
|||||
351 ArgArgLeuThrPheGlyAspGlyProHisTyrCysIleGlyGluGln 367
230 CGCCGAGCTGAGTCGCGACGATATGCGGCTACTGCGACGAGAGTTC 181
|||||
367 uAlaGlnLeuGlnSerArgThrMetIleGlyValLeuArgSerArgPhe 384
180 CGGAGCGCGACTGGCGCGCTGACGAGAGTTCGCGTGGTGGCGGAG 131
|||||

```

```

384 roGluAlaArgLeuAlaValProTyrAspGluLeuArgTrpCysArgLys 400
130 GGGGCGGACGCGCGGCTGCGACGAGCTCGGCTGCGTGGCTCGC 86
401 GlyAlaGlnThrAlaArgLeuThrGluLeuProValTrrPleuArg 415
seq_name: sp.Bacteria:Q59971

```

```

seq_documentation_block:
ID Q59971 PRELIMINARY: PRT: 422 AA.
AC Q59971;
DT 01-NOV-1996 (TREMBLrel. 01, Created)
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
DE 01-JUN-2001 (TREMBLrel. 17, Last annotation update)
DE CYTOCHROME P450 129A1 (DAUNOMYCIN C-14 HYDROXYLASE).
GN CYP129A1 OR DOXA.
OS Streptomyces sp.
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
OC Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.
OX NCBI_TaxID=1931;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CS;
RX MEDLINE=96236066; PubMed=8655529;
RA Dickens M.L., Strohl W.R.;
RT "Cloning, sequencing, and analysis of aklaviketone reductase from
RT Streptomyces sp. strain C5.";
RL J. Bacteriol. 178:3384-3388(1996).
CC -1- SIMILARITY: BELONGS TO THE CYTOCHROME P450 FAMILY.
DR EMBL: U50973; AMB08049.1; -.
DR HSSP: Q00441; IOXA.
DR InterPro: IPR001128; Cyt_P450.
DR Pfam: PF00067; P450; 2.
DR PROSITE: PS00086; CYTOCHROME P450; UNKNOWN_1.
KW Electron transport; Heme; Membrane; Monooxygenase; Oxidoreductase.
FT BINDING 369 369 HEME (BY SIMILARITY).
SQ SEQUENCE 422 AA; 46096 MW; F4EADCAID139052 CRC64;

```

```

alignment_scores:
Quality: 2087.00 Length: 422
Ratio: 5.041 Gaps: 0
Percent Similarity: 98.104 Percent Identity: 94.550
alignment_block:
US-09-673-254-1/rev x Q59971 ..

```

Align seg 1/1 to: Q59971 from: 1 to: 422

```

1351 GTGAGCGGCGAGGCGCGCGGCTGCGACCGGCTTCGCTGCCAT 1302
:::|||||
1 MetSerGlyGluAlaProArgValAlaValAspProPheSerCysPro 17
1301 GATGACCATGCGAGCGCGGAGCTGCGAGCGCTTCGCGGAGCGG 1252
|||||
17 TwetThrMetGlnArgLysProGluValHisAspAlaPheArgGluAlaG 34
1251 GCCCGGCTCTCGAGGTGAAGCGCCCGCGGCGGAGACCGCGCTGGTCA 1202
|||||
34 LyrProValIleGluValAsnAlaProAlaGlyGlyProAlaTrpValIle 50
1201 ACCGATGACCGCTCGCGCGGAGGTGCTGCGCATCCCGGCTTGCTGA 1152
|||||
51 ThrAspAspAlaLeuAlaArgGluValLeuAlaAspProArgPheVal 67
1151 GAGACCGGACCTCGCGCGCGCGCTGCGGCGGCGGAGCGAGCGGTCG 1102
|||||
67 SasPProAspPleuAlaProThrAlaTrpArgIlyValAspAspGlyLeu 84
1101 ACATCCCGCTTCGAGAGCTGCTCGTTCACCGCTATCGCTGAGCGC 1052
|||||
84 SplIleProValProGluLeuArgProPheThrLeuIleAlaValAspGly 100
|||||

```

1051 GAGGCCACCGGCGGCTGGCCGATCCAGCAGCCTGGCTTCACCGCGG 1002  
101 GIuAspHISArgIuArgIuArgIuHISAlaProAlaPheAsnProAr 117  
1001 CCGGCTGGCGGCGGAGGATGCGATCGCCGATCGCGCGGCTGC 952  
117 gArIuAlaIuArgIuArgIuArgIuAlaIuAlaIuAlaAspArgIuL 134  
951 TCACGAGACTGCGGAGCGCTCGGCGGCGGCGGCGGCGGAGCTG 902  
134 eUrThGlIuAlaIuAspSerSerAspArgSerGluProAlaGluIu 150  
901 ATGCGGCGCTTCGCTACCTTCCTGCTGCTGCTGCTGCTGCTGCT 852  
151 IlegIuGlyPheAlaIuTrHISpHeuProIuAlaIuIleCyGluIu 167  
951 CGGCTGGCGGCTACCGATCGCGGATGGCCGCGAGCGCTGACGCTTC 802  
167 uGlyAlaProValTrHISpProAlaMetValArgIuAlaValGlyValL 184  
801 TCACGAGCACTGGCGCTCGGCGGCGGCGGAGCGGCGGCTACGCGAG 752  
184 eUlyAlaIuAlaIuGlyIuGlyIuProGlnSerAlaGlyIuAspGlyTr 200  
751 GACCTGGCGGCGGCGGCGGAGCACTCGCGCTGAGAGCGCTGCTCT 702  
201 AspProAlaGlyAspValProAspHISpSerAlaIuGlnSerIuLeu 217  
701 CGAGCCGCTGACCTACCGCGGCGGAGCAACCGCCGATGACCGCGG 652  
217 uGluAlaValHISAlaIuArgArgIuAspHISpHISpHISpHISpHIS 234  
651 TGCTGTAGAGCGGCGGCGGAGCTCGCTGCTGCTGCTGCTGCTGCTG 602  
234 aLeuTrGlyIuArgIuAlaIuAlaIuAlaIuPheGlySerValSerAsp 250  
601 CTGCTGTACATGATCAGCGGCGCTATCTTCGCGGCGGAGCAACCG 552  
251 LeuValIuTrMetIleThrGlyIuLeuIlePheAlaGlyHISAspHIS 267  
551 CTGCTTCCTGGGCTTCGCTGCTGCGGAGGCTTCGCGGCGGCGCTG 502  
267 ySerPheIuGlyPheLeuLeuAlaIuAlaIuAlaIuAlaIuAlaIu 284  
501 CGGATCGGAGGAGCGGCGCTCGCTCGGCTGCTGAGGAGCGGCTGCG 452  
284 IaAspAlaIuAspIuAspAlaIuIleSerArgPheValGluIuAlaIu 300  
451 TACACCGCGGCGGCTGCTACAGCTGTGTGAGGCTGCTGCTGCTG 402  
301 HISpHISpProIuAlaIuProIuTrHISpHISpHISpHISpHISp 317  
401 GACCATCGGCGGCTGCGGCTGCGCGGAGCGCGGCTGCTGCTGAG 352  
317 IValIleArgGlyValArgIuProArgIuAlaProValIuAlaIuAsp 334  
351 TCGAGGAGCAACAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCTG 302  
334 IlegIuGlyTrHISpHISpHISpHISpHISpHISpHISpHISpHIS 350  
301 CACCGGAGCGGCTGCTGCTGCGGCGGCTGCTGCTGCTGCTGCTG 252  
351 HISpProAspArgProSerArgHISpHISpHISpHISpHISpHISp 367  
251 CTACGTCATCGGAGGAGCGGCTGCGGAGTGGAGTGGCGGAGTATG 202  
367 sTyIuArgIuGlyIuGlnIuAlaIuGlnIuSerArgHISpHISpHIS 384  
201 GCGTCTGCGGAGGAGTTCGCGGAGCGGCGGAGTGGCGGAGTATG 152  
384 IyValIleuArgSerArgPheProGlnAlaIuArgIuAlaIuProIuTr 400  
151 GAGTTCGCTGCTGCGGAGGAGGCGGAGGCGGCGGCGGCGGAGT 102

||||| 401 GIuLeuArgTrpCyArgIuGlyIuAlaIuTrHISpHISpHISpHISpHISp 417  
101 GCGGCTGGCTGCGGCGG 86  
417 uProValTrPleuAlaArg 422  
seq\_name: sp\_Bacteria:Q93MI2  
seq\_documentation\_block:  
ID\_Q93MI2 PRELIMINARY: PRT: 420 AA.  
AC\_Q93MI2;  
DT 01-DEC-2001 (TREMBLrel. 19, Created)  
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)  
DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)  
DE DAUNOMYCIN C-14 HYDROXYLASE.  
GN DOXA.  
OS Streptomyces peucetius subsp. caesiuss.  
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
OC Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.  
OX NCBI\_Taxid=55158;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=ATCC 27952;  
RA Hong Y.-S., Kim H.S., Lee J.-H., Kim K.-W., Lee J.J.;  
RT "Molecular Cloning and Characterization of the doxa Cytochrome P-450  
RT Hydroxylase Gene in Streptomyces peucetius subsp. caesiuss ATCC  
RT 27952."  
RL J. Microbiol. Biotechnol. 0:0-0(2001).  
DR EMBL: AF403708; AAK95626.1;  
SO SEQUENCE 420 AA; 45645 MW; 2083C9FE9BA802C6 CRC64;

alignment\_scores:  
Quality: 2052.00 Length: 422  
Ratio: 4.993 Gaps: 2  
Percent Similarity: 97.867 Percent Identity: 94.313

alignment\_block:  
US-09-673-254-1/rev x Q93MI2 ..

Align seg 1/1 to: Q93MI2 from: 1 to: 420

1351 GTGAGGCGGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCTG 1302  
1 MeuSerGlyIuAlaProArgValAlaValAspProPheAlaCysProIe 17  
1301 GATGACATGACAGCGCAACCGCGAGGTGCAGCAGCGCTTCGCGGAGCGG 1252  
17 tMetThrMetGlnArgIuGlyProGluValHISpHISpHISpHISpHISp 34  
1251 GCGGCGGCTGCGAGGTGAAGCGGCGGCGGCGGCGGCGGCGGCGGCTG 1202  
34 IyProValIuAlaIuValAsnAlaProAlaGlyIuProAlaTrPheIle 50  
1201 ACCGATGAGCGGCTGCGGCGGCGGAGGTGCTGCGGCGGCTGCTGTA 1152  
51 ThrAspAspAlaIuSerArgTrpValIuAlaAspProArgIuValIu 67  
1151 GGACCGGAGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCTG 1102  
67 sasProAspIuAlaIuProAlaIuAlaIuTrpArgIuValIuAspGlyIu 84  
1101 ACATCGGCTTCGCGAGCTGCGTCCGCTGCTGCTGCTGCTGCTGCTG 1052  
84 sPleProValProGluIuAlaIuArgProPheTrHISpHISpHISpHISp 100  
1051 GAGGCGGAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCTG 1002  
101 GIuAlaHISpArgIuHISpHISpHISpHISpHISpHISpHISpHISp 117  
1001 CCGGCTGGCGGAGCGGAGCGGATGCGCGCGGATGCGCGGCGGCGGCTGC 952

[illegible]

seq_name:	sp.Bacteria:Q9ZAU2
seq_documentation_block:	
ID	Q9ZAU2
PRELIMINARY:	PRT; 275 AA.
AC	Q9ZAU2;
DT	01-MAY-1999 (TREMBLrel, 10, Created)
DT	01-MAY-1999 (TREMBLrel, 10, last sequence update)
DT	01-DEC-2001 (TREMBLrel, 19, last annotation update)
DE	DOXORUBICIN BIOSYNTHESIS ENZYME DNRY.
GN	DNRY.
OS	Streptomyces peucetius.
OC	Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
OC	Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.
OX	NCBI_TaxID=1950;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	STRAIN=ATCC 29050;
RX	MEDLINE=99084971; PubMed=9864344;
RA	Limovskaya N., Otten S.L., Doi-Katayama Y., Forstén L., Liu X.-C.,
RA	Takatsu T., Invenit A., Filippi S., Torti F., Colombo A.L.,
RA	Hutchinson C.R.;
RT	"doxorubicin overproduction in Streptomyces peucetius: cloning and
RT	characterization of the dnry gene and the doxA
RT	cytochrome P-450 hydroxylase gene.";
RL	J. Bacteriol. 181:305-318(1999).
DR	EMBL: U77891; AAD04716.1; -
DR	InterPro: IPR004360; Gly_bldc_dtox.
DR	Pfam: PF00903; Glyoxalase; 2.
QO	SEQUENCE 275 AA: 28481 MW: DEE13C0E714D4397 CRC64;

Quality:	1465.00	Length:	275
Ratio:	5.327	Gaps:	0
Percent Similarity:	100.000	Percent Identity:	99.636

alignment\_block:  
US-09-673-254-1/rev x Q9ZAU2

Align seg 1/1 to: Q9ZAU2 from: 1 to: 275

2175	GTATACAGGTTGGAGCCGGGAGCCCGCCGATGGTTGAGACTCGGTTGGCC	2126
1	MetThrArgPheAlaProGlyAlaProAlaThrPheAspLeuGlySer	17
2125	CGATGTGGCGCGCTGGCGCACTTGTACACCGCGCTGTTCGGCTGGACCG	2076
17	oAspValAlaAlaIleSerAlaAspPheTyrThrGlyLeuPheGlyTrpPhe	34
2075	CCACCGTGGTCACGACGCCGGGCGCGGGGGATACACAGCTTACGTC	2026
34	IaThrValIleSerAspProGlyAlaGlyGlyTyrThrThrPheSerSer	50
2025	GACGGACACTGATGGCCGCGCTGCCCGCCGACACAGATCGACACCCCTA	1976
51	AspGlyLeuLeuValAlaAlaValAlaThrGlnGlnIleAspThrProTyr	67
1975	CCACCGCGCGTACGGGCCCGGGAGACGACGACGCGCATGCCGGCATCT	1926
67	ThrAspArgProTyrGlyProGlyAsnAspGlnHisGlyMetProAlaIle	84
1925	GGACCGCTACTCTGGCACCGACGAGCGCGGACGCACTGACACAGCGGGTC	1876
84	TrpThrValIleThrPheAlaThrAspAspAlaAspAlaLeuThrLysArgVal	100
1875	GAGACGCGCGGGGAGGTCATCATGACTCGCATGAGCACTCTCGGCT	1826
101	GluThrAlaGlyGlyGlyValIleMetThrProMetAspValLeuGlyLe	117
1825	CGGCGGATGGCGGTCTTGGCCGACCGCGCGGGCGCGGTTCGCGGCT	1776
117	uGlyArgMetAlaValAlaPheAlaAspProAlaGlyAlaAlaIlePheAlaVal	134

1775 GCGCGAAGGAGTCAATGAGGCGCGAGGTACGGGCTGCCGCTCG 1726  
|||||  
134 rPargylsGlyValMetGluGlyAlaGluValThrGlyValProGlySer 150  
|||||  
1725 GTGCGGTGGGTGAGCTGTGACCGGACGATCGGGGCGCGCGGACTT 1676  
|||||  
151 ValGlyThrValGlyLeuValThrAspGlyIleGlyAlaAlaArgAspH 167  
|||||  
1675 CTACCGGCGGACCTCGGCTGTCCGCGCGGACCGGACTGAAGGGCG 1626  
|||||  
167 eTyrrProAlaThrLeuGlyLeuAlaProAlaAspThrGlyLeuGly 184  
|||||  
1625 TCACCGACCCGGTGTGACATCGGTGACACACCGGTCGCGGACCCAG 1576  
|||||  
84 aLThrasProValThrPheHisIleGlyAspThrProValAlaGlyThrGln 200  
|||||  
1575 GAGCTGGGCGTACCGGCGGCTACCGCGGACCTGGGCGCTGTCTGCG 1526  
|||||  
201 GluLeuGlyValThrGlyAlaValAlaArgProHisThrAlaValLeuPheAl 217  
|||||  
1525 CGTGCACGACTGCGACGCGGCTCCGGGCGCGCTGTGAACCTCGGCGCT 1476  
|||||  
217 aValHisAspCysAspAlaThrValAlaArgAlaValGlyLeuGly 234  
|||||  
1475 CCGTGCAGAACGAGCCCGCGGACGCGGCGGCGGCGGCGGACTG 1426  
|||||  
234 eValGluGlnGlnProAlaAspThrProAlaGlyArgAlaAspLeu 250  
|||||  
1425 CTGCACCGCGACGCGGCGGCTTCTGCTGTGTCGAACTCGGAGGGGTA 1376  
|||||  
251 LeuAspProHisGlyAlaGlyPheSerValValGlyLeuArgGlyGly 267  
|||||  
1375 CCGCGGCGGCGGCGGCGGCTGCG 1351  
267 rProAlaAlaAlaGlyGlyAlaSer 275  
seq\_name: sp\_bacteria:Q55078

seq\_documentation\_block:  
ID Q55078 PRELIMINARY; PRT: 275 AA.  
AC Q55078;  
DT 01-NOV-1996 (TREMBlrel. 01, Created)  
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)  
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)  
ORA PROTEIN.  
ORA.  
Streptomyces sp.  
Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
Actinomycetales; Streptomycinae; Streptomycetaceae; Streptomyces.  
NCBI\_TaxID=1931;  
OX 11  
RN 11  
RP SEQUENCE FROM N.A.  
RC STRAIN=CS.  
RX MEDLINE=96236067; PubMed=8655530;  
RA Dickens M.L., Strohl W.R.;  
RT Isolation and characterization of a gene from Streptomyces sp. strain  
RT C5 that confers the ability to convert daunomycin to doxorubicin on  
RT Streptomycetes llydians TK24.  
RL J. Bacteriol. 178:3389-3395(1996).  
DR EMBL: U50973; AAB08048.1; .  
DR InterPro: IPR004360; Gly\_Dleo\_dlox.  
DR Pfam: PF00903; Glyoxalase; 2.  
SQ SEQUENCE 275 AA; 28840 MW; BCDDBBEA60BDE4AF CRC64;

alignment\_scores:  
Quality: 1385.00 Length: 275  
Ratio: 5.149 Gaps: 0  
Percent Similarity: 97.818 Percent Identity: 94.182

alignment\_block:  
US-09-673-254-1/rev x Q55078 ..

Align seg 1/1 to: Q55078 from: 1 to: 275  
2175 GTGACACAGTTGGCGCGCGCGCGCGCGCGCGATGTTGTGACCTGGTTCCG 2126  
:::  
1 MetThrArgPheAlaProGlyAlaProAlaThrPheAspLeuGlySer 17  
2125 CGATGTGCGCGCTGCGCGGCTGTACACGCGGCTGTGCGGCTGACCG 2076  
|||||  
17 oAspValAlaAlaSerAlaAspPheThrThrGlyLeuPheGlyThrPhe 34  
|||||  
2075 CCACCGTGTGACGACCGCGGCGCGGCGGATACAGAGTTCACTTCG 2026  
|||||  
34 lathValAlaSerAspProGlyAlaGlyGlyThrThrPheSerSer 50  
|||||  
2025 GACGCGAACCTGTGCGCGCGGCTGCGCGCGCGCGCGAGATGACACCCCTTA 1976  
|||||  
51 AspGlyGlyLeuValAlaAlaValAlaArgHisGlnIleAspThrProTy 67  
|||||  
1975 CCACCGCGCGTACGCGGCGCGGACGACGACGCGGATGCGCGGCT 1926  
|||||  
67 HisAspProTyThrGlyProGlyAsnAspGlnHisGlyMetProAlaIleT 84  
|||||  
1925 GACCGGTGTACTTGTGCGGACGACGACGCGGCGGCGGCTGACGAGCGGCTC 1876  
|||||  
84 rPThrValThrPheAlaThrAsnAspAlaAspAlaLeuThrLysArgVal 100  
|||||  
1875 GAGAGCGCGCGCGCGGCGGAGTCAATGACTCGGATGAGAGCTGCGGCT 1826  
|||||  
101 GluThrAlaGlyGlyAspValIleMetThrProMetAspValLeuGly 117  
|||||  
1825 CCGCGGATGCGGCGGCTTGTGCGGACCGCGGCGGCGGCTGCGGCT 1776  
|||||  
117 uGlyArgMetAlaValAlaPheAlaAspProSerGlyAlaAlaPheAlaValT 134  
|||||  
134 rPargylsGlyValMetGluGlyAlaGlyValThrGlyValProGlySer 150  
|||||  
1725 GTGCGGTGGGTGAGCTGTGACCGGACGATCGGCGCGCGCGGACTT 1676  
|||||  
151 ValGlyThrValGlyLeuValThrAspAspIleGlyThrAlaArgGly 167  
|||||  
1675 CTACCGGCGGACCTGCGGCTGCGGCTGCGGCGGACGCGGACTGAAGGGCG 1626  
|||||  
167 eTyrrArgAlaThrLeuGlyLeuAlaProAlaAspThrGlyArgLysGly 184  
|||||  
1625 TCACCGACCCGGTGTGACATCGGTGACACACCGGTCGCGGACCCAG 1576  
|||||  
184 aLThrasProValThrPheHisIleHisAspThrProValAlaGlyThrArg 200  
|||||  
1575 GAGCTGGGCGTACCGGCGGCTACCGGCGGACCTGGGCGGCTGTCTGCG 1526  
|||||  
201 GluLeuGlyThrThrGlyAlaValAlaArgProHisThrAlaValLeuPheHe 217  
|||||  
1525 CCGTGCACGACTGCGACGCGGCTCCGGGCGCGCTGTGAACCTCGGCGCT 1476  
|||||  
217 tValHisAspCysAspAlaThrValAlaArgAlaValGlyLeuGlyGly 234  
|||||  
1475 CCGTGCAGAACGAGCCCGCGGACGCGGCGGCGGCGGCGGACTG 1426  
|||||  
234 eValGluGlnGlnProValAlaAspThrProAlaGlyArgAlaAspLeu 250  
|||||  
1425 CTGCACCGCGACGCGGCGGCTTCTGCTGTGTCGAACTCGGAGGGGTA 1376  
|||||  
251 LeuAspProHisGlyAlaGlyPheSerValValGlyLeuArgGlyAlaTy 267  
|||||  
1375 CCGCGGCGGCGGCGGCGGCTGCG 1351  
267 rProAlaAlaAlaAspGlyAlaSer 275  
seq\_name: sp\_bacteria:Q92A01

seq\_documentation\_block:  
 ID Q9ZAU1 PRELIMINARY: PRT: 287 AA.  
 AC Q9ZAU1;  
 DT 01-MAY-1999 (TREMBlrel. 10, Created)  
 DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)  
 DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)  
 DE DAUNORUBICIN C-13 KETOREDUCTASE.  
 GN DNRU.  
 OS Streptomyces peuceletius.  
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
 OC Actinomycetales; Streptomycinae; Streptomycetaceae; Streptomyces.  
 OX NCBI\_TaxID=1950;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-ATCC 29050;  
 RX MEDLINE=99084971; PubMed=9864344;  
 RA Lomovskaya N., Otten S.L., Doi-Katayama Y., Foonstein L., Liu X.-C.,  
 RA Takatsu T., Inveneti A., Filippi S., Torti F., Colombo A.L.,  
 RA Hutchison C.R.;  
 RA "Doxorubicin overproduction in Streptomyces peuceletius: cloning and  
 characterization of the dnrV ketoreductase and dnrV genes and the doxa  
 cytochrome P-450 hydroxylase gene."  
 J. Bacteriol. 181:305-318(1999).  
 -1- SIMILARITY: BELONGS TO THE SHORT-CHAIN DEHYDROGENASES/REDUCTASES  
 (SDR) FAMILY.  
 CC EMBL: U77891; AAD04717.1; -;  
 DR InterPro: IPR002198; ADH\_short.  
 DR Pfam: PF00106; adh\_short; 1.  
 KM Oxidoreductase.  
 SQ SEQUENCE 287 AA: 30632 MW: 4F9448EAE55F6191 CRC64;

alignment\_scores:  
 Quality: 1014.00 Length: 196  
 Ratio: 5.173 Gaps: 0  
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment\_block:

US-09-673-254-1/rev x Q9ZAU1 ..

Align seg 1/1 to: Q9ZAU1 from: 1 to: 287

```

2869 CGGTACCCGCGATGATGTCATGGCCAGCAAGCGCGCGCATTTCTG 2820
|||||
92 ArgTyrProArgIleAspValMetAlaSerAsnAlaGlyGlyMetPheTr 108
2819 GTCCGGCACACGACCGACGGGTTCGAGCGCAATCCAGGCGCAATC 2770
|||||
108 pSerArgThrThrThrGlnAspGlyPheGlnAlaThrIleGlnValAsnH 125
2769 ACCTGCGAGGCTTCTGCTGGCAGCGGTGCTGCGGAGCGGCTCGCGGC 2720
|||||
25 IsteuAlaGlyPheLeuLeuAlaArgLeuAlaArgGluArgLeuAlaGly 141
19 GGGCGGCTGATCTCACTGCTGCGAGCGGTACACCGAGCGCGATCGA 2670
|||||
142 GlyArgLeuIleLeuThrSerSerAspAlaTyrThrGlnGlyArgIleAs 158
2669 CCGGAGACACTCAACGCGGAGACCGCTACCGGTACGCGCGCGCGGCGT 2620
|||||
158 pProAspAspLeuAsnGlyAspArgHisArgTyrSerAlaGlyGlnAlaTr 175
2619 ACGGACGCTCCAAACAGGCAACATCATGACCGCGCGAGCGCGCCAGG 2570
|||||
175 YrGlyThrSerTyrGlnAlaAsnIleMetThrAlaAlaGlnAlaValArg 191
2569 CGGTGCGCGGACGTGCTGGCGGTGAGCTATACCCGGGTGAGTCCGAC 2520
|||||
192 ArgTyrProAspValLeuAlaValSerTyrHisProGlyGluValArgTh 208
2519 CCGGATCGGAGGCGGCGGTGCGCTGCTCACTTCGCGTTCAACCGCT 2470
|||||
208 rArgIleGlyArgGlyThrValAlaSerSerTyrPheArgPheAsnProp 225

```

2469 TCCTGCGCCTCCGGCGGAGGCGCGACACCTGCTGCTGGCGCTCC 2420  
 |||||  
 225 heuLeuTyrSerAlaAlaGlyGlyAlaAspThrLeuValTrpLeuAlaSer 241  
 2419 GCGCGCGCGGAGAGTTGACACGAGCGGCGCTACTACAGCAGCGCGGCT 2370  
 |||||  
 242 AlaProAlaGluGluLeuThrThrGlyGlyTyrTyrSerAspArgIle 258  
 2369 GTCCCGGCTGAGCGCGCGCGACCGCGCGCGCTCGCGGGAAGCTCT 2320  
 |||||  
 258 uSerProValSerGlyProThrAlaAspAlaGlyLeuAlaAlaTyrLeuT 275  
 2319 GGGAGCGCGCGCGCGCGCGCTGCGGAGACGCGCGAC 2282  
 |||||  
 275 rPdluAlaGlyAlaAlaAlaValGlyAspThrAlaHis 287

seq\_name: sp\_bacteria:Q53877

seq\_documentation\_block:

ID Q53877 PRELIMINARY: PRT: 287 AA.

AC Q53877;

DT 01-NOV-1996 (TREMBlrel. 01, Created)

DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)

DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)

DE KETOREDUCTASE.

OS Streptomyces sp. C5.

OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;

OC Actinomycetales; Streptomycinae; Streptomycetaceae; Streptomyces.

OX NCBI\_TaxID=45212;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN-C5.

RX MEDLINE=96236066; PubMed=8655529;

RA Dickens M.L., Ye J., Strohl W.R.;

RT "Cloning, sequencing, and analysis of aklaviketone reductase from

Streptomyces sp. strain C5."

RL J. Bacteriol. 178:3384-3388(1996).

-1- SIMILARITY: BELONGS TO THE SHORT-CHAIN DEHYDROGENASES/REDUCTASES

(SDR) FAMILY.

CC EMBL: U43704; AAB08016.1; -;

DR InterPro: IPR002198; ADH\_short.

DR Pfam: PF00106; adh\_short; 1.

KM Oxidoreductase.

SQ SEQUENCE 287 AA: 30799 MW: 8FEB9D11BAFE1E78 CRC64;

alignment\_scores:  
 Quality: 980.00 Length: 195  
 Ratio: 5.026 Gaps: 0  
 Percent Similarity: 100.000 Percent Identity: 96.410

alignment\_block:

US-09-673-254-1/rev x Q53877 ..

Align seg 1/1 to: Q53877 from: 1 to: 287

```

2869 CGGTACCCGCGATGATGTCATGGCCAGCAAGCGCGCGCATTTCTG 2820
|||||
92 ArgTyrProArgIleAspValMetAlaSerAsnAlaGlyGlyMetPheTr 108
2819 GTCCGGCACACGACCGGAGGCTTCGAGCGCAATCCAGGCGCAATC 2770
|||||
108 pSerArgThrThrThrGlnAspGlyPheGlnAlaThrIleGlnValAsnH 125
2769 ACCTGCGAGGCTTCTGCTGGCAGCGGTGCTGCGGAGCGGCTCGCGGC 2720
|||||
125 IsteuAlaGlyPheLeuLeuAlaArgLeuAlaArgGluArgLeuAlaGly 141
2719 GGGCGGCTGATCTCACTGCTGCGAGCGGTACACCGAGCGCGGATCGA 2670
|||||
142 GlyArgLeuIleLeuThrSerSerAspAlaTyrThrGlnGlyArgIleAs 158

```



```
2669 CCGGAGACCTCAACGGCGACCGCTACCGCTACAGCCGCGGCGAGCGT 2620
|||||
158 pProAspAspLeuAsnGlyAspArgHisArgTyrSerAlaGlyGlnAlaIat 175
|||||
2619 ACGGACAGTCCAAACAGGCCCAACATCATGACCGCGGCGAGCGCCAGG 2570
|||||
175 yTgLyThrSerLysGlnAlaAsnIleMetThrAlaThrGlnAlaAlaArg 191
|||||
2569 CGCTGCGCGGACGCTGCGGCGTCACTATCAACCCGCGTGAAGTCCGAC 2520
|||||
192 ArgTrpProAspValLeuThrValSerTyrHisProGlyGlnValArgTh 208
|||||
2519 CCGCATCGGACGGGGGACGCGTCCCTCTACTTCCGGTTCAACCCCT 2470
|||||
208 rArgIleGlyArgGlyThrValAlaSerThrTyrPheArgPheAsnProp 225
|||||
69 TCCTGGCTCCCGGGGGAAGGGCGGACACCCCTCGTGGCTGGCGTCC 2420
|||||
225 heLeuArgSerAlaAlaLysGlyAlaAspThrLeuValTrpLeuAlaAla 241
|||||
2419 GCGCGGCGGAGAGTGTGACCAAGGGCGGCTACTACAGCGAGCGGCGT 2370
|||||
242 AlaProAlaGlnGluLeuThrThrGlyTyrTyrSerAspArgArgIle 258
|||||
2369 GTCCCGGGTGAGGGCGCGACCGCGACGCGGCTCGCGGGGAAGCTCT 2320
|||||
258 uSerProValSerGlyProThrAlaAspAlaGlyLeuAlaAlaLysLeuT 275
|||||
2319 GGGAGGCGGCGGCGGCGGCTCGGGGACACCGCG 2285
|||||
275 rpGlnAlaSerAlaAlaAlaAlaValGlyAspThrAla 286
```

